

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

BMJ Open

Mini-sternotomy versus conventional sternotomy for aortic valve replacement: a randomised controlled trial

Journal:	BMJ Open
Manuscript ID	bmjopen-2020-041398
Article Type:	Original research
Date Submitted by the Author:	08-Jun-2020
Complete List of Authors:	Hancock, Helen; Newcastle University, Newcastle Clinical Trials Unit Maier, Rebecca; Newcastle University, Newcastle Clinical Trials Unit Kasim, Adetayo; Durham University, Wolfson Research Institute for Health and Wellbeing Mason, James; University of Warwick, Warwick Medical School Murphy, Gavin; University of Leicester, Department of Cardiovascular Sciences and NIHR Leicester Biomedical Research Unit in Cardiovascular Medicine Goodwin, Andrew; South Tees Hospitals NHS Foundation Trust, James Cook Hospital Owens, W; South Tees Hospitals NHS Foundation Trust, James Cook Hospital Akowuah, Enoch; South Tees Hospitals NHS Foundation Trust, James Cook Hospital
Keywords:	Valvular heart disease < CARDIOLOGY, HEALTH ECONOMICS, Adult cardiology < CARDIOLOGY





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

2		
3	1	Title
4		
5	2	Mini-sternotomy versus conventional sternotomy for aortic valve replacement: a randomised
6		
7	3	controlled trial
8	5	
9		
10	4	Authors
11 12		
12	5	Helen C Hancock, PhD ¹ , Rebecca H Maier ¹ , MSc, Adetayo S Kasim, PhD ² , James M Mason, DPhil ³ ,
14		
15	6	Gavin J. Murphy, FRCS (C.Th) ^₄ , Andrew T Goodwin, FRCS (C.Th) ⁵ , W Andrew Owens, FRCS (C.Th) ⁵ ,
16		
17	7	Enoch F Akowuah, FRCS (C.Th) ⁵ .
18		
19	0	
20	8	1. Newcastle Clinical Trials Unit, Newcastle University; 2. Durham Research Methods Centre,
21		
22	9	Durham University; 3. Warwick Medical School, University of Warwick; 4. Department of
23		
24	10	Cardiovascular Sciences, University of Leicester; 5. Cardiothoracic Services, South Tees Hospitals NHS
25 26		
26 27	11	Foundation Trust, The James Cook University Hospital.
28		
29	12	
30	12	
31	12	Woul count 2025
32	13	Word count 2925
33	14	
34	15	Corresponding author: Enoch Akowuah
35		
36	16	Cardiothoracic Services, South Tees Hospitals NHS Foundation Trust, The James Cook
37	17	University Hospital.Marton Road, Middlesbrough. TS3 4BW.
38	18	E mail Enoch.Akowuah@nhs.net
39 40	19	
40		
42		
43		
44		
45		
46		
47		
48		
49		
50 51		
52		
53		
54		
55		
56		
57		
58		
59		
60		

2		
3	20	Abstract
4		
5	21	
6	- 1	
7	22	Objective
8		Objective
9 10	23	
10		To compare divised and booldb companie outcomes often menubaium limited wini store stores.
12	24	To compare clinical and health economic outcomes after manubrium-limited mini-sternotomy
13	25	(intermention) and convertional median starmatery (usual cons)
14	25	(intervention) and conventional median sternotomy (usual care)
15	26	
16	26	
17	27	Design
18	28	
19	29	A single blind, randomised controlled trial.
20		
21	30	Setting
22		
23	31	Single centre UK National Health Service tertiary hospital
24 25		
26	32	Participants
20		
28	33	Adult patients undergoing aortic valve replacement surgery
29		
30	34	Interventions
31	51	
32	35	Intervention was manubrium-limited mini-sternotomy performed using a 5-7cm midline incision.
33	55	intervention was manubrum innited mini steriotomy performed using a 5 ven midline meision.
34	36	Usual care was median sternotomy performed using a midline incision from the sternal notch to the
35	50	osual care was median steriotomy performed using a midline incision nom the sterial notch to the
36	37	vinhistornum
37	57	xiphisternum.
38	20	Defense of a second and a state of a second
39 40	38	Primary and secondary outcome measures
40	20	
42	39	The primary outcome was the proportion of patients who received a red cell transfusion post-
43		
44	40	operatively and within 7 days of index surgery. Secondary outcomes included proportion of patients
45		
46	41	receiving a non-red cell blood component transfusion and number of units transfused within 7 days
47		
48	42	and during index hospital stay, quality of life and cost effectiveness analyses.
49		
50	42	
51	43	Results
52		
53	44	
54	45	270 patients were randomised, received surgery and contributed to the intention to treat analysis.
55		
56 57	46	No difference between mini and conventional sternotomy in red-cell transfusion within 7 days was
57 58		
59	47	found; 23/135 patients in each arm received a transfusion, odds ratio 1.0 (95% CI: 0.5, 2.0) and risk
60		

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

48	difference 0·0 (95% CI: -0·1, 0·1). Mini-sternotomy reduced chest drain losses (mean 181·6ml (SD
49	138·7) vs conventional, mean 306·9ml (SD 348·6)); this did not reduce red-cell transfusions. Mean
50	valve size and post-operative valve function were comparable between mini-sternotomy and
51	conventional groups; 23mm vs 24mm, and 6/134 moderate or severe aortic regurgitation vs 3/130,
52	respectively. Mini-sternotomy resulted in longer bypass (82·7 minutes (SD 23·5) vs 59·6 minutes (SD
53	15·1)) and cross clamp times (64·1 minutes (SD 17·1) vs 46·3 minutes (SD 10·7)). Conventional
54	sternotomy was more cost-effective with only a 5.8% probability of mini-sternotomy being cost-
55	effective at a willingness to pay of £20,000/QALY.
56	Conclusions
57 58	AVR via mini-sternotomy did not reduce red blood cell transfusion within 7 days following surgery
59	when compared to conventional sternotomy.
60	
61	Clinical Trials Registry: ISRCTN29567910
62	
63 64	Clinical Trials Registry: ISRCTN29567910 Key word: minimally invasive, aortic valve
65	
66	
67	
68	
69	
70	
71	
72	
73	

2		
3	75	
4	13	
5	76	
6	76	
7	77	
8	77	
9	-0	
10	78	
11		
12 13	79	
13 14		
15	80	
16		
17	81	ARTICLE SUMMARY
18		
19	82	1. Large proportion of eligible patients recruited, and all patient randomised contributed to the
20		
21	83	primary outcome
22	00	
23	84	2. Clear protocols for transfusion of blood and blood products with high adherence throughout
24	01	2. Cicul protocols for transfusion of blood and blood products with high dufference throughout
25	85	the trial
26	05	
27	86	3. Patients were blinded to group allocation until two days following index surgery, reducing
28	80	3. Patients were blinded to group allocation until two days following index surgery, reducing
29 30	07	
31	87	the likelihood of bias.
32	0.0	
33	88	4. First randomised trial to perform detailed health economic evaluation of minimally invasive
34		
35	89	versus conventional sternotomy
36		
37	90	5. The trial was undertaken by three experienced minimally invasive surgeons who were expert
38		
39	91	at both techniques.
40		
41	92	
42		
43	93	
44		
45 46	94	
40 47		
47	95	
49	95	
50	06	
51	96	
52	~-	
53	97	
54		
55	98	
56		
57	99	
58		
59	100	
60	100	

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

1 2	
2	
4	
5	
6	
7	
8	
9 10	
11	
12	
13	
14	
15	
16 17	
18	
19	
20	
20 21 22	
22 23	
24	
25	
26	
27	
28 29	
30	
31	
32	
33	
34 35	
26	
37	
38	
39	
40 41	
42	
43	
44	
45 46	
40 47	
48	
49	
50	
51 52	
52 53	
55 54	
55	
56	
57	
58 59	
59 60	

101 Objectives

1

Aortic valve replacement (AVR) for severe symptomatic valvular disease is one of the most common
 cardiac surgical procedures performed worldwide. Outcomes are generally excellent with in-hospital
 observed mortality in the UK of 1.5% for first time elective procedures.¹

105 These results are not observed in all patients; in high risk groups, conventional surgery risks

106 perioperative organ injury and prolonged recovery, with death in up to 31% of patients within 1

107 year.² Minimally invasive surgery combines the durability of surgical repair with reductions in

108 surgical trauma that should reduce perioperative morbidity. Observational analyses demonstrating

109 reductions in morbidity and resource use^{3,4} may be confounded by multiple sources of bias and are

110 at odds with limited evidence from RCTs that have not shown improved outcomes.⁵ This uncertainty

⁶ 111 is reflected by variations in uptake internationally^{6,7}.⁸

112 The move towards minimally invasive surgery is also driven by patient perceptions of pain reduction and rapid recovery. However, minimally invasive cardiac surgery is not without risks; limiting access to the heart can result in technically sub-optimal surgery, including concern about the size of the

 $_{6}^{5}$ 115 prosthesis that can be inserted, and paravalvular leak rates.

This trial evaluated Manubrium-limited Mini-sternotomy versus Conventional Sternotomy for Aortic
Valve Replacement (MAVRIC). We hypothesised that mini-sternotomy would reduce red cell
transfusion rates, a contemporary marker of surgical trauma and indicator of adverse outcomes;⁹
this has been contested,¹⁰ though the evidence is not conclusive.¹¹ An embedded cost effectiveness
analysis evaluated whether the intervention was cost effective in a UK National Health Service (NHS)
setting.

² 122 Patients and Methods

123 Trial Design

MAVRIC was a single centre, single-blind, RCT comparing AVR via manubrium-limited mini-

59 125 sternotomy group (intervention) and AVR via conventional sternotomy group (usual care). A NHS

BMJ Open

1 2		
2 3 4	126	Research Ethics Committee approved the trial, which was conducted in accordance with the
5 6	127	principles of the International Conference on Harmonisation of Good Clinical Practice. ¹² South Tees
7 8 9	128	Hospitals NHS Foundation Trust was the Sponsor and recruiting centre.
9 10 11 12	129	Patient Public Involvement
13 14	130	In designing the study, we asked patients their view on what factors may affect whether they took
15 16	131	part in the study. This was done in an outpatient setting and via a postal questionnaire. They felt
17 18	132	expertise was important. Most patients felt that although the cosmetic benefit of the minimally
19 20 21	133	invasive approach was appealing, they expected some clinical benefit form minimally invasive
22 23	134	surgery as well. Importantly most patients said they would accept being blind to the type of surgery
24 25	135	they had received for 48 hours after the procedure.
26 27	136	Participants
28 29 30	137	Patients were eligible if they were aged 18 years or over; required first-time, non-emergency,
31 32	138	isolated AVR surgery; and were willing to provide written informed consent. Full details of the
33 34	139	eligibility criteria are in the Supplementary Material.
35 36	140	Randomisation
37 38	140	
39 40	141	Eligible patients were randomised by members of the research team using a 24-hour, central,
41 42	142	secure, web-based randomisation system with concealed allocation, managed by the Clinical Trials
43 44	143	Unit; randomisation was in a 1:1 ratio between mini and conventional sternotomy and stratified by
45 46	144	baseline logistic EuroSCORE and pre-operative Hemoglobin (Hb).
47 48 49	145	Interventions
50 51	146	Manubrium-limited mini-sternotomy was performed using a 5-7cm midline skin incision dividing the
52 53	147	manubrium from the sternal notch to 1cm below the manubrium-sternal junction. Cardiopulmonary
54 55	148	bypass was established with an ascending aortic cannula and percutaneous femoral venous
56 57 58 59	149	cannulation. Conventional median sternotomy was performed using a midline incision from the
60		

BMJ Open

1

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

2		
3 4	150	sternal notch to the xiphisternum. Key aspects of anaesthesia were standardised, and are detailed in
5 6 7	151	the protocol. ¹³
8 9	152	Blinding
10 11 12	153	All patients were blinded to type of sternotomy received until after their day 2 Quality of Life and
12 13 14	154	pain assessments. All patients had trial-specific opaque dressings applied to their sternal wound, and
15 16	155	groin before leaving theatre.
17 18	156	Transfusion Protocol
19 20	157	The post-operative period, and trial protocol in relation to red cell and non-red cell transfusion,
21 22 23	158	began on admission to the Cardiothoracic Intensive Care Unit (CICU); it specified that patient's
24 25	159	should receive a red cell transfusion if their Hb dropped below 80 g/L; or were bleeding by 400ml/h
26 27	160	or more, or were bleeding 100ml/h or more for 4 or more hours with a Hb equal to or greater than
28 29	161	80g/L; or had blood loss with haemodynamic instability irrespective of thromboelastography (TEG)
30 31 32	162	and/or clotting profile results. One unit of red cells was transfused and Hb level checked before
33 34	163	transfusing another unit.
35 36	164	Participants received a non-red cell transfusion if both of the following criteria were met: bleeding
37 38	165	defined by 400ml/h or more, or blood loss of 100ml/h or more for 4 hours or more; TEG or
39 40 41	166	coagulation guided transfusion indicated.
42 43	167	Outcomes All outomes were measured from index surgery.
44 45	168	All outomes were measured from index surgery.
46	169	
47 48	170	Primary Outcome
49 50	171	The primary outcome was the proportion of patients who received a red cell transfusion post-
51 52 53	172	operatively and within 7 days of index surgery.
55 54 55	173	Secondary Outcomes:
56 57	174	• proportion of patients receiving a red cell transfusion and number of units transfused within
58 59 60	175	7 days and during index hospital stay;

BMJ Open

2		
3 4	176	• proportion of patients receiving a non-red cell blood component transfusion and number of
5 6 7	177	units transfused within 7 days and during index hospital stay;
8 9	178	• volume in chest drains at 6 and 12 hours, and drain removal;
10 11 12	179	• degree of aortic regurgitation using echocardiogram within 6 weeks;
13 14 15	180	re-operation rates;
16 17 18	181	 conversion to conventional AVR during surgery;
19 20 21	182	 changes in lung function at 4 days and 6 weeks;
22 23	183	• Quality of life EuroQol (EQ-5D-3L, EQ-VAS) at 2 days, 6 and 12 weeks;
24 25 26	184	 time patients are deemed 'fit for discharge';
27 28 29	185	health care utilisation to 12 weeks;
30 31 32	186	cost and cost effectiveness analyses;
33 34	187	adverse events to 12 weeks.
35 36 37	188	Statistical Analysis
38 39	189	Audit data had indicated 30% of patients undergoing AVR via conventional sternotomy (15 of 50
40 41	190	patients) received a red cell transfusion compared with 13% of patients (8 of 60 patients)
42 43 44	191	undergoing AVR via mini-sternotomy. Using Fisher's Exact test, 90% power, 5% alpha, we estimated
45 46	192	that 260 patients would be required to detect a 17% reduction in the proportion of patients
47 48	193	requiring a red cell transfusion (13% compared with 30%), using a two-sided test. Allowing for loss to
49 50 51	194	follow up, the sample size was increased to 270.
52 53	195	The primary analysis was based on intention-to-treat principles, in accordance with a pre-specified
54 55 56	196	statistical analysis plan.
57 58	197	The primary efficacy analysis was based on a logistic regression model with only group (minimally
59 60	198	invasive and conventional) and stratifying factors (baseline logistic EuroSCORE and Hb) as the

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open

predictors. Odds ratios and their associated 95% confidence interval are reported in the primary analysis. Sensitivity analysis using alternating logistic regression was performed for the primary endpoint to sensitise for surgeon effects; the odds of receiving a red cell transfusion for two patients treated by the same surgeon was compared to two patients treated by different surgeons. All analyses of secondary continuous efficacy endpoints at single time points were based on linear models where, if appropriate, a log normal model was fitted to sensitise the linearity assumption. Longitudinal analysis was performed for all endpoints with repeated data over time to investigate changes in trends over the trial period. The trial period was defined as baseline, up to 7 days (post-operative period), 6 week follow-up and 12 week follow-up. All analyses of binary endpoints at a single time point were based on logistic regression. Generalised estimating equation was used to analyse repeated binary data per patient to account for intra-patient correlation. Further exploratory analysis was conducted to investigate the association between the treatment group and other clinical factors. All analyses were performed using R 3·3·3 (The R Foundation) and SAS 9.4 (SAS Institute Inc). **Economic Evaluation** A prospective economic evaluation applying a NHS perspective, following National Institute for Health and Care Excellence (NICE) reference case guidance,¹⁴ was employed. Health care utilisation was captured up to three months following discharge from index surgery. Resource use was valued in 2016 pounds sterling using national sources,^{15,16} and where necessary, local micro-costing (£1=\$1.50). Resources included surgery, transfusions, length of hospital stay (by level of care), complications and further surgery, and community care following discharge. Mechanisms of missingness within the data were explored and multiple imputation methods were applied to impute missing data and minimise bias, using chained equations and predictive mean matching. Imputation sets were analysed within a bivariate analysis of costs and QALYS, to generate incremental within-trial cost per QALY estimates and credible intervals. Findings were presented on

BMJ Open

2		
3 4	224	the ICER plane and with Cost-Effectiveness Acceptability Curves, using the net monetary benefit
5 6 7	225	approach.
8 9	226	Results
10 11	227	Trial Population
12 13	228	MAVRIC recruited to time and target; 313 patients were considered for the trial; 274 patients
14 15 16	229	consented between 20 th March 2014 and 25 th July 2016. The analysis population was 270 eligible
17 18	230	patients; 135 allocated to the AVR via mini-sternotomy group and 135 allocated to the AVR via
19 20 21	231	conventional sternotomy group (Figure 1).
22 23	232	All 270 patients underwent surgery. Sixteen patients required cross-over from minimally-invasive to
24 25	233	a conventional sternotomy due to anaesthetic emergency (n=2), difficulties due to vascular access
26 27	234	(n=9), and intra-operative complications (n=5); further details and the number of operations
28 29 30	235	performed by surgeon are in the Supplementary Material.
31 32 33	236	Baseline characteristics were similar between groups (Table 1).
34 35 36	237	Primary Outcome
37 38	238	There was no difference between groups in relation to the primary outcome (Table 2). The
39 40	239	proportion of patients receiving red cell transfusion transfusions was 23 of 135 in both groups, Odds
41 42 43	240	ratio 1·0 (95% Cl 0·5, 2·0; p=0·9052) and risk difference of 0·0 (95% Cl -0·1, 0·1; p=0·9999).
44 45	241	Secondary Outcomes
46 47 48	242	Red cell and non-red cell transfusion
49 50	243	There was no significant difference between groups with respect to any red cell transfusion at
51 52 53	244	discharge (Table 2). There was no difference between groups in Hb from baseline to 4 days following
54 55	245	index surgery (Supplementary Material). There was a statistically significant difference in the
56 57	246	proportion of patients receiving any non-red cell transfusion within 7 days of surgery; mini 6/135
58 59 60	247	versus conventional 18/135, Odds ratio: 0·3 (95% CI 0·1, 0·8; p=0·0137) (Table 3).

BMJ Open

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

248	Cross clamp time and cardiopulmonary bypass time

249 Mini-sternotomy resulted in longer Cardio Pulmonary Bypass times; mini group 82.7 minutes (SD

250 23.5), conventional 59.6 minutes (SD 15.1). Aortic cross clamp times were also longer; mini group

251 64·1 minutes (SD 17·1), conventional 46·3 minutes (SD 10·7) (**Table 4**).

252 Chest drain losses

- 253 Mini-sternotomy resulted in a 40.8% reduction in chest drain losses at 12 hours, the mini group
- 254 mean was 181.6ml (SD 138.7), conventional group mean was 306.9ml (SD 348.6); the mean
- difference was -127·7ml (95% CI -191·7, -63·8, p=0.0001). At drain removal mean difference was -
- $\frac{1}{3}$ 256 145·3ml (95% Cl -218·1, -72·3; p=0.0001) (**Table 4**).

257 Ventilation time

- ⁸ 258 Ventilation time between the groups was similar; 9.6 hours (SD 5.6) in the mini group and 9.8 hours
- $^{0}_{1}$ 259 (SD 6·9) in the conventional (**Table 4**).
- ³ 260 Intensive care unit length of stay
- 6 261 There was no difference in intensive care unit length of stay between groups (Supplementary
- ⁸ 262 Material).
- **Post-operative pain**
- ³ 264 There was no difference in pain scores between groups (**Supplementary Material**).

¹⁶ 265 Lung function

- There was no difference between groups in lung function at baseline. At 4 days post-surgery, mean
- Forced Expiratory Volume 1 (FEV1) 1123mls (SD 433) and Forced Vital Capacity, FVC 1479mls (SD
- 268 583) were significantly reduced in the mini group, compared to the conventional; FEV1 1321 (SD
- $_{6}^{-}$ 269 524), FVC 1698 (SD 707). Mean differences for FEV1 and FVC were statistically significant at 4 days
- 270 post-surgery; -171mls (95% CI -265, -77; p=0.0004) and -130mls (95% CI -269, 0; p=0.0498)

BMJ Open

2 3	271	non stinch, often adjustice for boarding EDV(4, EV(6, and an demination for targe (6, and an entern
4	271	respectively, after adjusting for baseline FEV1, FVC, and randomisation factors (Supplementary
5 6 7	272	Material).
8 9 10	273	Hospital length of stay
10 11 12	274	The mean time to patients being fit for hospital discharge following index surgery was similar
13 14	275	between groups. The mean post-operative hospital length of stay was 7.4 (SD 7.5, range 3-79) in the
15 16 17	276	mini group, and 6·3 days (SD 3·2, range 3-31) in the conventional (Supplementary Material).
18 19	277	Post-operative valve function
20 21 22	278	The distribution of valve types and valve sizes were similar; mean valve size inserted was 23mm in
23 24	279	the mini group and 24mm in the conventional (Table 4). Over 70% of patients in each group received
25 26	280	a tissue valve, over 25% received a mechanical valve and 2-3% received a sutureless tissue valve.
27 28	281	Post operative transthoracic echo showed a similar decrease in mean aortic valve gradient in both
29 30 31	282	groups to 16mmHg; peak gradient decreased to 30mmHg in both groups (Table 4). 6/134 patients
32 33	283	had moderate or severe aortic regurgitation in the mini group compared to 3/130 in the
34 35	284	conventional (Table 4).
36 37	285	Adverse events
38 39 40	286	Adverse events in each group were broadly similar and within acceptable clinical limits. By 12 weeks,
40 41 42	287	4/135 patients in the mini-sternotomy group and 1/135 in the conventional group had suffered a
43 44	288	stroke (defined as a persistent neurological deficit). Atrial arrhythmias were identified in 61/135
45 46	289	patients in the mini group and 51/135 in the conventional. By 12 weeks, 11/135 patients in the mini
47 48 49	290	group and 3/135 patients in the conventional had a sternal wound infection (Supplementary
50 51	291	Material).
52 53	292	Quality of Life, Costs and Cost-Effectiveness
54 55 56	293	Costs during the index admission were significantly greater for the mini group (mini-conventional:
57 58	294	mean difference £1140; 95% CI 303, 1977), primarily reflecting the additional cost of theatre time
59 60	295	(Supplementary Material). Overall costs were not significantly different (mini-conventional: mean

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

difference £746; 95% CI -245, 1737). There was no significant difference in quality of life between groups up to 12 weeks (mini-conventional: mean difference area under curve -0.009 QALYs; 95% CI 0.020, 0.002). Although differences in costs and quality-of-life were not individually significant, the bivariate cost-QALY distribution (combining these two) suggests conventional surgery might be more cost-effective (Figure 2). In the base-case model, mini was dominated by conventional surgery (due to greater cost and less benefit), with only a 5.8% probability of being cost-effective at a willingness to pay of £20,000/QALY (Table 5). Sensitivity and Subgroup Analyses There was no significant surgeon effect; the odds of receiving a red cell transfusion for two patients treated by the same surgeon compared to two patients treated by different surgeons was 1.2 (95% CI 0.9, 1.6; p=0.1379). Protocol deviations in respect of cell tranfusions did not affect the results of the primary analysis; excluding these patients produced the same results as those from the intention-to-treat analysis. Discussion Main findings Mini-sternotomy was not superior to conventional sternotomy with respect to red cell transfusion requirements within 7 days of surgery. Analysis of secondary endpoints showed a statistically significant difference in transfusion volumes of non-red cell blood components. Aortic valve size and post-operative function were comparable in the 2 groups. Mini-sternotomy resulted in a relative reduction in chest drain losses however, higher blood loss in the conventional group did not translate into red cell transfusions. Mini patients had substantially longer bypass and cross clamp times and worse lung function at 4 days post-surgery. Lung function at twelve weeks, and adverse event rates were otherwise not different between groups. Conventional sternotomy was found to be

more cost-effective. MAVRIC findings contradict those from other trials.^{17,18}

Strengths and limitations

1 2

BMJ Open

2	
3	
4	
5	
6	
7	
/	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
22	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
40 49	
50	
51	
52	
53	
54	
55	
56	
57	
57 58	
59	
60	

321	This is the largest single trial to have compared minimally invasive sternotomy to conventional
322	median sternotomy for AVR. A recent Cochrane review identified 511 patients from 7 previous
323	RCTs. ⁵ In MAVRIC, the mini-sternotomy technique divided only the manubrium and is therefore less
324	invasive than other minimally invasive techniques. The trial was undertaken by three experienced
325	minimally invasive surgeons who were expert at both techniques. Patients were blinded to group
326	allocation until two days following index surgery, reducing the likelihood of bias. The trial recruited a
327	significant proportion of eligible patients; 274/313 (86%), with few requiring conversion to
328	conventional sternotomy, increasing the likelihood that the trial findings are generalisable. A further
329	strength was the detailed health economic evaluation; this has not been performed previously.
330	The trial had some limitations, including the single centre design. This will tend to have biased
331	treatment effect estimates away from the null, which is at odds with our observed effect. There
332	were no significant levels of protocol non-adherence, with no effect on the main trial finding. The
333	event rate for the primary outcome, was much lower than expected at 17%; nationally red cell
334	transfusion rates following valve surgery are 46·4%. ¹⁹ In our pre-trial audit, 30% of mini-sternotomy
335	patients received a red cell transfusion. We attribute the observed transfusion rate in MAVRIC to the
336	restrictive red cell transfusion threshold applied; this followed evidence at the time of trial design.
337	The consultant (expert) led nature of the trial interventions is also likely to have reduced the need
338	for transfusions post-operatively and to have biased trial results towards the null.
339	Clinical importance
340	MAVRIC contributes important evidence to the minimally invasive AVR evidence base, summarised

341 in a Cochrane review.⁵ MAVRIC demonstrated longer cross-clamp and bypass times with the

342 manubrium-limited mini-sternotomy, attributed to known differences between the interventions.

Minimally-invasive techniques in MAVRIC required a number of surgical steps to be performed with

3 344 the aortic clamp in place (drain insertion and pacing wire insertion for example), meaning cross-

⁰ 345 clamp and bypass were longer. This is not an absolute requirement in other minimally invasive

14

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open

346	approaches; for example, where the incision is extended into the body of the sternum, or where
347	rapid deployment valves are used, there are no differences in cross clamp and bypass times. ⁵
348	The size of MAVRIC and event rate prevents formal comparison of adverse events between the
349	groups, of note is the difference in stroke rate; this would benefit from exploration in a future trial.
350	The cost-effectiveness plane indicates that conventional surgery is less costly and more beneficial
351	than minimally-invasive surgery; contact with healthcare professionals was greater in the mini
352	group, although there was no clear pattern of use. Wide confidence intervals mean that differences
353	are imprecise. MAVRIC does not support the use of funds to expand AVR via manubrium-limited
354	mini-sternotomy practice.
355	MAVRIC, the world's largest RCT at low risk of bias, found no additional clinical benefit of minimally
356	invasive AVR. Results are in agreement with the findings of a Cochrane review of trials that have
357	evaluated mini-sternotomy AVR. ⁵ This information should be disseminated to patients, clinicians and
358	commissioners to inform decisions about AVR surgery including commissioning.
359	
360	

2		
3 4	361	Role of funding source
5 6	362	This work was supported by the NIHR Research for Patient Benefit Programme (grant number PB-
7 8 9	363	PG-1112-29035). GJM is supported by the British Heart Foundation (CH/12/1/29419) and the NIHR
9 10 11	364	Leicester Biomedical Research Centre.
12 13 14	365	The views and opinions expressed are those of the authors and do not necessarily reflect those of
15 16	366	the National Institute for Health Research (NIHR) Research for Patient Benefit Programme, the
17 18 19	367	National Health Service or the Department of Health and Social Care.
20 21	368	Declaration of Interests
22 23 24	369	Helen C Hancock (HCH): None
25 26	370	Rebecca H Maier (RHM): None
27 28 29	371	Adetayo S Kasim (ASK): None
30 31 32	372	James M Mason (JMM): None
33 34	373	Gavin J Murphy (GJM) declares research grant funding from Zimmer Biomet for a trial of blood
35 36 37	374	transfusion.
38 39	375	Andrew T Goodwin (ATG): None
40 41 42	376	W Andrew Owens (WAO): None Enoch F Akowuah (EFA): None
43 44 45	377	Enoch F Akowuah (EFA): None
46 47	378	Authors contributions
48 49	379	EFA, HCH, RHM, and JMM and GJM designed the trial, and sought funding. EFA, ATG and WAO
50 51 52	380	recruited patients to the trial and performed surgery. ASK conducted the statistical analysis and
53 54	381	JMM conducted the health economic analysis. All authors contributed to the final manuscript.
55 56 57	382	Acknowledgements
57 58 59	383	We are grateful to the patients who agreed to take part in the MAVRIC trial. This trial would not
60	384	have been possible without the support of all staff in the Cardiothoracic Services in The James Cook

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

BMJ Open

University Hospital. We would like to thank Heather Robinson and Jonathan Broughton for their

assistance with recruitment, data collection and data entry. We would like to thank the team at the

Clinical Trials Unit, including Jennifer Wilkinson, Andrew Thorpe, Leanne Marsay and Catherine Frost

for their work in managing the trial and its data.

Data Sharing Statement

s stu., Anonymised data from this study may be available to the scientific community subject to

appropriate ethical approval. Requests for data should be directed to the senior author.

Table 1 – Baseline Characteristics

5	393			
6	595		Mini-sternotomy group	Conventional sternotomy
7				group
8			(n=135)	(n=135)
9		Baseline characteristics		
10		Age: (years)		
11		Mean ± SD	69·3 ± 9·3	68·7 ± 8·4
12		Range	43 - 85	39 - 88
13		Gender: n (%)		
14		Male	78 (57·8)	87 (64·4)
15		Female	57 (42·2)	48 (35·6)
16		Ethnicity: n (%)		
17		White British	135 (100)	135 (100)
18		Body Mass Index (kg.m ⁻²)		
10		Mean <u>+</u> SD	30.5 ± 5.6	30.4 ± 6.1
		Range (Min – Max)	19.0 - 45.4	19·3 - 52·0
20		EuroSCORE: Mean <u>+</u> SD (Min-Max)		
21		Logistic	5·2 ± 3·5 (1·5 - 29·5)	5·1 ± 3·5 (1·5 - 21·0)
22		II – Mean	1·5 ± 1·1 (0·5 - 10·2)	1·5 ± 1·2 (0·5 - 10·0)
23		Diagnosis echocardiogram: n (%)		
24		Regurgitation	3 (2·2)	8 (5·9)
25		Stenosis	132 (97·8)	127 (94·1)
26		NYHA class: n (%)		
27			24 (17·8)	18 (13·3)
28		II	68 (50·4)	66 (48·9)
29			40 (29.6)	46 (34·1)
30		IV	3 (2·2)	5 (3·7)
31		*Haemoglobin prior to randomisation: g/dl		
32		Mean <u>+</u> SD	137·9 ± 14·3	137·1 ± 16·1
		Range (Min – Max)	97 -173	90 -175
33		Surgery type: n (%)	111 (02 2)	112 (02 C)
34		Elective	111 (82·2)	112 (82·6)
35		In-house urgent	24 (17·8)	23 (17·4)
36		*One nationt had a baseline hemoglohin (Hh) of 05	g/l at randomization which had fa	llan ta 92 immadiataly prior ta

*One patient had a baseline hemoglobin (Hb) of 95 g/L at randomization, which had fallen to 83 immediately prior to surgery. This Hb drop was not identified until after surgery and the patient continued in the trial with their data included in the analyses based on the intention to treat principle.

Table 2 - Red Cell Transfusions*

5 6 7 8		Mini- sternotomy group	Conventional sternotomy group	Odds Ratio (95% Cl; p value)	Risk difference (95% Cl; p value)
9	Red Cell transfusions				
10 11	Post-operatively to 7 days number of patients (%)	23/135 (17·0)	23/135 (17·0)	1·0 (0·5, 2·0; p=0·9052)	0·0 (-0·1, 0·1; p=0·9999)
12	Post-operatively to discharge	34/135 (25·2)	29/135 (21·5)	1.4 (0.7, 2.7)	
13	number of patients (%)				
14	Red Cell Units – post operatively to 7 days				
15	Number of patients	23/135	23/135		
	Mean <u>+</u> SD	1.6 ± 0.7	2·3 ± 1·7		
16	Range (Min – Max)	1 - 3	1 - 9		
17	Red Cell Units – post operatively to				
18	discharge				
19	Number of patients	34/135	29/135		
20	Mean ± SD	2·5 ± 2·5	2.6 ± 2.0		
21	Range (Min – Max)	1 - 13	1 - 11		
22					
23					

*Reprinted from Journal of the American College of Cardiology Vol 73 (19); Hancock HC, Maier RH, Kasim AS, Mason JM,

Murphy GJ, Goodwin AT, Owens WA, Kirmani BH, Akowuah EF. Mini-Sternotomy Versus Conventional Sternotomy for

terez onz

Aortic Valve Replacement. pp. 2491-2492. 2019, with permission from Elsevier.

1					
2					
3					
4					
5					
6					
7			Mini-sternotomy	Conventional	Odds Ratio
8			group	sternotomy	(95% Cl; p
9				group	value)
10		Non-Red Cell transfusions			
11 12		Post-operatively to 7 days number of	6/135 (4·4)	18/135 (13·3)	0·3 (0·1, 0·8;
12		patients (%)			p=0·0137)
14		Post-operatively to discharge	13/135 (9·6)	21/135 (15·6)	0.6 (0.3, 1.2)
15		number of patients (%)			
16		Non-Red Cell Component Units – Post operatively to 7 days			
17		Number of patients	6	18	
18		Mean ± SD	3·2 ± 0·9	4.6 ± 1.6	
19		Range (Min – Max)	2 - 5	1 - 7	
20		Non-red Blood Cell Units – post operatively to			
21		discharge	40	24	
22		Number of patients Mean ± SD	13 4·8 ± 2·3	21 4·9 ± 2·3	
23		Range (Min – Max)	1-8	1 - 12	
24		Non-red Cell Component Transfusions	10	1 12	
25		Post-operatively to 7 days number of	6 (4·4)	18 (13·3)	0·3 (0·1, 0·8)
26		patients (%)			
27		Post-operatively to discharge	13 (9·6)	21 (15·6)	0.6 (0.3, 1.2)
28	200	number of patients (%)			
29 30	399				
30 31					
32					
33					
34					
35					
36					
37					
38					
39					
40					
41					
42					
43					
44					
45					
46 47					
47 48					
48 49					
49 50					
51					
52					
53					
54					
55					
56					
57					
58					
59					
60					
			20		

400 Table 4 - Secondary Outcomes

	Mini-sternotomy group (n=135)	Conventional sternotomy group (n=135)	Mean Difference (95% Cl; p value)
Cardio Pulmonary Bypass time (minutes)			
Mean + SD	82·7 ± 23·5	59·6 ± 15·1	
Range (Min – Max)	41.0 - 199	37.0 -170.0	
Aortic cross clamp time (minutes)			
Mean ± SD	64·1 ± 17·1	46·3 ± 10·7	
Range (Min – Max)	32.0 - 132.0	32.0 -97.0	
Drain losses at 12 hours	52 0 152 0	020070	
Mean ± SD	181·6 ± 138·7	306·9 ± 348·6	-127·7 (-191·7,-63·8; p=0·0001)
Range (Min – Max)	25 - 925	25 - 3000	(-1917,-058, p=00001)
Drain losses at drain removal	254 7 400 4		445.2
Mean ± SD	251·7 ± 198·4	393·7 ± 378·7	-145·3 (-218·1,-72·3; p=0·0001)
Range (Min – Max)	25 - 1425	50 - 3000	
Valve Characteristics			
Valve size: mm	22.1 ± 2.1	10.6± 1.F	
Mean <u>+</u> SD	23.1 ± 2.1	23.6 ± 2.5	
Range (Min – Max)	19.0 - 29.0	19·0 - 31·0	
Valve type: n (%) Biological and sutureless	4 (3.0)	3 (2·2)	
valve			
Biological prosthesis	96 (71.1)	98 (72·6)	
Mechanical prosthesis	35 (25·9)	34 (25·2)	
Valve function			
Mean Gradient			
Baseline			
n	111*	110*	
Mean ± SD	47·9± 15·7	47·7 ± 20·2	0·2 (-4·6,5·0)
Min - Max	10-93	8-110	
6 weeks	400*	1054	
n	120*	126*	a a b b
Mean ± SD	15·7 ± 5·5	15·7 ± 5·8	0·5** (-1·0,2·1)
Min - Max	6-33	4-34	(-1.0,2.1)
Peak Gradient	0.55	TUT	
Baseline			
	125*	124*	
n Mean ± SD	82·3 ± 25·9	124* 77·1 ± 29·1	5.2
iviedíl I SD	02°3 ± 23°3	11.1 7 72.1	(-1.7,2.3)
Min - Max	16-152	8-173	(17,23)
6 weeks	130*	130*	
n Moon + SD	29·9 ± 10·5	29·7 ± 10·8	-0·3**
Mean ± SD	73.3 I 10.2	73.1 I 10.9	(-2.9,2.3)
Min - Max	12-62	11-61	(-2 3,2-3)
* It was not possible to quantify valve **After adjusting for randomisation fa			
Aortic Valve Regurgitation Nil/trivial			
n/n (%)	109/134* (81·3)	109/130* (83·8)	218/264 (82·6)
Mild n/n (%)	19/134* (14·2)	18/130* (13·9)	37/264 (14·0)
Moderate			
n/n (%) Severe	5/134* (3·7)	2/130* (1.5)	7/264 (2·7)
JEVELE			

	n/n (%) was not possible to record valve				2/264	(0·8)
01 Tak	ole 5 - Cost-effectivenes				surgery	
	Model	Incremental cost (95%Cl)	Incremental QALYs (95%CI)	ICER (95%CI)	p1	p²
1	Multiple imputation,	508	-0.007	Dominated ³	0.058	0.05
_	covariate adjusted*	(-202 to 1217)	(-0.016 to 0.002)			
2	Multiple imputation, unadjusted	859 (-116 to 1833)	-0·008 (-0·018 to 0·003)	Dominated	0.023	0.02
	Complete case, covariate	630	-0.007	Dominated	0.013	0.01
3	adjusted ⁴	(25 to 1224)	(-0·016 to 0·002)			
	Complete case,	544	-0.009	Dominated	0.027	0.02
4	unadjusted	(-99 to 1142)	(-0·02 to 0·002)			

3	403	References	
4 5			
6	404		
7	405	1. Blue Book Online. The Society for Cardiothoracic Surgery in Great Britain & Ireland	
8	406	http://bluebook.scts.org/# (accessed 23 rd July, 2018).	
9	407	2. Leontyev S, Walther T, Borger MA, et al. Aortic Valve Replacement in Octogenarians: Ut	lity
10	408	of Risk Stratification With EuroSCORE. Ann Thorac Surg 2009; 87: 1440–5.	
11	409	3. Phan K, Xie A, Di Eusanio M, Yan TD. The Collaborative Research (CORE) Group. Meta-	
12	410	Analysis of Minimally Invasive Versus Conventional Sternotomy for Aortic Valve	
13	411	Replacement. <i>Ann Thorac Surg</i> 2014; 98 : 1499–511.	
14 15	412	4. Ghanta RK, Lapar DJ, Kern JA, et al. Minimally invasive aortic valve replacement provides	5
16	413	equivalent outcomes at reduced cost compared with conventional aortic valve replacem	ient:
17	414	A real-world multi-institutional analysis. J Thorac Cardiovasc Surg 2015; 149: 1060–5.	
18	415	5. Kirmani BH, Jones SG, Malaisrie SC, Chung DA, Williams RJ. Limited versus full sternotom	ıy
19	416	for aortic valve replacement. Cochrane Database Syst Rev 2017; 4: CD011793.	
20	417	6. Fujita B, Ensminger S, Bauer T, et al; GARY Executive Board. Trends in practice and outco	omes
21	418	from 2011 to 2015 for surgical aortic valve replacement: an update from the German Ac	ortic
22	419	Valve Registry on 42,776 patients. Eur J Cardiothorac Surg. 2018; 53: 552–559.	
23	420	7. Lehmann S, Merk DR, Etz CD, et al. Minimally invasive aortic valve replacement: the Leip	ozig
24 25	421	experience. Ann Cardiothorac Surg 2015 ; 4: 49–56.	
26	422	8. Johnston DR, Roselli EE. Minimally invasive aortic valve surgery: Cleveland Clinic Experie	nce.
27	423	Ann Cardiothorac Surg 2015; 4 : 140–147.	
28	424	9. Patel NN, Avlonitis VS, Jones HE, Reevesw BC, Sterne JA, Murphy GJ. Indications for red	
29	425	blood cell transfusion in cardiac surgery: a systematic review and meta-analysis. Lancet	
30	426	Haem 2015; 12 : e543–53.	
31	427	10. Chen QH, Wang HL, Liu L, Shao J, Yu J, Zheng RQ. Effects of restrictive red blood cell	
32	428	transfusion on the prognoses of adult patients undergoing cardiac surgery: a meta-analy	/sis
33 24	429	of randomized controlled trials. Crit Care 2018; 22: 142.	
34 35	430	11. Pagano D, Milojevic M, Meestersa MI, et al. The Task Force on Patient Blood Manageme	nt
36	431	for Adult Cardiac Surgery of the European Association for Cardio-Thoracic Surgery (EACT	S)
37	432	and the European Association of Cardiothoracic Anaesthesiology (EACTA). EACTS/EACTA	1
38	433	Guidelines on patient blood management for adult cardiac surgery. Eur J Cardio-Thorac	Surg
39	434	2018; 53 : 79–111.	-
40	435	12. Dixon JR. The International Conference on Harmonization Good Clinical Practice guidelir	ie.
41	436	ICH GCP Qual Assur 1998; 6: 65–74.	
42	437	13. Akowuah E, Goodwin AT, Owens WA, et al. Manubrium-limited ministernotomy versus	
43 44	438	conventional sternotomy for aortic valve replacement (MAVRIC): study protocol for a	
44	439	randomised controlled trial.	
46	440	https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-016-1768-4 Trials 201	7;
47	441	18 : 46.	
48	442	14. NICE. Guide to the methods of Technology Appraisal. London, National Institute for Hea	lth
49	443	and Care Excellence, 2013.	
50	444	15. NHS Reference Costs 2015-16. London: Department of Health, 2016.	
51	445	16. Curtis L, Burns A. Unit costs of health and social care 2015. Canterbury: the University of	Ē
52 53	446	Kent, 2015.	
55 54	447	17. Aris A, Camara ML, Montiel J Delgado LJ, Galan J, Litvan H. Ministernotomy versus media	an
55	448	sternotomy for aortic valve replacement: a prospective, randomized study. Ann Thor Su	rg
56	449	1999; 67 : 1583–7.	
57	450	18. Moustafa MA, Abdelsamad AA, Zakaria G, Omarah MM. Minimal vs median sternotomy	for
58	451	aortic valve replacement. Asian Cardiovasc Thorac Annals 2007; 15: 472–5.	
59			
60			

1 2 3 4 5 6 7 8 9 10 11 12 13 14	452 453 454 455 456 457 458 459 460	 National Comparative Audit of Blood Transfusion http://hospital.blood.co.uk/media/26859/nca- 2011_use_of_blood_in_adult_cardiac_surgery_report.pdf (accessed 23rd July, 2018). Higgins JPT, Sterne JAC, Savović J, et al. A revised tool for assessing risk of bias in randomized trials In: Chandler J, McKenzie J, Boutron I, Welch V (editors). Cochrane Methods. <i>Cochrane Database Syst Rev</i> 2016; 10: CD201601. Brown ML, McKellar SH, Sundt TM, Schaff HV. Ministernotomy versus conventional sternotomy for aortic valve replacement: a cochranceand meta-analysis. <i>J Thorac Cardiovasc Surg</i> 2009; 137: 670–79.
 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 		
37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60		

to beet teries only

1 2 3	
5 4 5 6	MAVRIC Trial Figures
7 8 9	Figure 1 – CONSORT Diagram Figure 2 - Cost-effectiveness plane: mini-sternotomy vs. conventional surgery (cost/QALY)
10 11 12	
13 14 15	
16 17 18	
19 20 21	
22 23 24 25	
25 26 27 28	
29 30 31	
32 33 34	
35 36 37	
38 39 40	
41 42 43	
44 45 46	
47 48 49	
50 51 52 53	
53 54 55 56	
50 57 58 59	
60	Page 1 of 3

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Figure 1 – CONSORT Diagram





Figure 2 - Cost-effectiveness plane: mini-sternotomy vs. conventional surgery (cost/QALY)



Appendix

Study Investigators: trial site, trial unit. Statistics, health economics, committees	2
Table 1-Eligibilty criteria	3
Figure 1- recruitment	4
Table 2- Conversion from mini-sternotomy to conventional sternotomy	5
Table 3- Number of operations by surgeon	6
Figure 2- Haemoglobin profiles	6
Table 4- Analgesic use	7
Table 4- Adverse Events	8
Table 6- Health status, resource use and cost (complete cases)	9

60

Study Investigators: trial site, trials unit, statistics, health economics, committees

Trial Site

The James Cook University Hospital, South Tees Hospitals NHS Foundation Trust, Middlesbrough, United Kingdom

Investigators

- Mr Enoch Akowuah (Chief Investigator)
- Mr Andrew Goodwin (co-Investigator)
- Professor W Andrew Owens (co-Investigator)

Research Team

- Heather Robinson
- Jonathan Broughton
- Dr Khalid Khan

Clinical Trials Unit

Durham Clinical Trials Unit, Durham University; now Newcastle Clinical Trials Unit, Newcastle University

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Investigators

- Professor Helen Hancock (co-Investigator)
- Rebecca Maier (co-Investigator)

Research Team

- Andrew Thorpe
- Jennifer Wilkinson
- Dr Leanne Marsay

Statistics

Statistics Group, Wolfson Research Institute for Health and Wellbeing, Durham University

Investigator

Dr Adetayo Kasim (co-Investigator)

Health Economics

Durham Clinical Trials Unit, Durham University; now University of Warwick

Investigator

• Professor James Mason (co-Investigator)

Committees

Data Monitoring Committee Membership

- Mr Graham Cooper (Chair)
- Mr Heyman Luckraz
- Professor Chris Rogers

Trial Steering Committee Membership

- Mr Sukumaran Nair (Chair until Sep 2014)
- Professor Gavin Murphy (Acting Chair Oct 2014 to June 2015)
- Mr Peter Braidley (Chair, from July 2015)
- Mr Paul Modi
- Mr Brendan Ellis

Table 1 - Eligibility criteria

Inclusion Criteria

- Aged 18 years or older at the time of consent
- Requiring first-time, non-emergency, isolated Aortic Valve Replacement surgery
- Able and willing to provide written informed consent


Exclusion Criteria

- requiring concomitant cardiac procedure(s) including redo surgery, emergency or salvage surgery,
- only conventional median sternotomy indicated,
- haemoglobin level < 90g/L,
- pregnant*,
- currently participating in another interventional clinical trial,
- previous cardiac surgery,
- are unable to stop currently prescribed treatment affecting clotting (e·g·, heparin, warfarin), **
- a history of thrombophilia, thrombocytopenia or other haematological conditions that would affect participation in the trial as determined by one of the three operating surgeons,
- infective endocarditis,
- prevented from having red blood cells and blood products according to a system of beliefs (e·g· -HKRØKW:LWQHVVHV
- having any other medical, psychiatric and or social reason as determined by the consenting surgeon that precludes participation.

* in women of child bearing age (18 ± 50) a pregnancy test was be performed within 14 days of surgery prior to randomisation.

**for patients in both trial arms, pre-operative antiplatelet drugs (including clopidogrel and ticagrelor), and anticoagulants (including warfarin and heparin) were discontinued 5 days prior to surgery. These drugs were restarted following surgery at the discretion of the clinical team. The exception to this was aspirin, which was stopped 5 days prior to surgery where possible, however continuation until the day of surgery did not exclude a patient from the trial.

Figure 1 - Recruitment






Table 2 - Conversion from mini-sternotomy to conventional sternotomy

Reason for conversion	Number of patients	Details
Anesthetic emergency	2	 Patient became unstable as they were transferred into theatre ar dropped ± required conventional to re-stabilise Anaphylactic reaction on induction needing CPR. Operation cancelled, patient taken to ITU. Widespread rash. Decision ma following morning to proceed to AVR (via full sternotomy)
Difficult vascular access (venous or arterial)	9	 Venous Femoral vessels unsuitable for cannulation Poor venous drainage Unable to pass venous dilators Unable to insert pipe. Resistance felt, no back flow of blood. Fe cannulation abandoned Impossible to dilate femoral vein. Despite re-wiring, guide wire coiling within pelvic venous system
		 Arterial Difficulties cannulating femoral artery leading to haemodynam instability Poor access, unable to clamp aorta Severe calcification of ascending aorta Difficult access; aorta displaced to the left. Body habitus limite access
Intra-operative complications	5	 Bleeding from aortotomy site Bleeding Intra-operative decision to performed bypass graft to LAD Post implant TOE showed small paravalvular leak and bleeding aortotomy incision Mild/moderate paravalvar leak on TOE. Required valve re-imp
TOTAL	16	

Table 3 - Number of operations by Surgeon

	Mini-sternotomy group n=patients (%)	Conventional sternotomy group n=patients (%)	Total n=patients (%)
Consultant Surgeon A	58 (43.0)	58 (430)	116 (43.0)
Consultant Surgeon B	43 (31.9)	35 (25.9)	78 (28.9)
Consultant Surgeon C	34 (25.1)	42 (31.1)	76 (28.1)

Figure 2 - Hemaglobin Profiles




Table 4 - Analgesic use

Medication	Mini-sternotomy Group (135 patients) n = patients (%)	Conventional Sternotomy Group (135 patients) n = patients (%)	Total (270 patients) n = patients (%)
Analgesic use at baseline	- F	- F	F (, , ,
Buprenorphine patch	3 (2.2)	1 (0.7)	4 (1.5)
Codeine Phosphate	4(3.0)	3 (0.7)	7 (2.6)
		. ,	. ,
Dihydrocodeine Tartrate	0 (0.0)	1 (0.7)	1 (0.4)
Durogesic patch	0	1 (0.7)	1 (0.4)
Fentanyl	1 (0.7)	0 (0.0)	1 (0.4)
Gabapentin	1 (0.7)	0 (0.0)	1 (0.4)
		. ,	
Morphine Sulfate	0.0	1 (0.7)	1 (0.4)
Naxoproxen	1 (0.7)	0 (0.0)	1 (0.4)
Paracetamol	13 (9.6)	8 (5.9)	21 (7.8)
Tramadol Hydrochloride	0 (0.0)	2 (1.5)	2 (0.7)
At least one med at baseline	16 (11.9)	12 (8.9)	28 (10.4)
Analgesic use at day 2			
Buprenorphine patch	1 (0.7)	0 (0.0)	1(0.4)
Codeine Phosphate	18 (13.3)	16 (11.9)	34 (12.6)
			· · · ·
Dihydrocodeine Tartrate	4 (3.0)	6 (4.4)	10 (3.7)
Fentanyl	1 (0.7)	0 (0.0)	1 (0.4)
Gabapentin	1 (0.7)	0 (0.0)	1 (0.4)
Morphine Sulfate	13 (9.6)	13 (9.6)	26 (9.6)
		· · · · ·	
Oramorph	1 (0.7)	1 (0.7)	2 (0.7)
Paracetamol	94 (69.6)	80 (59.3)	174 (64-4)
Pregabalin	1 (0.7)	0 (0.0)	1(0.1)
Tramadol Hydrochloride	7 (5.2)	5 (3.7)	12(4.4)
At least one med at day 2	99 (73·3)	86 (63·7)	12 (4·4) 185 (68·5)
Analgesic use at day 3			
	1 (0 7)	0(0,0)	1 (0 4)
Buprenorphine patch	1 (0.7)	0(0.0)	1(0.4)
Codeine Phosphate	14 (10.4)	21 (15.6)	35 (13.0)
Dihydrocodeine Tartrate	4 (3.0)	7 (5.2)	11 (4.1)
Fentanyl	0 (0.0)	1 (0.7)	1 (0.4)
		. ,	
Gabapentin	1 (0.7)	1 (0.7)	2 (0.7)
Ibuprofen	0	1 (0.7)	1 (0.4)
Morphine Sulfate	6 (4.4)	1 (0.7)	7 (2.6)
Nefopam Hydrochloride		1(0,7) 1(0.7)	1(0.4)
Oramorph	0	3 (2.2)	3 (1.1)
Paracetamol	89 (65.9)	99 (73.3)	188 (69.6)
Pregabalin	1 (0.7)	0 (0.0)	1 (0.4)
Tramadol Hydrochloride	8 (5.9)	$3(2\cdot 2)$	11(0.1) 11(4.1)
At least one med at day 3	90 (66·7)	101 (74·8)	191 (70·7)
Analgesic use at Day 4			
Buprenorphine patch	1 (0.7)	0 (0.0)	1 (0.4)
Codeine Phosphate	15 (11.1)	15 (11.1)	30 (11.1)
Dihydrocodeine Tartrate	4 (3.0)	9 (6.7)	13 (4.8)
Fentanyl	1 (0.7)	1 (0.7)	2 (0.7)
Gabapentin	1(0.7)	1(0,7) 1(0.7)	2 (0.7)
Ibuprofen	0 (0.0)	1 (0.7)	1 (0.4)
Paracetamol	86 (63.7)	75 (55.6)	161 (59.6)
Morphine Sulfate	1 (0.7)	2(1.5)	3 (1.1)
Pregabalin	1(0.7)	0(0.0)	1(0.4)
		· · ·	
Tramadol Hydrochloride	3 (2.2)	3 (2.2)	6 (2.2)
At least one med at day 4	88 (65-2)	81 (60•0)	169 (62.6)
Analgesic use at Week 6			
Buprenorphine Patch	3(2.2)	0(0.0)	3(1.1)
Codeine Phosphate	7(5.1)	5(3.7)	12(4.5)
Dihydrocodeine Tartrate	1(0.7)	3(2·2)	4(1.5)
Fentanyl	1(0.7)	0(0.0)	1(0.4)
Gabapentin	2(1.5)	1(0.7)	3(1.1)
Ibuprofen	0(0.0)	1(0.7)	1(0.4)
Morphine Sulfate	0(0.0)	1(0,7)	1(0.4) 1(0.4)
1		· · · · ·	
Paracetamol	35(25.9)	38(28.1)	73(27.0)
Pregabalin	1(0.7)	0(0.0)	1(0.4)
Tramadol Hydrochloride	2(1.5)	2(1.5)	4(1.5)
At least one med at week 6	41(30.4)	41(30·4)	82(30.4)
Analgesic use at Week 12			
Buprenorphine Patch	3(2.2)	0(0.0)	$3(1 \cdot 1)$
Codeine Phosphate	7(5.2)	4(3.0)	11(4.1)
Coucine i nospilate	/(3·2)	4(3.0)	11(4.1)

BMJ Open

2				
3	Dihyrocodeine Tartrate	0(0.0)	1(0.7)	1(0.4)
4	Gabapentin	2(1.5)	0(0.0)	2(0.7)
E	Ibuprofen	1(0.7)	0(0.0)	1(0.4)
5	Morphine Sulfate	1(0.7)	1(0.7)	2(0.7)
6	Naproxen	1(0.7)	0(0.0)	1(0.4)
7	Paracetamol	19(14.1)	20(14.8)	39(14.4)
8	Tramadol Hydrochloride	1(0.7)	1(0.7)	2(0.7)
-	At least one med at week 12	23(17.0)	22(16.3)	45(16.7)
9		- ()	()	()

tor peer teriew only

BMJ Open

Table 5 - Adverse Events

Death 0 In hospital 0/135 (0-0) 0/135 (0-1) 0/270 (0-0) Stroke 12 weeks 2/135 (1-5) 2/213 (1-5) 4/270 (1-5) Transient Exchangic 4/135 (0-0) 1/135 (0-7) 4/270 (1-5) Transient Exchangic 4/135 (0-0) 1/135 (0-7) 4/270 (1-5) Transient Exchangic 4/135 (0-2) 1/135 (0-7) 4/270 (1-5) Rend Tailure 1 1/135 (0-7) 4/270 (1-5) Taila Arrhythmias 1/135 (1-3) 1/135 (0-7) 4/270 (1-5) Traila Arrhythmias 1/135 (1-5) 2/135 (1-5) 4/270 (1-5) Taila Arrhythmias 2/135 (1-5) 2/135 (1-5) 4/270 (1-5) Tenospital 5/135 (2-3) 1/135 (0-7) 5/270 (1-9) Arrial Arrhythmias 2/135 (1-5) 2/135 (1-5) 4/270 (1-5) Tenospital 5/135 (2-3) 1/135 (0-7) 5/270 (1-9) Prevecks 2/135 (1-5) 2/135 (1-5) 2/270 (0-6) Thospital 0/135 (0-0) 2/135 (1-5) 2/270 (0-6) Pulmonary Embolism	Adverse Event	Mini-sternotomy Group n = patients (%)	Conventional Sternotomy Group n = patients (%)	Total n = patients (%)
12 weeks $2/135(1.5)$ $2/135(1.5)$ $4/270(1.5)$ Stroke In hospital $3/135(3.0)$ $1/135(0.7)$ $4/270(1.5)$ 12 weeks $4/135(3.0)$ $1/135(0.7)$ $4/270(1.5)$ Transient Ischaemic Attack In hospital $0/135(0.0)$ $1/135(0.7)$ $1/270(0.4)$ 12 weeks $3/135(2.2)$ $1/135(0.7)$ $4/270(1.5)$ Renal failure In hospital $4/135(2.3)$ $0/135(0.0)$ $4/270(1.5)$ 12 weeks $4/135(2.3)$ $0/135(0.0)$ $4/270(1.5)$ $2/270(1.5)$ Renal failure In hospital $4/135(2.3)$ $0/135(0.7)$ $5/270(1.9)$ Atrial Arrhythmias In hospital $51/135(37.8)$ $42/135(31.1)$ $93/270(34.4)$ I2 weeks $61/135(45.2)$ $51/135(37.8)$ $4/270(1.5)$ $4/270(1.5)$ Ventricular Arrhythmias In hospital $2/135(1.5)$ $2/135(1.5)$ $4/270(1.5)$ I2 weeks $2/135(1.5)$ $2/135(1.5)$ $2/135(1.5)$ $2/270(1.5)$ I2 weeks $9/135(0.0)$ $0/135(0.0)$	Death			
Stroke (1)<	In hospital	0/135 (0.0)	0/135 (0.0)	0/270 (0.0)
Stroke In hospital 3/135 (3.0) 1/135 (0.7) 4/270 (1.5) 12 weeks 4/135 (3.0) 1/135 (0.7) 5/270 (1.9) Transient Ischaemic Attack In hospital 0/135 (0.0) 1/135 (0.7) 1/270 (0.4) 12 weeks 3/135 (2.2) 1/135 (0.7) 4/270 (1.5) Renal failure In hospital 4/135 (2.3) 0/135 (0.0) 4/270 (1.5) Atrial Arrhythmias In hospital 5/1/35 (37.8) 42/135 (31.1) 93/270 (34.4) In hospital 51/135 (37.8) 42/135 (31.1) 93/270 (1.4) Atrial Arrhythmias In hospital 51/135 (1.5) 4/270 (1.5) In hospital 51/135 (1.5) 2/135 (1.5) 4/270 (1.5) In hospital 51/135 (1.5) 2/135 (1.5) 4/270 (1.5) In hospital 2/135 (1.5) 2/135 (1.5) 4/270 (1.5) I2 weeks 2/135 (1.5) 2/135 (1.5) 4/270 (1.5) I2 weeks 2/135 (1.5) 2/135 (1.5) 4/270 (1.5) I2 weeks 9/135 (6.7) 6/135 (4.4) 15/270 (5.6) Pulmonary Embolism In hospital 0/135 (0.0) 0/135 (0.0) <td>12 weeks</td> <td>2/135 (1.5)</td> <td>2/135 (1.5)</td> <td>4/270 (1.5)</td>	12 weeks	2/135 (1.5)	2/135 (1.5)	4/270 (1.5)
12 weeks $4/135$ (3·0) $1/135$ (0·7) $5/270$ (1·9) Transient Ischaemic Attack In hospital $0/135$ (0·0) $1/135$ (0·7) $1/270$ (0·4) 12 weeks $3/135$ (2·2) $1/135$ (0·7) $4/270$ (1·5) Renal failure In hospital $4/135$ (2·3) $0/135$ (0·0) $4/270$ (1·5) 12 weeks $4/135$ (2·3) $0/135$ (0·0) $4/270$ (1·5) 12 weeks $4/135$ (2·3) $0/135$ (0·0) $4/270$ (1·5) 12 weeks $4/135$ (2·3) $1/135$ (0·7) $5/270$ (1·9) Atrial Arrhythmias In hospital $51/135$ (37·8) $42/135$ (31·1) $93/270$ (34·4) 12 weeks $61/135$ (45·2) $51/135$ (37·8) $112/270$ (41·5) 12 weeks $2/135$ (1·5) $2/135$ (1·5) $4/270$ (1·5) 12 weeks $2/135$ (1·5) $2/135$ (1·5) $4/270$ (1·5) 12 weeks $9/135$ (6·7) $6/135$ (4·4) $15/270$ (5·6) Pulmonary Embolism In hospital $0/135$ (0·0) $0/135$ (0·0) $0/270$ (0·0) 12 weeks $0/135$ (0·0) $2/135$ (1·5) $2/270$ (0·7) Chest Infection <t< td=""><td>Stroke</td><td></td><td></td><td></td></t<>	Stroke			
Transient Ischaemic Attack In hospital 0/135 (0·0) 1/135 (0·7) 1/270 (0·4) 12 weeks 3/135 (2·2) 1/135 (0·7) 4/270 (1·5) Renal failure In hospital 4/135 (2·3) 0/135 (0·0) 4/270 (1·5) In hospital 4/135 (2·3) 0/135 (0·0) 4/270 (1·5) Atrial Arrhythmias In hospital 51/135 (37·8) 42/135 (31·1) 93/270 (34·4) 12 weeks 61/135 (45·2) 51/135 (37·8) 112/270 (41·5) Ventricular Arrhythmias In hospital 2/135 (1·5) 2/135 (1·5) 4/270 (1·5) In hospital 2/135 (1·5) 2/135 (1·5) 4/270 (1·5) 12/270 (41·5) I2 weeks 2/135 (1·5) 2/135 (1·5) 4/270 (1·5) 12/270 (1·5) 12 weeks 9/135 (0·7) 5/270 (1·9) 12/270 (1·5) 12/270 (1·5) 12/270 (1·5) Pericardial Effusion In hospital 4/135 (2·3) 1/135 (0·7) 5/270 (1·9) 12/270 (5·6) Pulmonary Embolism In hospital 0/135 (0·0) 0/135 (0·0) 0/270 (0·0) 12/270 (0·7) 2/270 (0·7) Chest Infection In hospital 7/135 (5·2)	In hospital	3/135 (3.0)	1/135 (0.7)	4/270 (1.5)
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	12 weeks	4/135 (3.0)	1/135 (0.7)	5/270 (1.9)
12 weeks $3/135$ (2·2) $1/135$ (0·7) $4/270$ (1·5) Renal failure In hospital $4/135$ (2·3) $0/135$ (0·0) $4/270$ (1·5) 12 weeks $4/135$ (2·3) $0/135$ (0·0) $4/270$ (1·5) 12 weeks $4/135$ (2·3) $1/135$ (0·7) $5/270$ (1·9) Atrial Arrhythmias In hospital $51/135$ (37·8) $42/135$ (31·1) $93/270$ (34·4) 12 weeks $61/135$ (45·2) $51/135$ (37·8) $112/270$ (4·5) Ventricular Arrhythmias $2/135$ (1·5) $2/135$ (1·5) $4/270$ (1·5) 12 weeks $9/135$ (0·7) $6/135$ (0·7) $5/270$ (1·9) 12 weeks $9/135$ (0·0) $0/135$ (0·0) $0/270$ (0·0) 12 weeks $0/135$ (0·0) $2/135$ (1·5) $2/270$ (0·7) Chest Infection In hospital $7/135$ (5·2) $10/135$ (7·4) $17/270$ (6·3) 12 weeks $18/135$ (13·3) $26/135$	Transient Ischaemic Attack			
Renal failure In hospital $4/135$ (2·3) $0/135$ (0·0) $4/270$ (1·5) 12 weeks $4/135$ (2·3) $1/135$ (0·7) $5/270$ (1·9) Atrial Arrhythmias In hospital $51/135$ (37·8) $42/135$ (31·1) $93/270$ (34·4) 12 weeks $61/135$ (45·2) $51/135$ (37·8) $12/270$ (34·4) 12 weeks $61/135$ (45·2) $51/135$ (37·8) $112/270$ (34·4) 12 weeks $61/135$ (45·2) $51/135$ (37·8) $112/270$ (34·4) 12 weeks $61/135$ (45·2) $51/135$ (37·8) $112/270$ (34·4) 12 weeks $2/135$ (1·5) $2/135$ (1·5) $4/270$ (1·5) 12 weeks $2/135$ (1·5) $2/135$ (1·5) $4/270$ (1·5) 12 weeks $9/135$ (0·7) $5/270$ (1·9) 12 weeks $9/135$ (0·7) $5/270$ (1·9) 12 weeks $9/135$ (0·0) $0/135$ (0·0) $0/270$ (0·0) $0/270$ (0·0) $0/270$ (0·0) 12 weeks $0/135$ (0·0) $0/135$ (0·0) $0/135$ (1·5) $2/270$ (0·7) Chest Infection In hospital $7/135$ (5·2) $10/135$ (7·4) $17/270$ (6·3) 12 weeks $18/135$ (13·3)	In hospital	0/135 (0.0)	1/135 (0.7)	1/270 (0.4)
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	12 weeks	3/135 (2.2)	1/135 (0.7)	4/270 (1.5)
12 weeks $4/135$ (2·3) $1/135$ (0·7) $5/270$ (1·9) Atrial Arrhythmias In hospital $51/135$ (37·8) $42/135$ (31·1) $93/270$ (34·4) 12 weeks $61/135$ (45·2) $51/135$ (37·8) $112/270$ (41·5) Ventricular Arrhythmias In hospital $2/135$ (1·5) $2/135$ (1·5) $4/270$ (1·5) 12 weeks $9/135$ (0·7) $5/270$ (1·9) 12 weeks $9/135$ (0·7) $5/270$ (1·9) 12 weeks $9/135$ (0·7) $6/135$ (4·4) $15/270$ (5·6) Pulmonary Embolism In hospital $0/135$ (0·0) $0/135$ (0·0) $0/270$ (0·0) 12 weeks $0/135$ (0·0) $2/135$ (1·5) $2/270$ (0·7) $2/270$ (0·7) Chest Infection In hospital $7/135$ (5·2) $10/135$ (7·4) $17/270$ (6·3) 12 weeks $18/135$ (13·3) $26/135$ (19·3) $44/270$ (16·3) Sternal wound infection IIII IIIIIIIIIIIIIIIIIIIIIIII	Renal failure			
Atrial Arrhythmias 51/135 (37.8) $42/135 (31.1)$ $93/270 (34.4)$ 12 weeks 61/135 (45.2) $51/135 (37.8)$ $112/270 (41.5)$ Ventricular Arrhythmias 112/270 (41.5) $2/135 (1.5)$ $2/135 (1.5)$ $4/270 (1.5)$ 12 weeks 2/135 (1.5) $2/135 (1.5)$ $4/270 (1.5)$ $4/270 (1.5)$ 12 weeks 2/135 (1.5) $2/135 (1.5)$ $4/270 (1.5)$ Pericardial Effusion 112/270 (5.6) $4/270 (1.5)$ In hospital $4/135 (2.3)$ $1/135 (0.7)$ $5/270 (1.9)$ 12 weeks $9/135 (6.7)$ $6/135 (4.4)$ $15/270 (5.6)$ Pulmonary Embolism 1 $0/135 (0.0)$ $0/135 (0.0)$ $0/270 (0.0)$ 12 weeks $0/135 (0.0)$ $0/135 (0.0)$ $0/270 (0.7)$ $0.70 (0.7)$ Chest Infection 1 $10/135 (5.2)$ $10/135 (7.4)$ $17/270 (6.3)$ 12 weeks $18/135 (13.3)$ $26/135 (19.3)$ $44/270 (16.3)$ Sternal wound infection 1 $10/145 (19.3)$ $10/142 (10.6)$ $10/142 (10.6)$	In hospital	4/135 (2.3)	0/135 (0.0)	4/270 (1.5)
Atrial Arrhythmias $51/135 (37.8)$ $42/135 (31.1)$ $93/270 (34.4)$ 12 weeks $61/135 (45.2)$ $51/135 (37.8)$ $112/270 (41.5)$ Ventricular Arrhythmias $112/270 (41.5)$ $2/135 (1.5)$ $2/135 (1.5)$ $4/270 (1.5)$ 12 weeks $2/135 (1.5)$ $2/135 (1.5)$ $4/270 (1.5)$ $4/270 (1.5)$ 12 weeks $2/135 (1.5)$ $2/135 (1.5)$ $4/270 (1.5)$ 12 weeks $2/135 (1.5)$ $2/135 (1.5)$ $4/270 (1.5)$ Pericardial Effusion $1135 (0.7)$ $5/270 (1.9)$ 12 weeks $9/135 (6.7)$ $6/135 (4.4)$ $15/270 (5.6)$ Pulmonary Embolism $11 hospital$ $0/135 (0.0)$ $0/135 (0.0)$ $0/270 (0.0)$ 12 weeks $0/135 (0.0)$ $0/135 (1.5)$ $2/270 (0.7)$ $2/270 (0.7)$ Chest Infection $11 hospital$ $7/135 (5.2)$ $10/135 (7.4)$ $17/270 (6.3)$ 12 weeks $18/135 (13.3)$ $26/135 (19.3)$ $44/270 (16.3)$ Sternal wound infection $110 + 10 + 10 + 10 + 10 + 10 + 10 + 10 $				
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Atrial Arrhythmias			· · · ·
12 weeks $61/135 (45 \cdot 2)$ $51/135 (37 \cdot 8)$ $112/270 (41 \cdot 5)$ Ventricular Arrhythmias $2/135 (1 \cdot 5)$ $2/135 (1 \cdot 5)$ $4/270 (1 \cdot 5)$ 12 weeks $2/135 (1 \cdot 5)$ $2/135 (1 \cdot 5)$ $4/270 (1 \cdot 5)$ 12 weeks $2/135 (1 \cdot 5)$ $2/135 (1 \cdot 5)$ $4/270 (1 \cdot 5)$ Pericardial Effusion $1/135 (2 \cdot 3)$ $1/135 (0 \cdot 7)$ $5/270 (1 \cdot 9)$ 12 weeks $9/135 (6 \cdot 7)$ $6/135 (4 \cdot 4)$ $15/270 (5 \cdot 6)$ Pulmonary Embolism $11/135 (0 \cdot 7)$ $5/270 (1 \cdot 9)$ In hospital $0/135 (0 \cdot 0)$ $0/135 (0 \cdot 0)$ $0/270 (0 \cdot 0)$ 12 weeks $0/135 (0 \cdot 0)$ $0/135 (0 \cdot 0)$ $0/270 (0 \cdot 0)$ 12 weeks $0/135 (0 \cdot 0)$ $2/135 (1 \cdot 5)$ $2/270 (0 \cdot 7)$ Chest Infection $11/135 (5 \cdot 2)$ $10/135 (7 \cdot 4)$ $17/270 (6 \cdot 3)$ 12 weeks $18/135 (13 \cdot 3)$ $26/135 (19 \cdot 3)$ $44/270 (16 \cdot 3)$ Sternal wound infection $110/145 (19 \cdot 4)$ $10/145 (19 \cdot 3)$ $10/145 (19 \cdot 3)$		51/135 (37.8)	42/135 (31.1)	93/270 (34.4)
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$				
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		01/155 (15 2)	51/155 (57 6)	112/2/0 (11 5)
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		2/135 (1.5)	2/135 (1.5)	4/270(1.5)
Pericardial Effusion 4/135 (2·3) 1/135 (0·7) 5/270 (1·9) 12 weeks 9/135 (6·7) 6/135 (4·4) 15/270 (5·6) Pulmonary Embolism 0/135 (0·0) 0/135 (0·0) 0/270 (0·0) 12 weeks 0/135 (0·0) 0/135 (0·0) 0/270 (0·0) 12 weeks 0/135 (0·0) 2/135 (1·5) 2/270 (0·7) Chest Infection 7/135 (5·2) 10/135 (7·4) 17/270 (6·3) 12 weeks 18/135 (13·3) 26/135 (19·3) 44/270 (16·3) Sternal wound infection 10/10000000000000000000000000000000000				
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		2/155 (1.5)	2/155 (1.5)	4/270 (1.5)
12 weeks 9/135 (6·7) 6/135 (4·4) 15/270 (5·6) Pulmonary Embolism In hospital 0/135 (0·0) 0/135 (0·0) 0/270 (0·0) 12 weeks 0/135 (0·0) 0/135 (0·0) 0/270 (0·0) 2/270 (0·7) Chest Infection 7/135 (5·2) 10/135 (7·4) 17/270 (6·3) 12 weeks 18/135 (13·3) 26/135 (19·3) 44/270 (16·3) Sternal wound infection 1100 (10.5) 100 (10.5)		4/125 (2.2)	1/125 (0 7)	5/270 (1.0)
Pulmonary Embolism 0/135 (0.0) 0/135 (0.0) 0/270 (0.0) 12 weeks 0/135 (0.0) 2/135 (1.5) 2/270 (0.7) Chest Infection 7/135 (5.2) 10/135 (7.4) 17/270 (6.3) 12 weeks 18/135 (13.3) 26/135 (19.3) 44/270 (16.3)				
In hospital 0/135 (0·0) 0/135 (0·0) 0/270 (0·0) 12 weeks 0/135 (0·0) 2/135 (1·5) 2/270 (0·7) Chest Infection 7/135 (5·2) 10/135 (7·4) 17/270 (6·3) 12 weeks 18/135 (13·3) 26/135 (19·3) 44/270 (16·3) Sternal wound infection 11000 (1000) 1000 (1000) 1000 (1000)		9/135 (6.7)	6/155 (4.4)	15/2/0 (5.6)
12 weeks 0/135 (0.0) 2/135 (1.5) 2/270 (0.7) Chest Infection 7/135 (5.2) 10/135 (7.4) 17/270 (6.3) 12 weeks 18/135 (13.3) 26/135 (19.3) 44/270 (16.3) Sternal wound infection 7/100 (0.10) 10/100 (0.10) 10/100 (0.10)		0/125 (0.0)	0/125 (0,0)	
Chest Infection 7/135 (5·2) 10/135 (7·4) 17/270 (6·3) 12 weeks 18/135 (13·3) 26/135 (19·3) 44/270 (16·3) Sternal wound infection 10/100 (1000) 10/100 (1000) 10/100 (1000)				
In hospital 7/135 (5·2) 10/135 (7·4) 17/270 (6·3) 12 weeks 18/135 (13·3) 26/135 (19·3) 44/270 (16·3) Sternal wound infection 44/270 (16·3) 44/270 (16·3)		0/135 (0.0)	2/135 (1.5)	2/2/0 (0.7)
12 weeks 18/135 (13·3) 26/135 (19·3) 44/270 (16·3) Sternal wound infection 44/270 (16·3) 44/270 (16·3)				
Sternal wound infection				
		18/135 (13.3)	26/135 (19.3)	44/270 (16.3)
In hospital 3/135 (2·2) 1/135 (0·7) 4/270 (1·5) 12 weeks 11/135 (8·1) 3/135 (2·2) 14/270 (5·2) Re-operation for bleeding 3/135 (2·2) 5/135 (3·7) 8/270 (3·0)				
12 weeks 11/135 (8-1) 3/135 (2-2) 14/270 (5-2) Re-operation for bleeding 3/135 (2-2) 5/135 (3-7) 8/270 (3-0)		3/135 (2.2)	1/135 (0.7)	
Re-operation for bleeding 3/135 (2·2) 5/135 (3·7) 8/270 (3·0)		11/135 (8.1)	3/135 (2·2)	14/270 (5.2)
	Re-operation for bleeding	3/135 (2·2)	5/135 (3.7)	8/270 (3.0)

3
4
5
6
7
7 8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
35 36
36 37
37 38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56

Table 6 - Health status, resource use and cost (complete cases)

	Conv	entional [C	[]	Mini-sternotomy [M]			[M]-[C] ¹	
	mean	(SD)	Ν	mean	(SD)	Ν	mean	(95%CI)
Health status ²								
EQ-5D Baseline	0.764	0.245	130	0.763	0.235	128	-0.001	(-0.060 to 0.057
EQ-5D 2 days	0.349	0.349	133	0.353	0.291	128	0.004	(-0.074 to 0.082
EQ-5D 6 weeks	0.798	0.194	118	0.751	0.221	112	-0.048	(-0.101 to 0.006
EQ-5D 12 weeks	0.838	0.207	124	0.782	0.248	127	-0.056	(-0.112 to 0.001
EQ-5D AUC (0-12 weeks)	0.162	0.041	105	0.153	0.040	98	-0.009	(-0.020 to 0.002
Resource use								
Index Admission								
Length of stay (d) ³	8.26	4.28	135	9.29	7.88	135	1.03	(-0.48 to 2.54)
CICU (d)	1.21	0.99	135	1.61	5.52	135	0.39	(-0.55 to 1.34)
HDU (d)	1.27	1.52	135	1.60	1.75	135	0.33	(-0.07 to 0.72)
Cardiac ward (d)	5.67	3.52	135	5.70	3.18	135	0.03	(-0.77 to 0.83)
Stroke ward (d)	0.03	0.34	135	0.11	$1 \cdot 00$	135	0.08	(-0·10 to 0·26)
Time in first surgery (h)	2.24	0.51	135	2.98	0.69	135	0.74	(0.60 to 0.89)
Time in further surgery $(h)^4$	0.08	0.34	135	0.03	0.17	135	-0.05	(-0.11 to 0.02)
Time in surgery (h) 4	2.32	0.63	135	3.01	0.71	135	0.69	(0.53 to 0.85)
RBC $(u)^4$	0.59	1.45	135	0.55	1.28	135	-0.04	(-0·37 to 0·28)
$FFP(u)^4$	0.57	1.43	135	0.34	1.21	135	-0.23	(-0.55 to 0.09)
Platelets (u) ⁴	0.22	0.64	135	0.12	0.46	135	-0.10	(-0·24 to 0·03)
Cryoprecipitate (u) ⁴	0.01	0.09	135	0.00	0.00	135	-0.01	(-0.02 to 0.01)
Post discharge contacts								
GP surgery	1.47	1.52	129	1.40	1.32	131	-0.07	(-0·41 to 0·28)
GP home	0.09	0.32	129	0.19	0.56	131	0.10	(-0.01 to 0.21)
GP telephone	0.12	0.45	129	0.15	0.63	131	0.03	(-0·10 to 0·16)
Nurse surgery	1.38	2.56	129	2.07	3.54	131	0.69	(-0.06 to 1.44)
Nurse home	0.43	1.30	129	0.56	1.87	131	0.12	(-0.27 to 0.51)
Nurse telephone	0.05	0.25	129	0.04	0.26	131	-0.01	(-0.07 to 0.05)
Outpatient hospital	0.40	0.78	129	0.57	1.98	131	0.17	(-0.20 to 0.53)
Inpatient hospital	0.30	0.68	129	0.27	0.60	131	-0.03	(-0.18 to 0.13)
Inpatient hospital (d)	2.09	7.79	129	1.09	2.69	131	-1.00	(-2·42 to 0·42)
Total Contacts	4.29	3.53	129	5.47	4.90	131	1.18	(0·14 to 2·22)
Cost ⁵								
Cost of index admission	7674	2055	135	8815	4517	135	1140	(303 to 1977)
Cost post discharge	824	2485	129	547	925	131	-277	(-734 to 180)
Cost	8527	3558	129	9274	4542	131	746	(-245 to 1737)

1 OLS regression-estimated means and 95% confidence intervals

2 EQ-5D-3L index score

3 Length stay by ward does not sum to length of stay due to theatre and transit time, and rounding

4 Item includes index and post-discharge usage

5 Resource items were costed using national reference costs except for the index procedures which were costed by South Tees Hospitals NHS Foundation Trust



CONSORT 2010 checklist of information to include when reporting a randomised trial*

Section/Topic	ltem No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	2
Introduction			
Background and	2a	Scientific background and explanation of rationale	3
objectives	2b	Specific objectives or hypotheses	3,5
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	3,4,5
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	NA
Participants	4a	Eligibility criteria for participants	4 (+appendix)
	4b	Settings and locations where the data were collected	4
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were	
		actually administered	4,5
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they	
		were assessed	6
	6b	Any changes to trial outcomes after the trial commenced, with reasons	NA
Sample size	7a	How sample size was determined	7
	7b	When applicable, explanation of any interim analyses and stopping guidelines	NA
Randomisation:			
Sequence	8a	Method used to generate the random allocation sequence	2,4
generation	8b	Type of randomisation; details of any restriction (such as blocking and block size)	2,4

Page	41	of	42
------	----	----	----

BMJ Open

mechanism Implementation Blinding	10	Whe reperted the render allocation economic who enrolled participants, and who economic participants to	2,4
	10	When represented the render allocation accurates whe enrolled participants, and who accigned participants to	
Blinding		Who generated the random allocation sequence, who enrolled participants, and who assigned participants to	
Blinding		interventions	4
	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	2,4,5
	11b	If relevant, description of the similarity of interventions	4 7
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	7
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	7
Results			—
Participant flow (a	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and	
diagram is strongly		were analysed for the primary outcome	9
recommended)	13b	For each group, losses and exclusions after randomisation, together with reasons	9,17
Recruitment	14a	Dates defining the periods of recruitment and follow-up	9
	14b	Why the trial ended or was stopped	9
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	Table
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	Table
Outcomes and	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its	—
estimation		precision (such as 95% confidence interval)	9, Ta
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	Table
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing	
		pre-specified from exploratory	12
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	11
Discussion			
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	13
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	13,14

BMJ Open

Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	13,14
Other information			
Registration	23	Registration number and name of trial registry	1,4
Protocol	24	Where the full trial protocol can be accessed, if available	4
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	4, 15

*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

For beer review only For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

BMJ Open

Mini-sternotomy versus conventional sternotomy for aortic valve replacement: a randomised controlled trial

Journal:	BMJ Open
Manuscript ID	bmjopen-2020-041398.R1
Article Type:	Original research
Date Submitted by the Author:	26-Oct-2020
Complete List of Authors:	Hancock, Helen; Newcastle University, Newcastle Clinical Trials Unit Maier, Rebecca; Newcastle University, Newcastle Clinical Trials Unit Kasim, Adetayo; Durham University, Wolfson Research Institute for Health and Wellbeing Mason, James; University of Warwick, Warwick Medical School Murphy, Gavin; University of Leicester, Department of Cardiovascular Sciences and NIHR Leicester Biomedical Research Unit in Cardiovascular Medicine Goodwin, Andrew; South Tees Hospitals NHS Foundation Trust, James Cook Hospital Owens, W; South Tees Hospitals NHS Foundation Trust, James Cook Hospital Akowuah, Enoch; South Tees Hospitals NHS Foundation Trust, James Cook Hospital
Primary Subject Heading :	Surgery
Secondary Subject Heading:	Evidence based practice, Intensive care, Research methods, Cardiovascular medicine
Keywords:	HEALTH ECONOMICS, Adult intensive & critical care < INTENSIVE & CRITICAL CARE, Adult surgery < SURGERY, Cardiac surgery < SURGERY, Clinical trials < THERAPEUTICS

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

reliez oni

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Title

Mini-sternotomy versus conventional sternotomy for aortic valve replacement: a randomised controlled trial

Authors

Helen C Hancock, PhD¹, Rebecca H Maier¹, MSc, Adetayo S Kasim, PhD², James M Mason, DPhil³,

Gavin J. Murphy, FRCS (C.Th)⁴, Andrew T Goodwin, FRCS (C.Th)⁵, W Andrew Owens, FRCS (C.Th)⁵,

Enoch F Akowuah, FRCS (C.Th)⁵.

1. Newcastle Clinical Trials Unit, Newcastle University; 2. Durham Research Methods Centre,

Durham University; 3. Warwick Medical School, University of Warwick; 4. Department of

Cardiovascular Sciences, University of Leicester; 5. Cardiothoracic Services, South Tees Hospitals NHS

Foundation Trust, The James Cook University Hospital.

Word count 3343

Corresponding author: Enoch Akowuah

Cardiothoracic Services, South Tees Hospitals NHS Foundation Trust, The James Cook University Hospital.Marton Road, Middlesbrough. TS3 4BW. E mail Enoch.Akowuah@nhs.net

Abstract

Objective

To compare clinical and health economic outcomes after manubrium-limited mini-sternotomy

(intervention) and conventional median sternotomy (usual care)

Design

A single blind, randomised controlled trial.

Setting

Single centre UK National Health Service tertiary hospital

Participants

Adult patients undergoing aortic valve replacement surgery

Interventions

Intervention was manubrium-limited mini-sternotomy performed using a 5-7cm midline incision.

Usual care was median sternotomy performed using a midline incision from the sternal notch to the

xiphisternum.

Primary and secondary outcome measures

The primary outcome was the proportion of patients who received a red cell transfusion postoperatively and within 7 days of index surgery. Secondary outcomes included proportion of patients receiving a non-red cell blood component transfusion and number of units transfused within 7 days and during index hospital stay, quality of life and cost effectiveness analyses.

Results

270 patients were randomised, received surgery and contributed to the intention to treat analysis. No difference between mini and conventional sternotomy in red-cell transfusion within 7 days was found; 23/135 patients in each arm received a transfusion, odds ratio 1.0 (95% CI: 0.5, 2.0) and risk difference 0.0 (95% CI: -0.1, 0.1). Mini-sternotomy reduced chest drain losses (mean 181.6ml (SD 138·7) vs conventional, mean 306·9ml (SD 348·6)); this did not reduce red-cell transfusions. Mean valve size and post-operative valve function were comparable between mini-sternotomy and conventional groups; 23mm vs 24mm, and 6/134 moderate or severe aortic regurgitation vs 3/130, respectively. Mini-sternotomy resulted in longer bypass (82·7 minutes (SD 23·5) vs 59·6 minutes (SD 15·1)) and cross clamp times (64·1 minutes (SD 17·1) vs 46·3 minutes (SD 10·7)). Conventional sternotomy was more cost-effective with only a 5·8% probability of mini-sternotomy being cost-effective at a willingness to pay of £20,000/QALY.

Conclusions

AVR via mini-sternotomy did not reduce red blood cell transfusion within 7 days following surgery when compared to conventional sternotomy.

Clinical Trials Registry: ISRCTN29567910

Key word: minimally invasive, aortic valve, clinical trial, cardiac surgery, replacement,

ARTICLE SUMMARY

- 1. Large proportion of eligible patients recruited, and all patient randomised contributed to the primary outcome
- 2. Clear protocols for transfusion of blood and blood products with high adherence throughout the trial
- 3. Patients were blinded to group allocation until two days following index surgery, reducing the likelihood of bias.
- 4. First randomised trial to perform detailed health economic evaluation of minimally invasive versus conventional sternotomy

5. The trial was undertaken by three experienced minimally invasive surgeons who were expert at both techniques.

Objectives

Aortic valve replacement (AVR) for severe symptomatic valvular disease is one of the most common cardiac surgical procedures performed worldwide. The current joint guidelines of the American College of Cardiology and American Heart Association (ACC/AHA) and the current European Society of Cardiology guidelines for the management of aortic valve disease, state that surgical AVR is recommended for symptomatic patients with severe aortic stenosis and asymptomatic patients with severe aortic stenosis who meet an indication for AVR when surgical risk is low or intermediate.¹

In the UK, the National adult cardiac cardiac surgery audit published by NICOR (National Institute for Cardiac Outcome Reporting) reported 13,027 procedures for aotic valve disease in the UK from April 2018 to March 2019.² Outcomes are generally excellent with in-hospital observed mortality in the UK of 1.5% for first time elective procedures.³ In low risk patients with a Euroscore 2 of less than 4, a mortality of less than 0.7% was observed in over 15,000 patients undergoing AVR surgery in the UK between 2016 and 2019.²

These results are not observed in all patients; in high risk groups, conventional surgery risks perioperative organ injury and prolonged recovery, with death in up to 31% of patients within 1 year.⁴ Minimally invasive surgery combines the durability of surgical repair with reductions in surgical trauma that should reduce perioperative morbidity. Observational analyses demonstrating reductions in morbidity and resource use^{5,6} may be confounded by multiple sources of bias and are at odds with limited evidence from RCTs that have not shown improved outcomes.⁷ This uncertainty is reflected by variations in uptake internationally.^{8,9,10}

The move towards minimally invasive surgery is also driven by patient perceptions of pain reduction and rapid recovery. However, minimally invasive cardiac surgery is not without risks; limiting access to the heart can result in technically sub-optimal surgery, including concern about the size of the prosthesis that can be inserted, and paravalvular leak rates.

This trial evaluated Manubrium-limited Mini-sternotomy versus Conventional Sternotomy for Aortic Valve Replacement (MAVRIC). We hypothesised that mini-sternotomy would reduce red cell

transfusion rates, a contemporary marker of surgical trauma and indicator of adverse outcomes;¹¹ this has been contested,¹² though the evidence is not conclusive.¹³ An embedded cost effectiveness analysis evaluated whether the intervention was cost effective in a UK National Health Service (NHS) setting.

Patients and Methods Trial Design

MAVRIC was a single centre, single-blind, RCT comparing AVR via manubrium-limited ministernotomy group (intervention) and AVR via conventional sternotomy group (usual care). A NHS Research Ethics Committee approved the trial, which was conducted in accordance with the principles of the International Conference on Harmonisation of Good Clinical Practice.¹⁴ South Tees Hospitals NHS Foundation Trust was the Sponsor and recruiting centre.

Patient Public Involvement

In designing the study, we asked patients their view on what factors may affect whether they took part in the study. This was done in an outpatient setting and via a postal questionnaire. They felt expertise was important. Most patients felt that although the cosmetic benefit of the minimally invasive approach was appealing, they expected some clinical benefit form minimally invasive surgery as well. Importantly most patients said they would accept being blind to the type of surgery they had received for 48 hours after the procedure.

Participants

Patients were eligible if they were aged 18 years or over; required first-time, non-emergency, isolated AVR surgery; and were willing to provide written informed consent. Full details of the eligibility criteria are in the **Supplementary Material**.

Randomisation

Eligible patients were randomised by members of the research team using a 24-hour, central, secure, web-based randomisation system with concealed allocation, managed by the Clinical Trials

Unit; randomisation was in a 1:1 ratio between mini and conventional sternotomy and stratified by baseline logistic EuroSCORE and pre-operative Hemoglobin (Hb).

Interventions

Manubrium-limited mini-sternotomy was performed using a 5-7cm midline skin incision dividing the manubrium from the sternal notch to 1cm below the manubrium-sternal junction. Cardiopulmonary bypass was established with an ascending aortic cannula and percutaneous femoral venous cannulation. Conventional median sternotomy was performed using a midline incision from the sternal notch to the xiphisternum. Key aspects of anaesthesia were standardised, and are detailed in the protocol.¹⁵

Blinding

All patients were blinded to type of sternotomy received until after their day 2 Quality of Life and pain assessments. All patients had trial-specific opaque dressings applied to their sternal wound, and groin before leaving theatre.

Transfusion Protocol

The post-operative period, and trial protocol in relation to red cell and non-red cell transfusion, began on admission to the Cardiothoracic Intensive Care Unit (CICU); it specified that patient's should receive a red cell transfusion if their Hb dropped below 80 g/L; or were bleeding by 400ml/h or more, or were bleeding 100ml/h or more for 4 or more hours with a Hb equal to or greater than 80g/L; or had blood loss with haemodynamic instability irrespective of thromboelastography (TEG) and/or clotting profile results. One unit of red cells was transfused and Hb level checked before transfusing another unit.

Participants received a non-red cell transfusion if both of the following criteria were met: bleeding defined by 400ml/h or more, or blood loss of 100ml/h or more for 4 hours or more; TEG or coagulation guided transfusion indicated.

1	
2 3	Outcomes
4	Outcomes
5 6	All outomes were measured from index surgery.
7 8 9	Primary Outcome
10 11	The primary outcome was the proportion of patients who received a red cell transfusion post-
12 13	operatively and within 7 days of index surgery.
14 15 16	Secondary Outcomes:
17 18	• proportion of patients receiving a red cell transfusion and number of units transfused within
19 20 21	7 days and during index hospital stay;
22 23	• proportion of patients receiving a non-red cell blood component transfusion and number of
24 25 26	units transfused within 7 days and during index hospital stay;
27 28	 volume in chest drains at 6 and 12 hours, and drain removal;
29 30 31	 degree of aortic regurgitation using echocardiogram within 6 weeks;
32 33 34	re-operation rates;
35 36	 conversion to conventional AVR during surgery;
37 38 39	 changes in lung function at 4 days and 6 weeks;
40 41 42	• Quality of life EuroQol (EQ-5D-3L, EQ-VAS) at 2 days, 6 and 12 weeks;
43 44 45	 time patients are deemed 'fit for discharge';
46 47 48	health care utilisation to 12 weeks;
49 50 51	 cost and cost effectiveness analyses;
52 53 54	• adverse events to 12 weeks.
55 56	Statistical Analysis
57 58 59	Audit data had indicated 30% of patients undergoing AVR via conventional sternotomy (15 of 50

patients) received a red cell transfusion compared with 13% of patients (8 of 60 patients)

undergoing AVR via mini-sternotomy. Using Fisher's Exact test, 90% power, 5% alpha, we estimated that 260 patients would be required to detect a 17% reduction in the proportion of patients requiring a red cell transfusion (13% compared with 30%), using a two-sided test. Allowing for loss to follow up, the sample size was increased to 270.

The primary analysis was based on intention-to-treat principles, in accordance with a pre-specified statistical analysis plan.

The primary efficacy analysis was based on a logistic regression model with only group (minimally invasive and conventional) and stratifying factors (baseline logistic EuroSCORE and Hb) as the predictors. Odds ratios and their associated 95% confidence interval are reported in the primary analysis. Sensitivity analysis using alternating logistic regression was performed for the primary endpoint to sensitise for surgeon effects; the odds of receiving a red cell transfusion for two patients treated by the same surgeon was compared to two patients treated by different surgeons.

All analyses of secondary continuous efficacy endpoints at single time points were based on linear models where, if appropriate, a log normal model was fitted to sensitise the linearity assumption. Longitudinal analysis was performed for all endpoints with repeated data over time to investigate changes in trends over the trial period. The trial period was defined as baseline, up to 7 days (post-operative period), 6 week follow-up and 12 week follow-up. All analyses of binary endpoints at a single time point were based on logistic regression. Generalised estimating equation was used to analyse repeated binary data per patient to account for intra-patient correlation.

Further exploratory analysis was conducted to investigate the association between the treatment group and other clinical factors. All analyses were performed using R 3·3·3 (The R Foundation) and SAS 9·4 (SAS Institute Inc).

Economic Evaluation

A prospective economic evaluation applying a NHS perspective, following National Institute for Health and Care Excellence (NICE) reference case guidance,¹⁶ was employed. Health care utilisation

BMJ Open

was captured up to three months following discharge from index surgery. Resource use was valued in 2016 pounds sterling using national sources,^{17,18} and where necessary, local micro-costing (£1=\$1.50). Resources included surgery, transfusions, length of hospital stay (by level of care), complications and further surgery, and community care following discharge.

Mechanisms of missingness within the data were explored and multiple imputation methods were applied to impute missing data and minimise bias, using chained equations and predictive mean matching. Imputation sets were analysed within a bivariate analysis of costs and QALYS, to generate incremental within-trial cost per QALY estimates and credible intervals. Findings were presented on the ICER plane and with Cost-Effectiveness Acceptability Curves, using the net monetary benefit approach.

Imputation was conducted according to good practice guidance.^{19,20} Multiple imputation provides unbiased estimates of treatment effect if data are missing at random (MAR) and the missingness process is adequately characterised : this assumption was explored in the data, for example by using logistic regression for missingness of costs and QALYs against baseline variables.²¹ A regression model was used to generate multiple imputed datasets (or 'draws') for individual treatment groups, where missing values were predicted drawing on predictive covariates. Outcome measures and costs (at each time point) contributed as predictors and imputed variables. Each draw provided a complete dataset, reflecting the distributions and correlations between variables. Predictive mean matching drawn from the five nearest neighbours (knn=5) was used to enhance the plausibility and robustness of imputed values; normality was not assumed. The imputation model used fully conditional (MCMC) methods. Draws were analysed using bivariate regression (see below) within the Stata MI framework, capturing within and between variances for imputed samples.²² After examining the fraction of missing information (FMI) from finite imputation sampling, 20 draws was taken in the final imputation model.

Results Trial Population

MAVRIC recruited to time and target; 313 patients were considered for the trial; 274 patients consented between 20th March 2014 and 25th July 2016. The analysis population was 270 eligible patients; 135 allocated to the AVR via mini-sternotomy group and 135 allocated to the AVR via conventional sternotomy group (**Figure 1.**).

All 270 patients underwent surgery. Sixteen patients required cross-over from minimally-invasive to a conventional sternotomy due to anaesthetic emergency (n=2), difficulties due to vascular access (n=9), and intra-operative complications (n=5); further details and the number of operations performed by surgeon are in the Supplementary Material.

Baseline characteristics were similar between groups (Table 1).

Primary Outcome

There was no difference between groups in relation to the primary outcome (**Table 2**). The proportion of patients receiving a red cell transfusion was 23 of 135 in both groups, Odds ratio 1.0 (95% Cl 0.5, 2.0; p=0.9052) and risk difference of 0.0 (95% Cl -0.1, 0.1; p=0.9999).

Secondary Outcomes

Red cell and non-red cell transfusion

There was no significant difference between groups with respect to any red cell transfusion at discharge (**Table 2**). There was no difference between groups in Hb from baseline to 4 days following index surgery (**Supplementary Material**). There was a statistically significant difference in the proportion of patients receiving any non-red cell transfusion within 7 days of surgery; mini 6/135 versus conventional 18/135, Odds ratio: 0.3 (95% Cl 0.1, 0.8; p=0.0137) (**Table 3**).

Cross clamp time and cardiopulmonary bypass time

Mini-sternotomy resulted in longer Cardio Pulmonary Bypass times; mini group 82·7 minutes (SD 23·5), conventional 59·6 minutes (SD 15·1). Aortic cross clamp times were also longer; mini group 64·1 minutes (SD 17·1), conventional 46·3 minutes (SD 10·7) (**Table 4**).

Chest drain losses

Mini-sternotomy resulted in a 40·8% reduction in chest drain losses at 12 hours, the mini group mean was 181·6ml (SD 138·7), conventional group mean was 306·9ml (SD 348·6); the mean difference was -127·7ml (95% Cl -191·7, -63·8, p=0.0001). At drain removal mean difference was -145·3ml (95% Cl -218·1, -72·3; p=0.0001) (**Table 4**).

Ventilation time

Ventilation time between the groups was similar; 9.6 hours (SD 5.6) in the mini group and 9.8 hours (SD 6.9) in the conventional (**Table 4**).

Intensive care unit length of stay

There was no difference in intensive care unit length of stay between groups (**Supplementary Material**).

Post-operative pain

There was no difference in pain scores between groups; analgesic use is also included to assist interpretation (**Supplementary Material**).

Lung function

There was no difference between groups in lung function at baseline. At 4 days post-surgery, mean Forced Expiratory Volume 1 (FEV1) 1123mls (SD 433) and Forced Vital Capacity, FVC 1479mls (SD 583) were significantly reduced in the mini group, compared to the conventional; FEV1 1321 (SD 524), FVC 1698 (SD 707). Mean differences for FEV1 and FVC were statistically significant at 4 days post-surgery; -171mls (95% CI -265, -77; p=0.0004) and -130mls (95% CI -269, 0; p=0.0498) respectively, after adjusting for baseline FEV1, FVC, and randomisation factors (**Supplementary Material**).

Hospital length of stay

The mean time to patients being fit for hospital discharge following index surgery was similar between groups. The mean post-operative hospital length of stay was 7.4 (SD 7.5, range 3-79) in the mini group, and 6.3 days (SD 3.2, range 3-31) in the conventional (**Supplementary Material**).

Post-operative valve function

The distribution of valve types and valve sizes were similar; mean valve size inserted was 23mm in the mini group and 24mm in the conventional (**Table 4**). Over 70% of patients in each group received a tissue valve, over 25% received a mechanical valve and 2-3% received a sutureless tissue valve. Post operative transthoracic echo showed a similar decrease in mean aortic valve gradient in both groups to 16mmHg; peak gradient decreased to 30mmHg in both groups (**Table 4**). 6/134 patients had moderate or severe aortic regurgitation in the mini group compared to 3/130 in the conventional (**Table 4**).

Adverse events

There were no in-hospital deaths in either group. At 12 weeks follow up, there were 4 deaths; 2 in each arm of the study. Adverse events in each group were broadly similar and within acceptable clinical limits. By 12 weeks, 4/135 patients in the mini-sternotomy group and 1/135 in the conventional group had suffered a stroke (defined as a persistent neurological deficit). Atrial arrhythmias were identified in 61/135 patients in the mini group and 51/135 in the conventional. By 12 weeks, 11/135 patients in the mini group and 3/135 patients in the conventional had a sternal wound infection (**Supplementary Material**).

Quality of Life, Costs and Cost-Effectiveness

Costs during the index admission were significantly greater for the mini group (mini-conventional: mean difference £1140; 95% CI 303, 1977), primarily reflecting the additional cost of theatre time

BMJ Open

(Supplementary Material). Overall costs were not significantly different (mini-conventional: mean difference £746; 95% CI -245, 1737). There was no significant difference in quality of life between groups up to 12 weeks (mini-conventional: mean difference area under curve -0.009 QALYs; 95% CI 0.020, 0.002). Although differences in costs and quality-of-life were not individually significant, the bivariate cost-QALY distribution (combining these two) suggests conventional surgery might be more cost-effective (Figure 2.). In the base-case model, mini was dominated by conventional surgery (due to greater cost and less benefit), with only a 5.8% probability of being cost-effective at a willingness to pay of £20,000/QALY (Table 5).

Sensitivity and Subgroup Analyses

There was no significant surgeon effect; the odds of receiving a red cell transfusion for two patients treated by the same surgeon compared to two patients treated by different surgeons was 1.2 (95% Cl 0.9, 1.6; p=0.1379).

Protocol deviations in respect of cell tranfusions did not affect the results of the primary analysis; excluding these patients produced the same results as those from the intention-to-treat analysis.

Discussion

Main findings

Mini-sternotomy was not superior to conventional sternotomy with respect to red cell transfusion requirements within 7 days of surgery. Analysis of secondary endpoints showed a statistically significant difference in transfusion volumes of non-red cell blood components. Aortic valve size and post-operative function were comparable in the 2 groups. Mini-sternotomy resulted in a relative reduction in chest drain losses however, higher blood loss in the conventional group did not translate into red cell transfusions. Mini patients had substantially longer bypass and cross clamp times and worse lung function at 4 days post-surgery. Lung function at twelve weeks, and adverse event rates were otherwise not different between groups. Conventional sternotomy was found to be more cost-effective. MAVRIC findings contradict those from other trials that pre-date it.^{23,24} Two 100 patient RCTs published since MAVRIC and the systematic review, do not alter the discussion.^{25,26}

Both found no difference in major clinical outcomes, and findings relating to shorter hospital stay in mini-sternotomy; a reduction in bleeding through chest drains, and mean difference in EQ-5D scores at baseline and at 6 weeks²⁵ are consistent with MAVRIC findings.

Strengths and limitations

This is the largest single trial to have compared minimally invasive sternotomy to conventional median sternotomy for AVR. A recent Cochrane review identified 511 patients from 7 previous RCTs.⁷ In MAVRIC, the mini-sternotomy technique divided only the manubrium and is therefore less invasive than other minimally invasive techniques. The trial was undertaken by three experienced minimally invasive surgeons who were expert at both techniques. Patients were blinded to group allocation until two days following index surgery, reducing the likelihood of bias. The trial recruited a significant proportion of eligible patients; 274/313 (86%), with few requiring conversion to conventional sternotomy, increasing the likelihood that the trial findings are generalisable. A further strength was the detailed health economic evaluation; this has not been performed previously. The trial had some limitations, including the single centre design. This will tend to have biased treatment effect estimates away from the null, which is at odds with our observed effect. There were no significant levels of protocol non-adherence, with no effect on the main trial finding. The event rate for the primary outcome, was much lower than expected at 17%; nationally red cell transfusion rates following valve surgery are 46.4%.²⁷ In our pre-trial audit conducted over 5 years, ending 2009, 30% of mini-sternotomy patients received a red cell transfusion. We attribute the observed transfusion rate in MAVRIC to the restrictive red cell transfusion threshold applied; this followed evidence at the time of trial design. The consultant (expert) led nature of the trial interventions is also likely to have reduced the need for transfusions post-operatively and to have biased trial results towards the null.

Clinical importance

MAVRIC contributes important evidence to the minimally invasive AVR evidence base, summarised in a Cochrane review.⁷ MAVRIC demonstrated longer cross-clamp and bypass times with the manubrium-limited mini-sternotomy, attributed to known differences between the interventions. Minimally-invasive techniques in MAVRIC required a number of surgical steps to be performed with the aortic clamp in place (drain insertion and pacing wire insertion for example), meaning crossclamp and bypass were longer. This is not an absolute requirement in other minimally invasive approaches; for example, where the incision is extended into the body of the sternum, or where rapid deployment valves are used, there are no differences in cross clamp and bypass times.⁷ The size of MAVRIC and event rate prevents formal comparison of adverse events between the groups, of note is the difference in stroke rate; this would benefit from exploration in a future trial. The cost-effectiveness plane indicates that conventional surgery is less costly and more beneficial than minimally-invasive surgery; contact with healthcare professionals was greater in the mini group, although there was no clear pattern of use. Wide confidence intervals mean that differences are imprecise. MAVRIC does not support the use of funds to expand AVR via manubrium-limited mini-sternotomy practice.

MAVRIC, the world's largest RCT at low risk of bias, found no additional clinical benefit, in terms of red blood cell transfusion rates of minimally invasive AVR. Results are in agreement with the findings of a Cochrane review of trials that have evaluated mini-sternotomy AVR.⁷ This information should be disseminated to patients, clinicians and commissioners to inform decisions about AVR surgery including commissioning.

Role of funding source

This work was supported by the NIHR Research for Patient Benefit Programme (grant number PB-PG-1112-29035). GJM is supported by the British Heart Foundation (CH/12/1/29419) and the NIHR Leicester Biomedical Research Centre.

The views and opinions expressed are those of the authors and do not necessarily reflect those of the National Institute for Health Research (NIHR) Research for Patient Benefit Programme, the National Health Service or the Department of Health and Social Care.

Declaration of Interests Helen C Hancock (HCH): None

Rebecca H Maier (RHM): None

Adetayo S Kasim (ASK): None

James M Mason (JMM): None

Gavin J Murphy (GJM) declares research grant funding from Zimmer Biomet for a trial of blood transfusion.

Andrew T Goodwin (ATG): None

W Andrew Owens (WAO): None

Enoch F Akowuah (EFA): None

Authors contributions

EFA, HCH, RHM, and JMM and GJM designed the trial, and sought funding. EFA, ATG and WAO recruited patients to the trial and performed surgery. ASK conducted the statistical analysis and JMM conducted the health economic analysis. All authors contributed to the final manuscript.

Acknowledgements

We are grateful to the patients who agreed to take part in the MAVRIC trial. This trial would not have been possible without the support of all staff in the Cardiothoracic Services in The James Cook University Hospital. We would like to thank Heather Robinson and Jonathan Broughton for their

 assistance with recruitment, data collection and data entry. We would like to thank the team at the Clinical Trials Unit, including Jennifer Wilkinson, Andrew Thorpe, Leanne Marsay and Catherine Frost for their work in managing the trial and its data.

Data Sharing Statement

Anonymised data from this study may be available to the scientific community subject to

appropriate ethical approval. Requests for data should be directed to the senior author.

to perteries only

Table 1. Baseline characteristics of participants by group

	Mini-sternotomy group	Conventional sternotomy group
	(n=135)	(n=135)
Baseline characteristics		
Age: (years)		
Mean ± SD	69·3 ± 9·3	68·7 ± 8·4
Range	43 - 85	39 - 88
Gender: n (%)		
Male	78 (57·8)	87 (64·4)
Female	57 (42·2)	48 (35·6)
Ethnicity: n (%)		
White British	135 (100)	135 (100)
Body Mass Index (kg.m ⁻²)		
Mean <u>+</u> SD	30·5 ± 5·6	30.4 ± 6.1
Range (Min – Max)	19.0 - 45.4	19.3 - 52.0
EuroSCORE: Mean + SD (Min-Max)		
Logistic	5·2 ± 3·5 (1·5 - 29·5)	5·1 ± 3·5 (1·5 - 21·0)
II – Mean	1·5 ± 1·1 (0·5 - 10·2)	1·5 ± 1·2 (0·5 - 10·0)
Diagnosis echocardiogram: n (%)		
Regurgitation	3 (2·2)	8 (5·9)
Stenosis	132 (97.8)	127 (94·1)
NYHA class: n (%)		
	24 (17·8)	18 (13·3)
	68 (50·4)	66 (48·9)
III III III III III III III III III II	40 (29.6)	46 (34·1)
IV	3 (2.2)	5 (3.7)
*Haemoglobin prior to randomisation: g/dl		
Mean + SD	137·9 ± 14·3	137.1 ± 16.1
Range (Min – Max)	97 -173	90 -175
Surgery type: n (%)		
Elective	111 (82·2)	112 (82.6)
In-house urgent	24 (17·8)	23 (17·4)
in nouse angent	. ()	- ()

*One patient had a baseline hemoglobin (Hb) of 95 g/L at randomisation, which had fallen to 83 immediately prior to surgery. This Hb drop was not identified until after surgery and the patient continued in the trial with their data included in the analyses based on the intention to treat principle.

Table 2. The number and proportion of patients receiving a Red Cell Transfusion*, and the number of units received, to 7 days and to discharge following index surgery, by group.

	Mini- sternotomy group	Conventional sternotomy group	Odds Ratio (95% Cl; p value)	Risk difference (95% Cl; p value)
Red Cell Transfusions				
Post-operatively to 7 days number of patients (%)	23/135 (17·0)	23/135 (17·0)	1·0 (0·5, 2·0; p=0·9052)	0·0 (-0·1, 0·1; p=0·9999)
Post-operatively to discharge number of patients (%)	34/135 (25·2)	29/135 (21·5)	1.4 (0.7, 2.7)	
Red Cell Units – post operatively to 7 days				
Number of patients	23/135	23/135		
Mean <u>+</u> SD	1·6 ± 0·7	2·3 ± 1·7		
Range (Min – Max)	1 - 3	1 - 9		
Red Cell Units – post operatively to				
discharge				
Number of patients	34/135	29/135		
Mean ± SD	2·5 ± 2·5	2.6 ± 2.0		
Range (Min – Max)	1 - 13	1 - 11		

*Reprinted from Journal of the American College of Cardiology Vol 73 (19); Hancock HC, Maier RH, Kasim AS, Mason JM, Murphy GJ, Goodwin AT, Owens WA, Kirmani BH, Akowuah EF. Mini-Sternotomy Versus Conventional Sternotomy for Aortic Valve Replacement. pp. 2491-2492. 2019²⁸, with permission from Elsevier.

Table 3. The number and proportion of patients receiving a Non-Red Cell Transfusion, and the number of units received, to 7 days and to discharge following index surgery, by group.

	Mini-sternotomy group	Conventional sternotomy group	Odds Ratio (95% Cl; p value)
Non-Red Cell Transfusions			
Post-operatively to 7 days number of patients (%)	6/135 (4·4)	18/135 (13·3)	0·3 (0·1, 0·8; p=0·0137)
Post-operatively to discharge number of patients (%)	13/135 (9·6)	21/135 (15·6)	0.6 (0.3, 1.2)
Non-Red Cell Component Units – Post			
operatively to 7 days			
Number of patients	6	18	
Mean ± SD	3.2 ± 0.9	4·6 ± 1·6	
Range (Min – Max)	2 - 5	1 - 7	
Non-red Blood Cell Units – post operatively to discharge			
Number of patients	13	21	
Mean ± SD	4·8 ± 2·3	4·9 ± 2·3	
Range (Min – Max)	1 - 8	1 - 12	
Non-red Cell Component Transfusions			
Post-operatively to 7 days number of patients (%)	6 (4·4)	18 (13·3)	0·3 (0·1, 0·8)
Post-operatively to discharge number of patients (%)	13 (9·6)	21 (15·6)	0.6 (0.3, 1.2)

Table 4. Outcomes during index hospital stay for cardiopulmonary bypass and aortic cross clamp times, drain losses, valve size and type, and for valve function and regurgitation to 6 weeks by group.

		Mini-sternotomy group (n=135)	Conventional sternotomy group (n=135)	Mean Differen (95% Cl; p valu
Cardio Po (minutes	ulmonary Bypass time :)			
-	Mean <u>+</u> SD	82·7 ± 23·5	59·6 ± 15·1	
		41.0 - 199	37.0 -170.0	
Aortic cr (minutes	oss clamp time			
(initiates	Mean ± SD	64·1 ± 17·1	46·3 ± 10·7	
		32.0 - 132.0	32.0 -97.0	
Dualu las	Range (Min – Max)	52.0 - 152.0	52.0 -97.0	
Drain los	ses at 12 hours	181·6 ± 138·7	306·9 ± 348·6	-127.7
	Mean ± SD	191.0 ± 129.7	500.9 ± 548.0	(-191·7,-63·8 p=0·0001)
	Range (Min – Max)	25 - 925	25 - 3000	p=0 0001)
Drain los	sses at drain removal	25 525	25 5000	
Diamios	Mean ± SD	251·7 ± 198·4	393·7 ± 378·7	-145-3
		2317 1 1984	393.7 1 378.7	(-218.1,-72.3
				p=0.0001)
	Range (Min – Max)	25 - 1425	50 - 3000	- 0 0001)
Valve Ch	aracteristics			
Valve siz				
- 4 C 512	Mean + SD	23·1 ± 2·1	23·6 ± 2·5	
	Range (Min – Max)	19.0 - 29.0	19·0 - 31·0	
Valve typ		13 0 25 0	130 310	
vaive typ	Biological and	4 (3.0)	3 (2·2)	
	-	+ (5.0)	5 (2.2)	
	sutureless Biological prosthosis	96 (71.1)	98 (72.6)	
	Biological prosthesis	96 (71.1)		
	Mechanical prosthesis	35 (25·9)	34 (25·2)	
Valve fui Mean Gr	adient			
Baseline				
	n	111*	110*	
	Mean ± SD	47·9± 15·7	47·7 ± 20·2	0·2 (-4·6,5·0)
	Min - Max	10-93	8-110	
6 weeks				
	n	120*	126*	
	Mean ± SD	15·7 ± 5·5	15·7 ± 5·8	0·5** (-1·0,2·1)
	Min - Max	6-33	4-34	
Peak Gra	dient			
Baseline				
	n	125*	124*	
	Mean ± SD	82·3 ± 25·9	77·1 ± 29·1	5·2 (-1·7,2·3)
	Min Man	16-152	8-173	
6 weeks	Min - Max	10-152		
6 weeks			130*	
6 weeks	n	130*	130* 29.7 + 10.8	_0.2**
6 weeks	n Mean ± SD	130* 29·9 ± 10·5	29·7 ± 10·8	-0·3** (-2·9,2·3)
	n Mean ± SD Min - Max	130* 29·9 ± 10·5 12-62	29·7 ± 10·8 11-61	
**After a Aortic Va	n Mean ± SD Min - Max not possible to quantify va adjusting for randomisatio alve Regurgitation	130* 29·9 ± 10·5 12-62 alve function in all pa	29·7 ± 10·8 11-61 tients	
* It was r **After a Aortic Va	n Mean ± SD Min - Max not possible to quantify va adjusting for randomisatio alve Regurgitation	130* 29·9 ± 10·5 12-62 alve function in all pa on factors and baselin	29·7 ± 10·8 11-61 tients e data	
* It was r **After a	n Mean ± SD Min - Max not possible to quantify va adjusting for randomisatio alve Regurgitation	130* 29·9 ± 10·5 12-62 alve function in all pa	29·7 ± 10·8 11-61 tients	(-2·9,2·3)
* It was r **After a Aortic Va	n Mean ± SD Min - Max not possible to quantify va adjusting for randomisatio alve Regurgitation	130* 29·9 ± 10·5 12-62 alve function in all pa on factors and baselin	29·7 ± 10·8 11-61 tients e data	(-2·9,2·3)
* It was r **After a Aortic Va Nil/trivia	n Mean ± SD Min - Max not possible to quantify va adjusting for randomisatio alve Regurgitation	130* 29·9 ± 10·5 12-62 alve function in all pa on factors and baselin	29·7 ± 10·8 11-61 tients e data	
* It was r **After a Aortic Va Nil/trivia	n Mean ± SD Min - Max not possible to quantify va adjusting for randomisation alve Regurgitation al n/n (%) n/n (%)	130* 29·9 ± 10·5 12-62 alve function in all pa on factors and baselin 109/134* (81·3)	29·7 ± 10·8 11-61 tients e data 109/130* (83·8)	(-2·9,2·3) 218/264 (82·6

Severe n/n (%) * It was not possible to record	1/134* (0·8) d valve regurgitation in all patients	1/130* (0.8)	2/264 (0·8)

Table 5. Cost-effectiveness, cost/QALY (£): mini-sternotomy versus conventional surgery

- 1 probability cost-effective or net monetary benefit if willing to pay £20,000/QALY
- 2 probability cost-effective or net monetary benefit if willing to pay £30,000/QALY
- 3 dominance indicates average costs were less and average benefit greater for conventional surgery

4 regression estimates adjusted for trial stratifying covariates and baseline EQ-5D

	Model	Incremental cost (95%CI)	Incremental QALYs (95%CI)	ICER (95%CI)	p¹	p²
1	Multiple imputation,	508	-0.002	Dominated ³	0.058	0.052
	covariate adjusted ⁴ Multiple imputation,	(-202 to 1217) 859	(-0·016 to 0·002) -0·008			
2	unadjusted	(-116 to 1833)	(-0·018 to 0·003)	Dominated	0.023	0.021
3	Complete case, covariate adjusted ⁴	630	-0.007	Dominated	0.013	0.011
		(25 to 1224)	(-0·016 to 0·002)			
4	Complete case,	544	-0.009	Dominated	0.027	0.022
4	unadjusted	(-99 to 1142)	(-0·02 to 0·002)			

References

- 1. Matiasz R, Rigolin VH. 2017 Focused Update for Management of Patients With Valvular Heart Disease: Summary of New Recommendations. Journal of the American Heart Association 2018: https://doi.org/10.1161/JAHA.117.007596
- 2. NATIONAL ADULT CARDIAC SURGERY AUDIT 2020 Summary Report (2016/17-2018/19 data)
- Blue Book Online. The Society for Cardiothoracic Surgery in Great Britain & Ireland http://bluebook.scts.org/# (accessed 23rd July, 2018).
- 4. Leontyev S, Walther T, Borger MA, et al. Aortic Valve Replacement in Octogenarians: Utility of Risk Stratification With EuroSCORE. *Ann Thorac Surg* 2009; **87**: 1440–5.
- Phan K, Xie A, Di Eusanio M, Yan TD. The Collaborative Research (CORE) Group. Meta-Analysis of Minimally Invasive Versus Conventional Sternotomy for Aortic Valve Replacement. Ann Thorac Surg 2014; 98: 1499–511.
- 6. Ghanta RK, Lapar DJ, Kern JA, et al. Minimally invasive aortic valve replacement provides equivalent outcomes at reduced cost compared with conventional aortic valve replacement: A real-world multi-institutional analysis. *J Thorac Cardiovasc Surg* 2015; **149**: 1060–5.
- 7. Kirmani BH, Jones SG, Malaisrie SC, Chung DA, Williams RJ. Limited versus full sternotomy for aortic valve replacement. *Cochrane Database Syst Rev* **2017**; 4: CD011793.
- 8. Fujita B, Ensminger S, Bauer T, et al; GARY Executive Board. Trends in practice and outcomes from 2011 to 2015 for surgical aortic valve replacement: an update from the German Aortic Valve Registry on 42,776 patients. *Eur J Cardiothorac Surg.* **2018**; 53: 552–559.
- 9. Lehmann S, Merk DR, Etz CD, et al. Minimally invasive aortic valve replacement: the Leipzig experience. *Ann Cardiothorac Surg* **2015**; 4: 49–56.
- 10. Johnston DR, Roselli EE. Minimally invasive aortic valve surgery: Cleveland Clinic Experience. *Ann Cardiothorac Surg* 2015; **4**: 140–147.
- 11. Patel NN, Avlonitis VS, Jones HE, Reevesw BC, Sterne JA, Murphy GJ. Indications for red blood cell transfusion in cardiac surgery: a systematic review and meta-analysis. *Lancet Haem* 2015; **12**: e543–53.
- 12. Chen QH, Wang HL, Liu L, Shao J, Yu J, Zheng RQ. Effects of restrictive red blood cell transfusion on the prognoses of adult patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials. *Crit Care* 2018; **22**: 142.
- Pagano D, Milojevic M, Meestersa MI, et al. The Task Force on Patient Blood Management for Adult Cardiac Surgery of the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Cardiothoracic Anaesthesiology (EACTA). EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery. *Eur J Cardio-Thorac Surg* 2018; 53: 79–111.
- 14. Dixon JR. The International Conference on Harmonization Good Clinical Practice guideline. ICH GCP *Qual Assur* 1998; **6**: 65–74.
- 15. Akowuah E, Goodwin AT, Owens WA, et al. Manubrium-limited ministernotomy versus conventional sternotomy for aortic valve replacement (MAVRIC): study protocol for a randomised controlled trial.

https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-016-1768-4 Trials 2017; 18: 46.


- 16. NICE. Guide to the methods of Technology Appraisal. London, National Institute for Health and Care Excellence, 2013.
- 17. NHS Reference Costs 2015-16. London: Department of Health, 2016.
- 18. Curtis L, Burns A. Unit costs of health and social care 2015. Canterbury: the University of Kent, 2015.


- 19. Sterne Jonathan A C, White Ian R, Carlin John B, Spratt Michael, Royston Patrick, Kenward Michael G et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls BMJ 2009; 338 :b2393
- 20. White Ian R, Horton Nicholas J, Carpenter James, Pocock Stuart J. Strategy for intention to treat analysis in randomised trials with missing outcome data BMJ 2011; 342 :d40
- Faria R, Gomes M, Epstein D, White IR. A Guide to Handling Missing Data in Cost-Effectiveness Analysis Conducted Within Randomised Controlled Trials. PharmacoEconomics (2014) 32:1157–1170
- 22. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011 Feb 20;30(4):377-99
- 23. Aris A, Camara ML, Montiel J Delgado LJ, Galan J, Litvan H. Ministernotomy versus median sternotomy for aortic valve replacement: a prospective, randomized study. *Ann Thor Surg* 1999; **67**: 1583–7.
- 24. Moustafa MA, Abdelsamad AA, Zakaria G, Omarah MM. Minimal vs median sternotomy for aortic valve replacement. *Asian Cardiovasc Thorac Annals* 2007; **15**: 472–5.
- Rodríguez-Caulo EA, ArantzaGuzón A, Otero-Forero J, José Mataró M, Sánchez-Espín G, Porras C, Villaescusa J.M, Melero-Tejedor JM, Jiménez-Navarro M. Quality of life after ministernotomy versus full sternotomy aortic valve replacement doi.org/10.1053/j.semtcvs.2020.07.013
- 26. Vukovic P.M, Milojevic P, Stojanovic I, Micovic S, Zivkovic I, Miodrag P, Milicic M, Milacic P, Milojevic M, Bojic M. The role of ministernotomy in aortic valve surgery-A prospective randomized study doi: 10.1111/jocs.14053. Epub 2019 Apr 24.
- National Comparative Audit of Blood Transfusion http://hospital.blood.co.uk/media/26859/nca-2011_use_of_blood_in_adult_cardiac_surgery_ report.pdf (accessed 23rd July, 2018).
- 28. Hancock HC, Maier RH, Kasim AS, Mason JM, Murphy GJ, Goodwin AT, Owens WA, Kirmani BH, Akowuah EF. Mini-Sternotomy Versus Conventional Sternotomy for Aortic Valve Replacement. Journal of the American College of Cardiology 2019 Vol 73; 2491-2492

Figure 1. CONSORT Diagram. Flow of participants through trial.

Figure 2. Cost-effectiveness plane, cost/QALY (£): mini-sternotomy versus conventional surgery.

.εν(





Supplementary Material

Study Investigators: trial site, clinical trials unit, statistics, health economics, committees	2
Table 1. Eligibility criteria	3
Figure 1. Trial recruitment by month	4
Table 2. Conversion from mini-sternotomy to conventional sternotomy	5
Table 3. Number of operations by Consultant Surgeon	6
Figure 2. Haemoglobin profiles	7
Table 4. Analgesic use and Pain scores	8-9
Table 5. Adverse Events	10
Table 6. Health status, resource use and cost (complete cases)	11
Table 7. ICU Length of Stay, Fitness for Discharge and Hospital Length of Stay	12
Table 8. Pulmonary function tests	13

r function tests

Study Investigators: trial site, trials unit, statistics, health economics, committees

Trial Site

1 2 3

4 5

6

7

8 9

10

11

12

13 14

15

16

17

18 19

20

21

22

23

24 25

26

27

28 29

30

31

32 33

34

35 36

37

38

39

40 41

42

43

44

45

46

47

48

49 50

51

52

53

The James Cook University Hospital, South Tees Hospitals NHS Foundation Trust, Middlesbrough, United Kingdom

Investigators

- Mr Enoch Akowuah (Chief Investigator)
- Mr Andrew Goodwin (co-Investigator)
- Professor W Andrew Owens (co-Investigator)

Research Team

- Heather Robinson
- Jonathan Broughton
- Dr Khalid Khan

Clinical Trials Unit

Durham Clinical Trials Unit, Durham University; now Newcastle Clinical Trials Unit, Newcastle University

Investigators

- Professor Helen Hancock (co-Investigator)
- Rebecca Maier (co-Investigator)

Research Team

- Andrew Thorpe
- Jennifer Wilkinson
- Dr Leanne Marsay

Statistics

Statistics Group, Wolfson Research Institute for Health and Wellbeing, Durham University

Investigator

• Dr Adetayo Kasim (co-Investigator)

Health Economics

Durham Clinical Trials Unit, Durham University; now University of Warwick

Investigator

• Professor James Mason (co-Investigator)

Committees

Data Monitoring Committee Membership

- Mr Graham Cooper (Chair)
- Mr Heyman Luckraz
- Professor Chris Rogers

Trial Steering Committee Membership

- Mr Sukumaran Nair (Chair until Sep 2014)
- Professor Gavin Murphy (Acting Chair Oct 2014 to June 2015)
- Mr Peter Braidley (Chair, from July 2015)
- Mr Paul Modi
- Mr Brendan Ellis

Table 1. Eligibility criteria

Inclusion Criteria

- Aged 18 years or older at the time of consent
- Requiring first-time, non-emergency, isolated Aortic Valve Replacement surgery
- Able and willing to provide written informed consent

Exclusion Criteria

- requiring concomitant cardiac procedure(s) including redo surgery, emergency or salvage surgery,
- only conventional median sternotomy indicated*,
- haemoglobin level < 90g/L,
- pregnant**,
- currently participating in another interventional clinical trial,
- previous cardiac surgery,
- are unable to stop currently prescribed treatment affecting clotting (e.g., heparin, warfarin), ***
- a history of thrombophilia, thrombocytopenia or other haematological conditions that would affect participation in the trial as determined by one of the three operating surgeons,
- infective endocarditis,
- prevented from having red blood cells and blood products according to a system of beliefs (e·g· Jehovah's Witnesses),
- having any other medical, psychiatric and or social reason as determined by the consenting surgeon that precludes participation.

* patients were excluded if only conventional median sternotomy was indicated, for example in the presence of significant skeletal abnormalities like kyphosis. They were also excluded if transoesophageal echocardiography could not be performed, as this was mandatory to perform safe peripheral venous cannulation. All 3 surgeons used consistent criteria.

** in women of child bearing age (18 - 50) a pregnancy test was be performed within 14 days of surgery prior to randomisation.

***for patients in both trial arms, pre-operative antiplatelet drugs (including clopidogrel and ticagrelor), and anti-coagulants (including warfarin and heparin) were discontinued 5 days prior to surgery. These drugs were re-started following surgery at the discretion of the clinical team. The exception to this was aspirin, which was stopped 5 days prior to surgery where possible, however continuation until the day of surgery did not exclude a patient from the trial.




Figure 1. Trial recruitment by month.

R ON

Table 2. Conversion from mini-sternotomy to conventional sternotomy

Reason for conversion	Number of patients	Details
Anaesthetic emergency	2	 Patient became unstable as they were transferred into theatre dropped – required conventional to re-stabilise Anaphylactic reaction on induction needing CPR. Operation cancelled, patient taken to ITU. Widespread rash. Decision n following morning to proceed to AVR (via full sternotomy)
Difficult vascular access (venous or arterial)	9	 Venous Femoral vessels unsuitable for cannulation Poor venous drainage Unable to pass venous dilators Unable to insert pipe Resistance felt, no back flow of blood-cannulation abandoned Impossible to dilate femoral vein. Despite re-wiring, guide w coiling within pelvic venous system
		 Difficulties cannulating femoral artery leading to haemodyna instability Poor access, unable to clamp aorta Severe calcification of ascending aorta Difficult access; aorta displaced to the left. Body habitus limi access
Intra-operative complications	5	 Bleeding from aortotomy site Bleeding Intra-operative decision to performed bypass graft to LAD Post implant TOE showed small paravalvular leak and bleedin aortotomy incision Mild/moderate paravalvar leak on TOE. Required valve re-im

Table 3. Number of operations performed by Consultant Surgeon

	Mini-sternotomy group n=patients (%)	Conventional sternotomy group	Total n=patients (%)
	n-patients (70)	n=patients (%)	n-patients (70)
Consultant Surgeon A	58 (43.0)	58 (430)	116 (43.0)
Consultant Surgeon B	43 (31.9)	35 (25.9)	78 (28.9)
Consultant Surgeon C	34 (25.1)	42 (31.1)	76 (28.1)




Figure 2. Haemoglobin profiles at Baseline, during CICU stay, and day 1 to day 4 post index surgery, by group

Table 4. Analgesic use and pain scores

Medication	Mini-sternotomy Group (135 patients) n = patients (%)	Conventional Sternotomy Group (135 patients) n = patients (%)	Total (270 patier n = patients
Analgesic use at baseline			n putteria
Buprenorphine patch	3 (2.2)	1 (0.7)	4 (1.5)
Codeine Phosphate	4(3.0)	3 (0.7)	7 (2.6)
		· · · · · · · · · · · · · · · · · · ·	. ,
Dihydrocodeine Tartrate	0 (0.0)	1 (0.7)	1 (0.4)
Durogesic patch	0	1 (0.7)	1 (0.4)
Fentanyl	1 (0.7)	0 (0.0)	1(0.4)
Gabapentin	1 (0.7)	0 (0.0)	1(0.4)
Morphine Sulfate	0.0	1(0.7)	1(0.4)
1			
Naxoproxen	1 (0.7)	0 (0.0)	1 (0.4)
Paracetamol	13 (9.6)	8 (5.9)	21 (7.8)
Tramadol Hydrochloride	0 (0.0)	2 (1.5)	2(0.7)
At least one med at baseline	16 (11.9)	12 (8.9)	28 (10.4
Analgesic use at day 2			
Buprenorphine patch	1 (0.7)	0 (0.0)	1(0.4)
Codeine Phosphate	18 (13.3)	16 (11.9)	34 (12.6
		· · · · · · · · · · · · · · · · · · ·	
Dihydrocodeine Tartrate	4 (3.0)	6 (4.4)	10 (3.7)
Fentanyl	1 (0.7)	0 (0.0)	1(0.4)
Gabapentin	1 (0.7)	0 (0.0)	1(0.4)
Morphine Sulfate	13 (9.6)	13 (9.6)	26 (9.6)
		· · · ·	
Oramorph	1 (0.7)	1 (0.7)	2 (0.7)
Paracetamol	94 (69.6)	80 (59.3)	174 (64-4
Pregabalin	1(0.7)	0 (0.0)	1(0.1)
Tramadol Hydrochloride	7 (5.2)	5 (3.7)	12(4.4)
At least one med at day 2	99 (73·3)	86 (63·7)	185 (68-
Analgesic use at day 3			
		0(0,0)	1 (0 1)
Buprenorphine patch	1 (0.7)	0(0.0)	1 (0.4)
Codeine Phosphate	14 (10.4)	21 (15.6)	35 (13-0
Dihydrocodeine Tartrate	4 (3.0)	7 (5.2)	11 (4.1)
Fentanyl	0 (0.0)	1 (0.7)	1(0.4)
		· · · · · · · · · · · · · · · · · · ·	. ,
Gabapentin	1 (0.7)	1 (0.7)	2 (0.7)
Ibuprofen	0	1 (0.7)	1 (0.4)
Morphine Sulfate	6 (4.4)	1 (0.7)	7 (2.6)
Nefopam Hydrochloride	0	1 (0.7)	1(0.4)
Oramorph	0	3 (2.2)	$3(1\cdot1)$
-			
Paracetamol	89 (65.9)	99 (73.3)	188 (69-0
Pregabalin	1 (0.7)	0 (0.0)	1(0.4)
Tramadol Hydrochloride	8 (5.9)	3 (2.2)	11 (4.1)
At least one med at day 3	90 (66·7)	101 (74.8)	191 (70-2
Analgesic use at Day 4			
Buprenorphine patch	1 (0.7)	0 (0.0)	1 (0.4)
			. ,
Codeine Phosphate	15 (11.1)	15 (11.1)	30 (11.1
Dihydrocodeine Tartrate	4 (3.0)	9 (6.7)	13 (4.8)
Fentanyl	1 (0.7)	1 (0.7)	2(0.7)
Gabapentin	1(0,7)	1(0,7)	2(0.7)
Ibuprofen	0 (0.0)	1 (0.7)	1 (0.4)
Paracetamol	86 (63.7)	75 (55.6)	161 (59-
Morphine Sulfate	1 (0.7)	2 (1.5)	3 (1.1)
Pregabalin	1 (0.7)	0 (0.0)	1(0.4)
Tramadol Hydrochloride	$3(2\cdot 2)$	3 (2.2)	6 (2.2)
At least one med at day 4	88 (65·2)	81 (60·0)	169 (62·
Analgesic use at Week 6			
Buprenorphine Patch	3(2.2)	0(0.0)	3(1.1)
Codeine Phosphate	7(5.1)	5(3.7)	12(4.5)
Dihydrocodeine Tartrate	1(0.7)	3(2.2)	4(1.5)
Fentanyl	1(0,7) 1(0.7)	0(0.0)	
			1(0.4)
Gabapentin	2(1.5)	1(0.7)	3(1.1)
Ibuprofen	0(0.0)	1(0.7)	1(0.4)
Morphine Sulfate	0(0.0)	1(0.7)	1(0.4)
1			
Paracetamol	35(25.9)	38(28.1)	73(27.0
Pregabalin	1(0.7)	0(0.0)	1(0.4)
Tramadol Hydrochloride	2(1.5)	2(1.5)	4(1.5)
At least one med at week 6	41(30·4)	41(30.4)	82(30.4
Analgesic use at Week 12			
	3(2.2)	0(0.0)	$3(1 \cdot 1)$
Buprenorphine Patch	5(2:2)	0(0.0)	.1(1+1)

At least one med at week 12	23(17·0)	22(16·3)	45(16.7)
Tramadol Hydrochloride	1(0.7)	1(0.7)	2(0.7)
Paracetamol	19(14.1)	20(14.8)	39(14.4)
Naproxen	1(0.7)	0(0.0)	1(0.4)
Morphine Sulfate	1(0.7)	1(0.7)	2(0.7)
Ibuprofen	1(0.7)	0(0.0)	1(0.4)
Gabapentin	2(1.5)	0(0.0)	2(0.7)
Dihyrocodeine Tartrate	0(0.0)	1(0.7)	1(0.4)

	Mini-sternotomy Group (n=135 patients)	Conventional sternotomy group (n=135)
Baseline pain score		
n	128*	130*
Mean± SD	$1 \cdot 3 \pm 2 \cdot 1$	0.9 ± 1.9
(min-max)	0 - 10	0 - 8
Day 2 pain score**		
n	123*	126*
Mean± SD	3.4 ± 2.4	3.7 ± 2.7
(min-max)	0 - 10	0 - 10
Day 3 pain score		
n	120*	129*
Mean± SD	$2 \cdot 8 \pm 2 \cdot 5$	$2 \cdot 7 \pm 2 \cdot 3$
(min-max)	0 - 9	0 - 8
Day 4 pain score		
n	116*	120*
Mean± SD	2.5 ± 2.2	$2 \cdot 1 \pm 2 \cdot 3$
(min-max)	0 - 8	0 - 10
6 week pain score		
n	112*	118*
Mean± SD	1.5 ± 1.9	$1 \cdot 2 \pm 1 \cdot 8$
(min-max)	0 - 8	0 - 8
12 week pain score		
n	128*	122*
Mean± SD	1.1 ± 1.9	1.0 ± 1.7
(min-max)	0 - 8	0-6

*Pain scores were assessed wherever possible

**Assessment on Day 2 was conducted with the patient blinded to their surgical allocation

Table 5. Adverse Events

0/135 (0·0) 2/135 (1·5) 3/135 (3·0) 4/135 (3·0) 0/135 (0·0) 3/135 (2·2) 4/135 (2·3) 4/135 (2·3)	0/135 (0·0) 2/135 (1·5) 1/135 (0·7) 1/135 (0·7) 1/135 (0·7) 1/135 (0·7)	0/270 (0·0) 4/270 (1·5) 4/270 (1·5) 5/270 (1·9) 1/270 (0·4)
2/135 (1.5) 3/135 (3.0) 4/135 (3.0) 0/135 (0.0) 3/135 (2.2) 4/135 (2.3)	2/135 (1.5) 1/135 (0.7) 1/135 (0.7) 1/135 (0.7) 1/135 (0.7)	4/270 (1.5) 4/270 (1.5) 5/270 (1.9) 1/270 (0.4)
3/135 (3·0) 4/135 (3·0) 0/135 (0·0) 3/135 (2·2) 4/135 (2·3)	1/135 (0·7) 1/135 (0·7) 1/135 (0·7) 1/135 (0·7)	4/270 (1·5) 5/270 (1·9) 1/270 (0·4)
4/135 (3·0) 0/135 (0·0) 3/135 (2·2) 4/135 (2·3)	1/135 (0·7) 1/135 (0·7) 1/135 (0·7)	5/270 (1·9) 1/270 (0·4)
4/135 (3·0) 0/135 (0·0) 3/135 (2·2) 4/135 (2·3)	1/135 (0·7) 1/135 (0·7) 1/135 (0·7)	5/270 (1·9) 1/270 (0·4)
0/135 (0·0) 3/135 (2·2) 4/135 (2·3)	1/135 (0·7) 1/135 (0·7)	1/270 (0.4)
3/135 (2·2) 4/135 (2·3)	1/135 (0.7)	· · · ·
3/135 (2·2) 4/135 (2·3)	1/135 (0.7)	· · · ·
4/135 (2.3)		4/270(1.5)
		4/270 (1.5)
	0/135 (0.0)	4/270 (1.5)
1,100 (2 0)	1/135 (0.7)	5/270 (1.9)
	1/135 (07)	5/2/0 (1))
51/135 (37.8)	42/135 (31.1)	93/270 (34.4)
61/135 (45.2)	51/135 (37.8)	112/270 (41.5)
2/135 (1.5)	2/135 (1.5)	4/270 (1.5)
2/135 (1.5)	2/135 (1.5)	4/270 (1.5)
		· · · · ·
4/135 (2.3)	1/135 (0.7)	5/270 (1.9)
9/135 (6.7)	6/135 (4-4)	15/270 (5.6)
0/135 (0.0)	0/135 (0.0)	0/270 (0.0)
0/135 (0.0)	2/135 (1.5)	2/270 (0.7)
		17/270 (6.3)
18/135 (13.3)	26/135 (19.3)	44/270 (16.3)
	· · · · ·	4/270 (1.5)
11/135 (8.1)	3/135 (2.2)	14/270 (5.2)
3/135 (2·2)	5/135 (3.7)	8/270 (3.0)
	4/135 (2·3) 9/135 (6·7) 0/135 (0·0) 0/135 (0·0) 7/135 (5·2) 18/135 (13·3) 3/135 (2·2)	4/135 (2·3) 1/135 (0·7) 9/135 (6·7) 6/135 (4·4) 0/135 (0·0) 0/135 (0·0) 0/135 (0·0) 2/135 (1·5) 7/135 (5·2) 10/135 (7·4) 18/135 (13·3) 26/135 (19·3) 3/135 (2·2) 1/135 (0·7) 11/135 (8·1) 3/135 (2·2) 3/135 (2·2) 5/135 (3·7)

Table 6. Health status, resource use and cost (complete cases)

	Conv	entional [C]	Mini-st	ernotomy [M]	[M]-[C] ¹	
	mean	(SD)	Ν	mean	(SD)	Ν	mean	(95%CI)
Health status ²								
EQ-5D Baseline	0.764	0.245	130	0.763	0.235	128	-0.001	(-0.060 to 0.057
EQ-5D 2 days	0.349	0.349	133	0.353	0.291	128	0.004	(-0.074 to 0.082
EQ-5D 6 weeks	0.798	0.194	118	0.751	0.221	112	-0.048	(-0.101 to 0.006
EQ-5D 12 weeks	0.838	0.207	124	0.782	0.248	127	-0.056	(-0·112 to 0·001
EQ-5D AUC (0-12 weeks)	0.162	0.041	105	0.153	0.040	98	-0.009	(-0.020 to 0.002
Resource use								
Index Admission								
Length of stay $(d)^3$	8.26	4.28	135	9.29	7.88	135	1.03	(-0.48 to 2.54)
CICU (d)	1.21	0.99	135	1.61	5.52	135	0.39	(-0.55 to 1.34)
HDU (d)	1.27	1.52	135	1.60	1.75	135	0.33	(-0.07 to 0.72)
Cardiac ward (d)	5.67	3.52	135	5.70	3.18	135	0.03	(-0.77 to 0.83)
Stroke ward (d)	0.03	0.34	135	0.11	$1 \cdot 00$	135	0.08	(-0.10 to 0.26)
Time in first surgery (h)	2.24	0.51	135	2.98	0.69	135	0.74	(0.60 to 0.89)
Time in further surgery (h) ⁴	0.08	0.34	135	0.03	0.17	135	-0.05	(-0·11 to 0·02)
Time in surgery (h) 4	2.32	0.63	135	3.01	0.71	135	0.69	(0.53 to 0.85)
RBC (u) ⁴	0.59	1.45	135	0.55	1.28	135	-0.04	(-0·37 to 0·28)
$FFP(u)^4$	0.57	1.43	135	0.34	1.21	135	-0.23	(-0.55 to 0.09)
Platelets (u) ⁴	0.22	0.64	135	0.12	0.46	135	-0.10	(-0·24 to 0·03)
Cryoprecipitate (u) ⁴	0.01	0.09	135	0.00	0.00	135	-0.01	(-0.02 to 0.01)
Post discharge contacts								
GP surgery	1.47	1.52	129	1.40	1.32	131	-0.07	(-0·41 to 0·28)
GP home	0.09	0.32	129	0.19	0.56	131	0.10	(-0.01 to 0.21)
GP telephone	0.12	0.45	129	0.15	0.63	131	0.03	(-0.10 to 0.16)
Nurse surgery	1.38	2.56	129	2.07	3.54	131	0.69	(-0.06 to 1.44)
Nurse home	0.43	1.30	129	0.56	1.87	131	0.12	(-0·27 to 0·51)
Nurse telephone	0.05	0.25	129	0.04	0.26	131	-0.01	(-0.07 to 0.05)
Outpatient hospital	0.40	0.78	129	0.57	1.98	131	0.17	(-0.20 to 0.53)
Inpatient hospital	0.30	0.68	129	0.27	0.60	131	-0.03	(-0.18 to 0.13)
Inpatient hospital (d)	2.09	7.79	129	1.09	2.69	131	-1.00	(-2·42 to 0·42)
Total Contacts	4.29	3.53	129	5.47	4.90	131	1.18	(0·14 to 2·22)
Cost ⁵								
Cost of index admission	7674	2055	135	8815	4517	135	1140	(303 to 1977)
Cost post discharge	824	2485	129	547	925	131	-277	(-734 to 180)
Cost	8527	3558	129	9274	4542	131	746	(-245 to 1737)

1 OLS regression-estimated means and 95% confidence intervals

2 EQ-5D-3L index score

3 Length stay by ward does not sum to length of stay due to theatre and transit time, and rounding

4 Item includes index and post-discharge usage

5 Resource items were costed using national reference costs except for the index procedures which were costed by South Tees Hospitals NHS Foundation Trust

Table 7. ICU Length of Stay, Fitness for Discharge and Hospital Length of Stay

	Mini-sternotomy group (n=135)	Conventional sternotomy group (n=135)
ICU stay (days)		
n	135	135
Mean \pm SD	1.9 ± 5.8	$1 \cdot 3 \pm 1 \cdot 1$
Min-Max	0 - 64*	0 - 7
Fitness for discharge (days)		
n	129**	133**
Mean \pm SD	6.5 ± 3.7	6.3 ± 3.2
Min - Max	3 - 36	3 - 31
Post-operative length of stay (days)		
n	135	135
Mean \pm SD	7.4 ± 7.5	$6 \cdot 3 \pm 3 \cdot 1$
Min - Max	3 - 79	3 - 31

*3 patients in the mini-sternotomy group were in ICU for more than 7 days. Excluding these patients, the range would have been 0-5 days for the mini-sternotomy group.

**Fitness for discharge was assessed by the surgical and physiotherapy teams. For 6 patients in the mini-sternotomy group and 2 patients in the conventional sternotomy group this was not possible due staff availability at the point of discharge.

or oper teries only

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

FEV1 Baseline n 123* 123* 123* 123* Min + Max 1000-4340 1020-4090 (-169-2,138.4) Day 4 n 105* 110* Min - Max 1005* 11320-7 ± 523-5 (-171.3** 6 weeks n 106* 97* (-265-3,-77.2; p=0-00) n 106* 97* (-164-2,138.4) (-265-3,-77.2; p=0-00) 6 weeks n 106* 97* (-265-3,-77.2; p=0-00) Nin - Max 99-2400 76-2910 (-164-3,39-6) FVC Baseline n 106* 97* Mean ± SD 1962-0 ± 468-7 2018-1 ± 662-8 -7.3** Min - Max 650-3570 870-3570 (-164-3,39-6) FVC Baseline n 123* 123* Mean ± SD 2008-5 ± 926.4 229-2 ± 955.7 -31-6 Mean ± SD 1478-9 ± 583-3 1697.5 ± 706.8 -129.7** Mean ± SD 1478-9 ± 583-3 1697.5 ± 706.8 -129.7** Mean ± SD 2529.4 ± 824-0 2615.9 ± 864-0 -36.0**	FEV1 Baseline n 123^* 123^* 123^* 123^* $1-5.4$ $Mean \pm SD$ 2196.2 ± 712.2 2207.7 ± 748.2 -15.4 $(-169.2, 138.4)$ $Day 4$ n $1000-4340$ $1020-4090$ $(-169.2, 138.4)$ $Day 4$ n 105^* 110^* $(-169.2, 138.4)$ $Maa \pm SD$ 1122.6 ± 433.0 1320.7 ± 523.5 -171.3^{**} 6 weeks n 106^* 97^* $(-265.3, -77.2; p=0.0)$ 6 weeks n 106^* 97^* $(-265.3, -77.2; p=0.0)$ $Baseline$ n 106^* 97^* $(-265.3, -77.2; p=0.0)$ $Baseline$ n 106^* 97^* $(-265.3, -77.2; p=0.0)$ $Baseline$ n 106^* 97^* $(-238.8, 175.7)$ $Baseline$ n 123^* 123^* $(-238.8, 175.7)$ $Day 4$ n 105^* 110^* $(-238.8, 175.7)$ $Ama \pm SD$ $1250-6060$ $1200-5650$ $(-238.8, 175.7)$ $Ama \pm SD$ $1250-6060$ $1200-5650$ $(-259.2, -0.1; p=0.04$			Mini-sternotomy group (n=135)	Conventional sternotomy group (n=135)	Mean Difference (95% CI; p value)
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	FEV1 Baseline				
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$					15.4
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		Mean \pm SD	$2196 \cdot 2 \pm /12 \cdot 2$	2207.7 ± 748.2	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Day A	Min - Max	1000- 4340	1020-4090	
$ \begin{array}{c} {\mathop{\rm Min\ -Max}} & 99{\text{-}}2400 & 76{\text{-}}2910 \\ 6 \text{ weeks} & & & & & & & & & & & & & & & & & & &$	$ \begin{array}{c} {\mathop{\rm Min\ -Max}} & 99{\text{-}}2400 & 76{\text{-}}2910 \\ 6 \text{ weeks} & & & & & & & & & & & & & & & & & & &$	Day 4				
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		Mean \pm SD	$1122{\cdot}6\pm433{\cdot}0$	$1320{\cdot}7\pm523{\cdot}5$	
$\frac{n}{Mean \pm SD} = \frac{106^{*}}{1962 \cdot 0 \pm 468 \cdot 7} = \frac{97^{*}}{2018 \cdot 1 \pm 662 \cdot 8} = \frac{7 \cdot 3^{**}}{(-104 \cdot 3, 89 \cdot 6)}$ FVC Baseline $\frac{n}{Mean \pm SD} = \frac{123^{*}}{2908 \cdot 5 \pm 926 \cdot 4} = \frac{123^{*}}{2929 \cdot 2 \pm 955 \cdot 7} = \frac{-31 \cdot 6}{(-238 \cdot 8, 175 \cdot 7)}$ Day 4 $\frac{n}{Mean \pm SD} = \frac{105^{*}}{1478 \cdot 9 \pm 583 \cdot 3} = \frac{110^{*}}{1697 \cdot 5 \pm 706 \cdot 8} = \frac{-129 \cdot 7^{**}}{(-259 \cdot 2, -0 \cdot 1; p = 0 \cdot 04)}$ 6 weeks $\frac{n}{Mean \pm SD} = \frac{106^{*}}{2529 \cdot 4 \pm 824 \cdot 0} = \frac{97^{*}}{2615 \cdot 9 \pm 864 \cdot 0} = \frac{-36 \cdot 0^{**}}{(-173 \cdot 2, 101 \cdot 2)}$ Win - Max = 1180 - 4760 = 1000 - 4840 *It was not possible for all patients to complete pulmonary function tests **After adjusting for randomisation factors and baseline data	$\frac{n}{Mean \pm SD} = \frac{106^{*}}{1962 \cdot 0 \pm 468 \cdot 7} = \frac{97^{*}}{2018 \cdot 1 \pm 662 \cdot 8} = \frac{7 \cdot 3^{**}}{(-104 \cdot 3, 89 \cdot 6)}$ FVC Baseline $\frac{n}{Mean \pm SD} = \frac{123^{*}}{2908 \cdot 5 \pm 926 \cdot 4} = \frac{123^{*}}{2929 \cdot 2 \pm 955 \cdot 7} = \frac{-31 \cdot 6}{(-238 \cdot 8, 175 \cdot 7)}$ Day 4 $\frac{n}{Mean \pm SD} = \frac{105^{*}}{1478 \cdot 9 \pm 583 \cdot 3} = \frac{110^{*}}{1697 \cdot 5 \pm 706 \cdot 8} = \frac{-129 \cdot 7^{**}}{(-259 \cdot 2, -0 \cdot 1; p = 0 \cdot 04)}$ 6 weeks $\frac{n}{Mean \pm SD} = \frac{106^{*}}{2529 \cdot 4 \pm 824 \cdot 0} = \frac{97^{*}}{2615 \cdot 9 \pm 864 \cdot 0} = \frac{-36 \cdot 0^{**}}{(-173 \cdot 2, 101 \cdot 2)}$ Win - Max = 1180 - 4760 = 1000 - 4840 *It was not possible for all patients to complete pulmonary function tests **After adjusting for randomisation factors and baseline data		Min - Max	99-2400	76-2910	(-205 ⁻⁵ ,-77 ⁻ 2, p=0 ⁻ 00
$\begin{array}{c} \mbox{Mean \pm SD} & 1962.0 \pm 468.7 & 2018.1 \pm 662.8 & .7.3** \\ (-104.3,89.6) & (-104.3,89.6) \\ \mbox{FVC} Baseline & & & & & & & & & & & & & & & & & & &$	$\begin{array}{c} \mbox{Mean \pm SD} & 1962.0 \pm 468.7 & 2018.1 \pm 662.8 & .7.3** \\ (-104.3,89.6) & (-104.3,89.6) \\ \mbox{FVC} Baseline & & & & & & & & & & & & & & & & & & &$	6 weeks	n	106*	97*	
$\begin{array}{c} \mbox{Min - Max} & 650-3570 & 870-3570 \\ \mbox{FVC} \\ \mbox{Baseline} & n & 123^* & 123^* \\ \mbox{Mean \pm SD} & 2908-5 \pm 926\cdot4 & 2929\cdot2 \pm 955\cdot7 & -31\cdot6 \\ (-238\cdot8,175\cdot7) & -31\cdot6 & (-238\cdot8,175\cdot7) \\ \mbox{Min - Max} & 1250-6060 & 1200-5650 & -310\cdot6 & (-238\cdot8,175\cdot7) \\ \mbox{Mean \pm SD} & 1478\cdot9 \pm 583\cdot3 & 1697\cdot5 \pm 706\cdot8 & -129\cdot7^{**} & (-259\cdot2,-0\cdot1; p=0\cdot04) \\ \mbox{6 weeks} & n & 106^* & 97^* & (-259\cdot2,-0\cdot1; p=0\cdot04) \\ \mbox{mean \pm SD} & 2529\cdot4 \pm 824\cdot0 & 2615\cdot9 \pm 864\cdot0 & -36\cdot0^{**} & (-173\cdot2,101\cdot2) \\ \mbox{Min - Max} & 1180-4760 & 1000-4840 & (-173\cdot2,101\cdot2) \\ \mbox{*It was not possible for all patients to complete pulmonary function tests} & **After adjusting for randomisation factors and baseline data & -360^{**} & (-173\cdot2,101\cdot2) \\ \end{tabular}$	$\begin{array}{c} \mbox{Min - Max} & 650-3570 & 870-3570 \\ \mbox{FVC} \\ \mbox{Baseline} & n & 123^* & 123^* \\ \mbox{Mean \pm SD} & 2908\cdot5 \pm 926\cdot4 & 2929\cdot2 \pm 955\cdot7 & -31\cdot6 \\ (-238\cdot8,175\cdot7) & -31\cdot6 & (-238\cdot8,175\cdot7) \\ \mbox{Min - Max} & 1250-6060 & 1200-5650 & -129\cdot7^{**} \\ \mbox{Mean \pm SD} & 1478\cdot9 \pm 583\cdot3 & 1697\cdot5 \pm 706\cdot8 & -129\cdot7^{**} \\ \mbox{Mean \pm SD} & 1478\cdot9 \pm 583\cdot3 & 1697\cdot5 \pm 706\cdot8 & -129\cdot7^{**} \\ \mbox{Min - Max} & 139-2910 & 109-3920 & -259\cdot2, -0\cdot1; p=0\cdot04 \\ \mbox{6 weeks} & n & 106^* & 97^* \\ \mbox{Mean \pm SD} & 2529\cdot4 \pm 824\cdot0 & 2615\cdot9 \pm 864\cdot0 & -36\cdot0^{**} \\ \mbox{Min - Max} & 1180\cdot4760 & 1000-4840 & (-173\cdot2,101\cdot2) \\ \mbox{*It was not possible for all patients to complete pulmonary function tests} & **After adjusting for randomisation factors and baseline data & -1000-4840 & -1000$					
Baseline n 123* 123* Mean \pm SD 2908 $\cdot 5 \pm 926 \cdot 4$ 2929 $\cdot 2 \pm 955 \cdot 7$ 31.6 (-238 $\cdot 8,175 \cdot 7$) Min - Max 1250-6060 1200-5650 n 105* 110* Mean \pm SD 1478 $\cdot 9 \pm 583 \cdot 3$ 1697 $\cdot 5 \pm 706 \cdot 8$ 129 $\cdot 7**$ (-259 $\cdot 2, -0.1; p=0.04$ 6 weeks n 106* 97* Mean \pm SD 2529 $\cdot 4 \pm 824 \cdot 0$ 2615 $\cdot 9 \pm 864 \cdot 0$ 36 $\cdot 0**$ (-173 $\cdot 2,101 \cdot 2$) Min - Max 1180-4760 1000-4840 *It was not possible for all patients to complete pulmonary function tests **After adjusting for randomisation factors and baseline data	Baseline n 123* 123* Mean \pm SD 2908 $\cdot 5 \pm 926 \cdot 4$ 2929 $\cdot 2 \pm 955 \cdot 7$ 31.6 (-238 $\cdot 8,175 \cdot 7$) Min - Max 1250-6060 1200-5650 n 105* 110* Mean \pm SD 1478 $\cdot 9 \pm 583 \cdot 3$ 1697 $\cdot 5 \pm 706 \cdot 8$ 129 $\cdot 7**$ (-259 $\cdot 2, -0.1; p=0.04$ 6 weeks n 106* 97* Mean \pm SD 2529 $\cdot 4 \pm 824 \cdot 0$ 2615 $\cdot 9 \pm 864 \cdot 0$ 36 $\cdot 0**$ (-173 $\cdot 2,101 \cdot 2$) Min - Max 1180-4760 1000-4840 *It was not possible for all patients to complete pulmonary function tests **After adjusting for randomisation factors and baseline data		Min - Max	650-3570	870-3570	(-104-3,89-6)
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$					
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Baseline	n	123*	123*	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$			$2908{\cdot}5\pm926{\cdot}4$		
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	n 105* 110* 10* 129.7** (-259.2,-0.1; p=0.04) Min - Max 139-2910 109-3920 6 weeks n 106* 97* 106-3920 Min - Max 1180-4760 1000-4840 (-173-2,101-2) Min - Max 1180-4760 1000-4840 (-173-2,101-2) **After adjusting for randomisation factors and baseline data		Min - Max	1250-6060	1200-5650	(-238.8,173.7)
Mean \pm SD 1478.9 \pm 583.3 1697.5 \pm 706.8 -129.7** Min - Max 139-2910 109-3920 (-259.2, -0.1; p=0.04) 6 weeks n 106* 97* Mean \pm SD 2529.4 \pm 824.0 2615.9 \pm 864.0 -36.0** Min - Max 1180-4760 1000-4840 (-173.2,101.2) *It was not possible for all patients to complete pulmonary function tests **After adjusting for randomisation factors and baseline data 1000-4840	Mean \pm SD 1478.9 \pm 583.3 1697.5 \pm 706.8 -129.7** Min - Max 139-2910 109-3920 (-259.2, -0.1; p=0.04) 6 weeks n 106* 97* Mean \pm SD 2529.4 \pm 824.0 2615.9 \pm 864.0 -36.0** Min - Max 1180-4760 1000-4840 (-173.2,101.2) *It was not possible for all patients to complete pulmonary function tests **After adjusting for randomisation factors and baseline data 1000-4840	Day 4	n	105*	110*	
Min - Max139-2910 $109-3920$ 6 weeksn $106*$ $97*$ Mean \pm SD $2529\cdot 4 \pm 824\cdot 0$ $2615\cdot 9 \pm 864\cdot 0$ $-36\cdot 0**$ Min - Max $1180-4760$ $1000-4840$ *It was not possible for all patients to complete pulmonary function tests $**After adjusting for randomisation factors and baseline data$	Min - Max139-2910 $109-3920$ 6 weeksn $106*$ $97*$ Mean \pm SD $2529\cdot 4 \pm 824\cdot 0$ $2615\cdot 9 \pm 864\cdot 0$ $-36\cdot 0**$ Min - Max $1180-4760$ $1000-4840$ *It was not possible for all patients to complete pulmonary function tests $**After adjusting for randomisation factors and baseline data$					
n 106* 97* Mean \pm SD 2529·4 \pm 824·0 2615·9 \pm 864·0 -36·0** (-173·2,101·2) Min - Max 1180-4760 1000-4840 *It was not possible for all patients to complete pulmonary function tests **After adjusting for randomisation factors and baseline data	n 106* 97* Mean \pm SD 2529·4 \pm 824·0 2615·9 \pm 864·0 -36·0** (-173·2,101·2) Min - Max 1180-4760 1000-4840 *It was not possible for all patients to complete pulmonary function tests **After adjusting for randomisation factors and baseline data		Min - Max	139-2910	109-3920	$(-259\cdot2,-0\cdot1; p=0\cdot049)$
Mean \pm SD2529.4 \pm 824.02615.9 \pm 864.0-36.0**Min - Max1180-47601000-4840*It was not possible for all patients to complete pulmonary function tests1000-4840**After adjusting for randomisation factors and baseline data1000-4840	Mean \pm SD2529.4 \pm 824.02615.9 \pm 864.0-36.0**Min - Max1180-47601000-4840*It was not possible for all patients to complete pulmonary function tests1000-4840**After adjusting for randomisation factors and baseline data1000-4840	6 weeks	n	106*	07*	
Min - Max 1180-4760 1000-4840 *It was not possible for all patients to complete pulmonary function tests **After adjusting for randomisation factors and baseline data	Min - Max 1180-4760 1000-4840 *It was not possible for all patients to complete pulmonary function tests **After adjusting for randomisation factors and baseline data					
*It was not possible for all patients to complete pulmonary function tests **After adjusting for randomisation factors and baseline data	*It was not possible for all patients to complete pulmonary function tests **After adjusting for randomisation factors and baseline data		Min - Max	1180-4760	1000-4840	(-173.2,101.2)



CONSORT 2010 checklist of information to include when reporting a randomised trial*

Section/Topic	ltem No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	2
Introduction			
Background and	2a	Scientific background and explanation of rationale	3
objectives	2b	Specific objectives or hypotheses	3,5
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	3,4,5
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	NA
Participants	4a	Eligibility criteria for participants	4 (+appendix)
	4b	Settings and locations where the data were collected	4
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were	
		actually administered	4,5
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they	
		were assessed	6
	6b	Any changes to trial outcomes after the trial commenced, with reasons	NA
Sample size	7a	How sample size was determined	7
	7b	When applicable, explanation of any interim analyses and stopping guidelines	NA
Randomisation:			
Sequence	8a	Method used to generate the random allocation sequence	2,4
generation	8b	Type of randomisation; details of any restriction (such as blocking and block size)	2,4

Page	45	of	46
------	----	----	----

BMJ Open

Blinding 11a If at 11b If Statistical methods 12a S 12b M Results Participant flow (a 13a F diagram is strongly w recommended) 13b F Recruitment 14a D 14b M Baseline data 15 A Numbers analysed 16 F outcomes and 17a F estimation p 17b F Ancillary analyses 18 R	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how If relevant, description of the similarity of interventions Statistical methods used to compare groups for primary and secondary outcomes Methods for additional analyses, such as subgroup analyses and adjusted analyses For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up Why the trial ended or was stopped A table showing baseline demographic and clinical characteristics for each group For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	2,4 4 2,4,5 4 7 7 9 9,17 9 9 7 10 10 10 10 10 10 10 10 10 10 10 10 10
Blinding11ain If ar ar arStatistical methods11bIf ar ar ar ar 12aS ar ar ar ar 12bNStatistical methods12aS 12bNResults12aS 12bNParticipant flow (a diagram is strongly13aF r ar diagram is stronglyNRecruitment14aD 14bNBaseline data15A b Numbers analysed16F b bOutcomes and estimation17aF c an 17bF cAncillary analyses18R	interventions If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how If relevant, description of the similarity of interventions Statistical methods used to compare groups for primary and secondary outcomes Methods for additional analyses, such as subgroup analyses and adjusted analyses For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up Why the trial ended or was stopped A table showing baseline demographic and clinical characteristics for each group For each group, number of participants (denominator) included in each analysis and whether the analysis was	2,4,5 4 7 7 9 9,17 9 9 Table
Ancillary analysesanalyses11bIf11bIf12aS12bN12bNResults12aParticipant flow (a13aF13bGiagram is stronglywrecommended)13bF14bNumbers analysed16FbyOutcomes and17aF17bF17bAncillary analyses18	assessing outcomes) and how If relevant, description of the similarity of interventions Statistical methods used to compare groups for primary and secondary outcomes Methods for additional analyses, such as subgroup analyses and adjusted analyses For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up Why the trial ended or was stopped A table showing baseline demographic and clinical characteristics for each group For each group, number of participants (denominator) included in each analysis and whether the analysis was	2,4,5 4 7 7 9 9,17 9 9 Table
Statistical methods11bIfStatistical methods12aS12bNResults12bNParticipant flow (a13aFdiagram is stronglywrecommended)13bFRecruitment14aD14bNBaseline data15ANumbers analysed16FOutcomes and17aFestimation17bFAncillary analyses18R	If relevant, description of the similarity of interventions Statistical methods used to compare groups for primary and secondary outcomes Methods for additional analyses, such as subgroup analyses and adjusted analyses For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up Why the trial ended or was stopped A table showing baseline demographic and clinical characteristics for each group For each group, number of participants (denominator) included in each analysis and whether the analysis was	7 7 9 9,17 9 9 Table
Statistical methods12aS12bNResultsParticipant flow (a13aFdiagram is stronglywrecommended)13bFRecruitment14aD14bWBaseline data15ANumbers analysed16FOutcomes and17aFestimation17bFAncillary analyses18R	Statistical methods used to compare groups for primary and secondary outcomes Methods for additional analyses, such as subgroup analyses and adjusted analyses For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up Why the trial ended or was stopped A table showing baseline demographic and clinical characteristics for each group For each group, number of participants (denominator) included in each analysis and whether the analysis was	7 7 9 9,17 9 9 Table
12bNResults13aFParticipant flow (a13aFdiagram is stronglywrecommended)13bFRecruitment14aD14bWBaseline data15ANumbers analysed16FOutcomes and17aFestimation17bFAncillary analyses18R	Methods for additional analyses, such as subgroup analyses and adjusted analyses For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up Why the trial ended or was stopped A table showing baseline demographic and clinical characteristics for each group For each group, number of participants (denominator) included in each analysis and whether the analysis was	7 9 9,17 9 7 8 7 8
ResultsParticipant flow (a13aFdiagram is stronglywrecommended)13bFRecruitment14aD14bWBaseline data15ANumbers analysed16FOutcomes and17aFestimation17bFAncillary analyses18R	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up Why the trial ended or was stopped A table showing baseline demographic and clinical characteristics for each group For each group, number of participants (denominator) included in each analysis and whether the analysis was	9 9,17 9 9 Table
Participant flow (a13aFdiagram is stronglywrecommended)13bFRecruitment14aD14bWBaseline data15ANumbers analysed16FOutcomes and17aFestimation17bFAncillary analyses18R	were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up Why the trial ended or was stopped A table showing baseline demographic and clinical characteristics for each group For each group, number of participants (denominator) included in each analysis and whether the analysis was	9,17 9 9 Table
diagram is stronglywrecommended)13bFRecruitment14aD14bWBaseline data15ANumbers analysed16FOutcomes and17aFestimation17bFAncillary analyses18R	were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up Why the trial ended or was stopped A table showing baseline demographic and clinical characteristics for each group For each group, number of participants (denominator) included in each analysis and whether the analysis was	9,17 9 9 Table
recommended) 13b F Recruitment 14a D 14b W Baseline data 15 A Numbers analysed 16 F Outcomes and 17a F estimation p 17b F Ancillary analyses 18 R	For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up Why the trial ended or was stopped A table showing baseline demographic and clinical characteristics for each group For each group, number of participants (denominator) included in each analysis and whether the analysis was	9,17 9 9 Table
Recruitment14aD14bWBaseline data15ANumbers analysed16FOutcomes and17aFestimationp17bFAncillary analyses18R	Dates defining the periods of recruitment and follow-up Why the trial ended or was stopped A table showing baseline demographic and clinical characteristics for each group For each group, number of participants (denominator) included in each analysis and whether the analysis was	9 9 Table
14bWBaseline data15ANumbers analysed16FOutcomes and17aFestimationp17bFAncillary analyses18	Why the trial ended or was stopped A table showing baseline demographic and clinical characteristics for each group For each group, number of participants (denominator) included in each analysis and whether the analysis was	9 Table
Baseline data15ANumbers analysed16FOutcomes and17aFestimationp17bFAncillary analyses18R	A table showing baseline demographic and clinical characteristics for each group For each group, number of participants (denominator) included in each analysis and whether the analysis was	Table
Numbers analysed16FbyOutcomes and17aFestimationp17bFAncillary analyses18	For each group, number of participants (denominator) included in each analysis and whether the analysis was	
Outcomes and 17a F estimation p 17b F Ancillary analyses 18 R		Table
estimation p 17b F Ancillary analyses 18 R		
17b F Ancillary analyses 18 R	For each primary and secondary outcome, results for each group, and the estimated effect size and its	
Ancillary analyses 18 R	precision (such as 95% confidence interval)	9, Ta
5 5	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	Table
۲	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	12
Harms 19 A	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	11
Discussion		
	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	13
	Generalisability (external validity, applicability) of the trial findings	13,14
		,

BMJ Open

Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	13,14
Other information			
Registration	23	Registration number and name of trial registry	1,4
Protocol	24	Where the full trial protocol can be accessed, if available	4
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	4, 15

*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

 BMJ Open

For peer review only For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

BMJ Open

Mini-sternotomy versus conventional sternotomy for aortic valve replacement: a randomised controlled trial

Journal:	BMJ Open
Manuscript ID	bmjopen-2020-041398.R2
Article Type:	Original research
Date Submitted by the Author:	04-Dec-2020
Complete List of Authors:	Hancock, Helen; Newcastle University, Newcastle Clinical Trials Unit Maier, Rebecca; Newcastle University, Newcastle Clinical Trials Unit Kasim, Adetayo; Durham University, Wolfson Research Institute for Health and Wellbeing Mason, James; University of Warwick, Warwick Medical School Murphy, Gavin; University of Leicester, Department of Cardiovascular Sciences and NIHR Leicester Biomedical Research Unit in Cardiovascular Medicine Goodwin, Andrew; South Tees Hospitals NHS Foundation Trust, James Cook Hospital Owens, W; South Tees Hospitals NHS Foundation Trust, James Cook Hospital Akowuah, Enoch; South Tees Hospitals NHS Foundation Trust, James Cook Hospital
Primary Subject Heading :	Surgery
Secondary Subject Heading:	Evidence based practice, Intensive care, Research methods, Cardiovascular medicine
Keywords:	HEALTH ECONOMICS, Adult intensive & critical care < INTENSIVE & CRITICAL CARE, Adult surgery < SURGERY, Cardiac surgery < SURGERY, Clinical trials < THERAPEUTICS

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

reliez oni

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Title

 Mini-sternotomy versus conventional sternotomy for aortic valve replacement: a randomised controlled trial

Authors

Helen C Hancock, PhD¹, Rebecca H Maier¹, MSc, Adetayo Kasim, PhD², James Mason, DPhil³, Gavin Murphy, FRCS (C.Th)⁴, Andrew Goodwin, FRCS (C.Th)⁵, W Andrew Owens, FRCS (C.Th)⁵, Enoch

Marphy, rikes (c.m), Andrew Goodwin, rikes (c.m), w Andrew Owens, rikes (c.m

Akowuah, FRCS (C.Th)⁵.

1. Newcastle Clinical Trials Unit, Newcastle University; 2. Durham Research Methods Centre,

Durham University; 3. Warwick Medical School, University of Warwick; 4. Department of

Cardiovascular Sciences, University of Leicester; 5. Cardiothoracic Services, South Tees Hospitals NHS

Foundation Trust, The James Cook University Hospital.

Word count 3703

Corresponding author: Enoch Akowuah

Cardiothoracic Services, South Tees Hospitals NHS Foundation Trust, The James Cook University Hospital. Marton Road, Middlesbrough. TS3 4BW. E mail Enoch.Akowuah@nhs.net

Abstract

Objective

To compare clinical and health economic outcomes after manubrium-limited mini-sternotomy

(intervention) and conventional median sternotomy (usual care)

Design

A single blind, randomised controlled trial.

Setting

Single centre UK National Health Service tertiary hospital

Participants

Adult patients undergoing aortic valve replacement surgery

Interventions

Intervention was manubrium-limited mini-sternotomy performed using a 5-7cm midline incision.

Usual care was median sternotomy performed using a midline incision from the sternal notch to the

xiphisternum.

Primary and secondary outcome measures

The primary outcome was the proportion of patients who received a red cell transfusion postoperatively and within 7 days of index surgery. Secondary outcomes included proportion of patients receiving a non-red cell blood component transfusion and number of units transfused within 7 days and during index hospital stay, quality of life and cost effectiveness analyses.

Results

270 patients were randomised, received surgery and contributed to the intention to treat analysis. No difference between mini and conventional sternotomy in red-cell transfusion within 7 days was found; 23/135 patients in each arm received a transfusion, odds ratio 1.0 (95% CI: 0.5, 2.0) and risk difference 0.0 (95% CI: -0.1, 0.1). Mini-sternotomy reduced chest drain losses (mean 181.6ml (SD 138·7) vs conventional, mean 306·9ml (SD 348·6)); this did not reduce red-cell transfusions. Mean valve size and post-operative valve function were comparable between mini-sternotomy and conventional groups; 23mm vs 24mm, and 6/134 moderate or severe aortic regurgitation vs 3/130, respectively. Mini-sternotomy resulted in longer bypass (82·7 minutes (SD 23·5) vs 59·6 minutes (SD 15·1)) and cross clamp times (64·1 minutes (SD 17·1) vs 46·3 minutes (SD 10·7)). Conventional sternotomy was more cost-effective with only a 5·8% probability of mini-sternotomy being cost-effective at a willingness to pay of £20,000/QALY.

Conclusions

AVR via mini-sternotomy did not reduce red blood cell transfusion within 7 days following surgery when compared to conventional sternotomy.

Clinical Trials Registry: ISRCTN29567910

Key word: minimally invasive, aortic valve, clinical trial, cardiac surgery, replacement,

ARTICLE SUMMARY

- Large proportion of eligible patients recruited, and all patient randomised contributed to the primary outcome
- Clear protocols for transfusion of blood and blood products with high adherence throughout the trial
- Patients were blinded to group allocation until two days following index surgery, reducing the likelihood of bias.
- 4. First randomised trial to perform detailed health economic evaluation of minimally invasive versus conventional sternotomy

5. The trial was undertaken by three experienced minimally invasive surgeons who were expert at both techniques.

Objectives

Aortic valve replacement (AVR) for severe symptomatic valvular disease is one of the most common cardiac surgical procedures performed worldwide. The current joint guidelines of the American College of Cardiology and American Heart Association (ACC/AHA) and the current European Society of Cardiology guidelines for the management of aortic valve disease, state that surgical AVR is recommended for symptomatic patients with severe aortic stenosis and asymptomatic patients with severe aortic stenosis who meet an indication for AVR when surgical risk is low or intermediate.¹

In the UK, the National adult cardiac cardiac surgery audit published by NICOR (National Institute for Cardiac Outcome Reporting) reported 13,027 procedures for aotic valve disease in the UK from April 2018 to March 2019.² Outcomes are generally excellent with in-hospital observed mortality in the UK of 1.5% for first time elective procedures.³ In low risk patients with a Euroscore 2 of less than 4, a mortality of less than 0.7% was observed in over 15,000 patients undergoing AVR surgery in the UK between 2016 and 2019.²

These results are not observed in all patients; in high risk groups, conventional surgery risks perioperative organ injury and prolonged recovery, with death in up to 31% of patients within 1 year.⁴ Minimally invasive surgery combines the durability of surgical repair with reductions in surgical trauma that should reduce perioperative morbidity. Observational analyses demonstrating reductions in morbidity and resource use^{5,6} may be confounded by multiple sources of bias and are at odds with limited evidence from RCTs that have not shown improved outcomes.⁷ This uncertainty is reflected by variations in uptake internationally.^{8,9,10}

The move towards minimally invasive surgery is also driven by patient perceptions of pain reduction and rapid recovery. However, minimally invasive cardiac surgery is not without risks; limiting access to the heart can result in technically sub-optimal surgery, including concern about the size of the prosthesis that can be inserted, and paravalvular leak rates.

This trial evaluated Manubrium-limited Mini-sternotomy versus Conventional Sternotomy for Aortic Valve Replacement (MAVRIC). We hypothesised that mini-sternotomy would reduce red cell

transfusion rates, a contemporary marker of surgical trauma and indicator of adverse outcomes;¹¹ this has been contested,¹² though the evidence is not conclusive.¹³ An embedded cost effectiveness analysis evaluated whether the intervention was cost effective in a UK National Health Service (NHS) setting.

Patients and Methods Trial Design

MAVRIC was a single centre, single-blind, RCT comparing AVR via manubrium-limited ministernotomy group (intervention) and AVR via conventional sternotomy group (usual care). A NHS Research Ethics Committee approved the trial, which was conducted in accordance with the principles of the International Conference on Harmonisation of Good Clinical Practice.¹⁴ South Tees Hospitals NHS Foundation Trust was the Sponsor and recruiting centre.

Patient Public Involvement

In designing the study, we asked patients their view on what factors may affect whether they took part in the study. This was done in an outpatient setting and via a postal questionnaire. They felt expertise was important. Most patients felt that although the cosmetic benefit of the minimally invasive approach was appealing, they expected some clinical benefit form minimally invasive surgery as well. Importantly most patients said they would accept being blind to the type of surgery they had received for 48 hours after the procedure.

Participants

Patients were eligible if they were aged 18 years or over; required first-time, non-emergency, isolated AVR surgery; and were willing to provide written informed consent. Full details of the eligibility criteria are in the **Supplementary Material**.

Randomisation

Eligible patients were randomised by members of the research team using a 24-hour, central, secure, web-based randomisation system with concealed allocation, managed by the Clinical Trials

Unit; randomisation was in a 1:1 ratio between mini and conventional sternotomy and stratified by baseline logistic EuroSCORE and pre-operative Hemoglobin (Hb).

Interventions

Manubrium-limited mini-sternotomy was performed using a 5-7cm midline skin incision dividing the manubrium from the sternal notch to 1cm below the manubrium-sternal junction. Cardiopulmonary bypass was established with an ascending aortic cannula and percutaneous femoral venous cannulation. Conventional median sternotomy was performed using a midline incision from the sternal notch to the xiphisternum. Key aspects of anaesthesia were standardised, and are detailed in the protocol.¹⁵

Blinding

All patients were blinded to type of sternotomy received until after their day 2 Quality of Life and pain assessments. All patients had trial-specific opaque dressings applied to their sternal wound, and groin before leaving theatre.

Transfusion Protocol

The post-operative period, and trial protocol in relation to red cell and non-red cell transfusion, began on admission to the Cardiothoracic Intensive Care Unit (CICU); it specified that patient's should receive a red cell transfusion if their Hb dropped below 80 g/L; or were bleeding by 400ml/h or more, or were bleeding 100ml/h or more for 4 or more hours with a Hb equal to or greater than 80g/L; or had blood loss with haemodynamic instability irrespective of thromboelastography (TEG) and/or clotting profile results. One unit of red cells was transfused and Hb level checked before transfusing another unit.

Participants received a non-red cell transfusion if both of the following criteria were met: bleeding defined by 400ml/h or more, or blood loss of 100ml/h or more for 4 hours or more; TEG or coagulation guided transfusion indicated.

1	
2 3	Outcomes
4	Outcomes
5 6	All outomes were measured from index surgery.
7 8 9	Primary Outcome
10 11	The primary outcome was the proportion of patients who received a red cell transfusion post-
12 13	operatively and within 7 days of index surgery.
14 15 16	Secondary Outcomes:
17 18	• proportion of patients receiving a red cell transfusion and number of units transfused within
19 20 21	7 days and during index hospital stay;
22 23	• proportion of patients receiving a non-red cell blood component transfusion and number of
24 25 26	units transfused within 7 days and during index hospital stay;
27 28	 volume in chest drains at 6 and 12 hours, and drain removal;
29 30 31	• degree of aortic regurgitation using echocardiogram within 6 weeks;
32 33 34	re-operation rates;
35 36 37	 conversion to conventional AVR during surgery;
38 39	 changes in lung function at 4 days and 6 weeks;
40 41 42	• Quality of life EuroQol (EQ-5D-3L, EQ-VAS) at 2 days, 6 and 12 weeks;
43 44 45	 time patients are deemed 'fit for discharge';
46 47 48	health care utilisation to 12 weeks;
49 50 51	cost and cost effectiveness analyses;
52 53	• adverse events to 12 weeks.
54 55 56	Statistical Analysis
57 58 59	Audit data had indicated 30% of patients undergoing AVR via conventional sternotomy (15 of 50
<i></i>	

patients) received a red cell transfusion compared with 13% of patients (8 of 60 patients)

undergoing AVR via mini-sternotomy. Using Fisher's Exact test, 90% power, 5% alpha, we estimated that 260 patients would be required to detect a 17% reduction in the proportion of patients requiring a red cell transfusion (13% compared with 30%), using a two-sided test. Allowing for loss to follow up, the sample size was increased to 270.

The primary analysis was based on intention-to-treat principles, in accordance with a pre-specified statistical analysis plan.

The primary efficacy analysis was based on a logistic regression model with only group (minimally invasive and conventional) and stratifying factors (baseline logistic EuroSCORE and Hb) as the predictors. Odds ratios and their associated 95% confidence interval are reported in the primary analysis. Sensitivity analysis using alternating logistic regression was performed for the primary endpoint to sensitise for surgeon effects; the odds of receiving a red cell transfusion for two patients treated by the same surgeon was compared to two patients treated by different surgeons.

All analyses of secondary continuous efficacy endpoints at single time points were based on linear models where, if appropriate, a log normal model was fitted to sensitise the linearity assumption. Longitudinal analysis was performed for all endpoints with repeated data over time to investigate changes in trends over the trial period. The trial period was defined as baseline, up to 7 days (post-operative period), 6 week follow-up and 12 week follow-up. All analyses of binary endpoints at a single time point were based on logistic regression. Generalised estimating equation was used to analyse repeated binary data per patient to account for intra-patient correlation.

Further exploratory analysis was conducted to investigate the association between the treatment group and other clinical factors. All analyses were performed using R 3·3·3 (The R Foundation) and SAS 9·4 (SAS Institute Inc).

Economic Evaluation

A prospective economic evaluation applying a NHS perspective, following National Institute for Health and Care Excellence (NICE) reference case guidance,¹⁶ was employed. Health care utilisation

BMJ Open

was captured up to three months following discharge from index surgery. Resource use was valued in 2016 pounds sterling using national sources,^{17,18} and where necessary, local micro-costing (£1=\$1.50). Resources included surgery, transfusions, length of hospital stay (by level of care), complications and further surgery, and community care following discharge.

Mechanisms of missingness within the data were explored and multiple imputation methods were applied to impute missing data and minimise bias, using chained equations and predictive mean matching. Imputation sets were analysed within a bivariate analysis of costs and QALYS, to generate incremental within-trial cost per QALY estimates and credible intervals. Findings were presented on the ICER plane and with Cost-Effectiveness Acceptability Curves, using the net monetary benefit approach.

Imputation was conducted according to good practice guidance.^{19,20} Multiple imputation provides unbiased estimates of treatment effect if data are missing at random (MAR) and the missingness process is adequately characterised : this assumption was explored in the data, for example by using logistic regression for missingness of costs and QALYs against baseline variables.²¹ A regression model was used to generate multiple imputed datasets (or 'draws') for individual treatment groups, where missing values were predicted drawing on predictive covariates. Outcome measures and costs (at each time point) contributed as predictors and imputed variables. Each draw provided a complete dataset, reflecting the distributions and correlations between variables. Predictive mean matching drawn from the five nearest neighbours (knn=5) was used to enhance the plausibility and robustness of imputed values; normality was not assumed. The imputation model used fully conditional (MCMC) methods. Draws were analysed using bivariate regression (see below) within the Stata MI framework, capturing within and between variances for imputed samples.²² After examining the fraction of missing information (FMI) from finite imputation sampling, 20 draws was taken in the final imputation model.

Results Trial Population

MAVRIC recruited to time and target; 313 patients were considered for the trial; 274 patients consented between 20th March 2014 and 25th July 2016. The analysis population was 270 eligible patients; 135 allocated to the AVR via mini-sternotomy group and 135 allocated to the AVR via conventional sternotomy group (**Figure 1.**).

All 270 patients underwent surgery. Sixteen patients required cross-over from minimally-invasive to a conventional sternotomy due to anaesthetic emergency (n=2), difficulties due to vascular access (n=9), and intra-operative complications (n=5); further details and the number of operations performed by surgeon are in the Supplementary Material.

Baseline characteristics were similar between groups (Table 1).

Primary Outcome

There was no difference between groups in relation to the primary outcome (**Table 2**). The proportion of patients receiving a red cell transfusion was 23 of 135 in both groups, Odds ratio 1.0 (95% CI 0.5, 2.0; p=0.9052) and risk difference of 0.0 (95% CI -0.1, 0.1; p=0.9999).

Secondary Outcomes

Red cell and non-red cell transfusion

There was no significant difference between groups with respect to any red cell transfusion at discharge (**Table 2**). There was no difference between groups in Hb from baseline to 4 days following index surgery (**Supplementary Material**). There was a statistically significant difference in the proportion of patients receiving any non-red cell transfusion within 7 days of surgery; mini 6/135 versus conventional 18/135, Odds ratio: 0.3 (95% Cl 0.1, 0.8; p=0.0137) (**Table 3**).

Cross clamp time and cardiopulmonary bypass time

Mini-sternotomy resulted in longer Cardio Pulmonary Bypass times; mini group 82·7 minutes (SD 23·5), conventional 59·6 minutes (SD 15·1). Aortic cross clamp times were also longer; mini group 64·1 minutes (SD 17·1), conventional 46·3 minutes (SD 10·7) (**Table 4**).

Chest drain losses

Mini-sternotomy resulted in a 40·8% reduction in chest drain losses at 12 hours, the mini group mean was 181·6ml (SD 138·7), conventional group mean was 306·9ml (SD 348·6); the mean difference was -127·7ml (95% Cl -191·7, -63·8, p=0.0001). At drain removal mean difference was -145·3ml (95% Cl -218·1, -72·3; p=0.0001) (**Table 4**).

Ventilation time

Ventilation time between the groups was similar; 9.6 hours (SD 5.6) in the mini group and 9.8 hours (SD 6.9) in the conventional (**Table 4**).

Intensive care unit length of stay

There was no difference in intensive care unit length of stay between groups (**Supplementary Material**).

Post-operative pain

There was no difference in pain scores between groups; analgesic use is also included to assist interpretation (**Supplementary Material**).

Lung function

There was no difference between groups in lung function at baseline. At 4 days post-surgery, mean Forced Expiratory Volume 1 (FEV1) 1123mls (SD 433) and Forced Vital Capacity, FVC 1479mls (SD 583) were significantly reduced in the mini group, compared to the conventional; FEV1 1321 (SD 524), FVC 1698 (SD 707). Mean differences for FEV1 and FVC were statistically significant at 4 days post-surgery; -171mls (95% CI -265, -77; p=0.0004) and -130mls (95% CI -269, 0; p=0.0498) respectively, after adjusting for baseline FEV1, FVC, and randomisation factors (**Supplementary Material**).

Hospital length of stay

The mean time to patients being fit for hospital discharge following index surgery was similar between groups. The mean post-operative hospital length of stay was 7.4 (SD 7.5, range 3-79) in the mini group, and 6.3 days (SD 3.2, range 3-31) in the conventional (**Supplementary Material**).

Post-operative valve function

The distribution of valve types and valve sizes by group were similar; mean valve size inserted was 23mm in the mini group and 24mm in the conventional (**Table 5, Figure 2,3**). Over 70% of patients in each group received a tissue valve, over 25% received a mechanical valve and 2-3% received a sutureless tissue valve.

Post operative transthoracic echo showed a similar decrease in mean aortic valve gradient in both groups to 16mmHg; peak gradient decreased to 30mmHg in both groups (**Table 5**). 6/134 patients had moderate or severe aortic regurgitation in the mini group compared to 3/130 in the conventional (**Table 5**). Only 2 patients in the trial, 1 in each arm, suffered a paravalvular leak; both were severe. One of these patients, in the mini sternotomy arm had a sutureless valve prosthesis. 7 further patients had moderate regurgitation; these were all intravalvular leaks. Transoesophageal echo was performed in all patients prior to leaving the operating theatre.

Adverse events

There were no in-hospital deaths in either group. At 12 weeks follow up, there were 4 deaths; 2 in each arm of the study. Adverse events in each group were broadly similar and within acceptable clinical limits. By 12 weeks, 4/135 patients in the mini-sternotomy group and 1/135 in the conventional group had suffered a stroke (defined as a persistent neurological deficit). Atrial arrhythmias were identified in 61/135 patients in the mini group and 51/135 in the conventional. By

BMJ Open

12 weeks, 11/135 patients in the mini group and 3/135 patients in the conventional had a sternal wound infection (**Supplementary Material**).

Quality of Life, Costs and Cost-Effectiveness

Costs during the index admission were significantly greater for the mini group (mini-conventional: mean difference £1140; 95% CI 303, 1977), primarily reflecting the additional cost of theatre time (**Supplementary Material**). Overall costs were not significantly different (mini-conventional: mean difference £746; 95% CI -245, 1737). There was no significant difference in quality of life between groups up to 12 weeks (mini-conventional: mean difference area under curve -0.009 QALYs; 95% CI 0.020, 0.002). Although differences in costs and quality-of-life were not individually significant, the bivariate cost-QALY distribution (combining these two) suggests conventional surgery might be more cost-effective (**Figure 4.**). In the base-case model, mini was dominated by conventional surgery (due to greater cost and less benefit), with only a 5.8% probability of being cost-effective at a willingness to pay of £20,000/QALY (**Table 6**).

Sensitivity and Subgroup Analyses

There was no significant surgeon effect; the odds of receiving a red cell transfusion for two patients treated by the same surgeon compared to two patients treated by different surgeons was 1.2 (95% Cl 0.9, 1.6; p=0.1379).

Protocol deviations in respect of cell tranfusions did not affect the results of the primary analysis; excluding these patients produced the same results as those from the intention-to-treat analysis.

Discussion

Main findings

Mini-sternotomy was not superior to conventional sternotomy with respect to red cell transfusion requirements within 7 days of surgery. Analysis of secondary endpoints showed a statistically significant difference in transfusion volumes of non-red cell blood components. Aortic valve size and post-operative function were comparable in the 2 groups. Mini-sternotomy resulted in a relative

BMJ Open

reduction in chest drain losses however, higher blood loss in the conventional group did not translate into red cell transfusions. Mini patients had substantially longer bypass and cross clamp times and worse lung function at 4 days post-surgery. Lung function at twelve weeks, and adverse event rates were otherwise not different between groups. Conventional sternotomy was found to be more cost-effective. MAVRIC findings contradict those from other trials that pre-date it.^{23,24} Two 100 patient RCTs published since MAVRIC and the systematic review, do not alter the discussion.^{25,26} Both found no difference in major clinical outcomes, and findings relating to shorter hospital stay in mini-sternotomy; a reduction in bleeding through chest drains, and mean difference in EQ-5D scores at baseline and at 6 weeks²⁵ are consistent with MAVRIC findings.

Strengths and limitations

This is the largest single trial to have compared minimally invasive sternotomy to conventional median sternotomy for AVR. A recent Cochrane review identified 511 patients from 7 previous RCTs.⁷ In MAVRIC, the mini-sternotomy technique divided only the manubrium and is therefore less invasive than other minimally invasive techniques. The trial was undertaken by three experienced minimally invasive surgeons who were expert at both techniques. Patients were blinded to group allocation until two days following index surgery, reducing the likelihood of bias. The trial recruited a significant proportion of eligible patients; 274/313 (86%), with few requiring conversion to conventional sternotomy, increasing the likelihood that the trial findings are generalisable. A further strength was the detailed health economic evaluation; this has not been performed previously. The trial had some limitations, including the single centre design. This will tend to have biased treatment effect estimates away from the null, which is at odds with our observed effect. There were no significant levels of protocol non-adherence, with no effect on the main trial finding. The event rate for the primary outcome, was much lower than expected at 17%; nationally red cell transfusion rates following valve surgery are 46-4%.²⁷ In our pre-trial audit conducted over 5 years , ending 2009, 30% of mini-sternotomy patients received a red cell transfusion. We attribute the

BMJ Open

observed transfusion rate in MAVRIC to the restrictive red cell transfusion threshold applied; this followed evidence at the time of trial design. The consultant (expert) led nature of the trial interventions is also likely to have reduced the need for transfusions post-operatively and to have biased trial results towards the null.

Clinical importance

MAVRIC contributes important evidence to the minimally invasive AVR evidence base, summarised in a Cochrane review.⁷ MAVRIC demonstrated longer cross-clamp and bypass times with the manubrium-limited mini-sternotomy, attributed to known differences between the interventions. Minimally-invasive techniques in MAVRIC required a number of surgical steps to be performed with the aortic clamp in place (drain insertion and pacing wire insertion for example), meaning crossclamp and bypass were longer. This is not an absolute requirement in other minimally invasive approaches; for example, where the incision is extended into the body of the sternum, or where rapid deployment valves are used, there are no differences in cross clamp and bypass times.⁷ The size of MAVRIC and event rate prevents formal comparison of adverse events between the groups, of note is the difference in stroke rate; this would benefit from exploration in a future trial. The cost-effectiveness plane indicates that conventional surgery is less costly and more beneficial than minimally-invasive surgery; contact with healthcare professionals was greater in the mini group, although there was no clear pattern of use. Wide confidence intervals mean that differences are imprecise. MAVRIC does not support the use of funds to expand AVR via manubrium-limited mini-sternotomy practice.

MAVRIC, the world's largest RCT at low risk of bias, found no additional clinical benefit, in terms of red blood cell transfusion rates of minimally invasive AVR. Results are in agreement with the findings of a Cochrane review of trials that have evaluated mini-sternotomy AVR.⁷ This information should be disseminated to patients, clinicians and commissioners to inform decisions about AVR surgery including commissioning.

Role of funding source

This work was supported by the NIHR Research for Patient Benefit Programme (grant number PB-

PG-1112-29035).

The views and opinions expressed are those of the authors and do not necessarily reflect those of the National Institute for Health Research (NIHR) Research for Patient Benefit Programme, the National Health Service or the Department of Health and Social Care.

Declaration of Interests

Helen C Hancock (HCH): None

Rebecca H Maier (RHM): None

Adetayo Kasim (AK): None

James Mason (JM): None

Gavin Murphy (GM): Declares research grant funding from Zimmer Biomet for a trial of blood transfusion. He is supported by the British Heart Foundation (CH/12/1/29419) and the NIHR

Leicester Biomedical Research Centre.

Andrew Goodwin (AG): None

W Andrew Owens (WAO): None

Enoch Akowuah (EA): None

Authors contributions

EA, HCH, RHM, and JM and GM designed the trial, and sought funding. EA, AG and WAO recruited patients to the trial and performed surgery. AK conducted the statistical analysis and JM conducted the health economic analysis. All authors contributed to the final manuscript.

Acknowledgements

We are grateful to the patients who agreed to take part in the MAVRIC trial. This trial would not have been possible without the support of all staff in the Cardiothoracic Services in The James Cook University Hospital. We would like to thank Heather Robinson and Jonathan Broughton for their

assistance with recruitment, data collection and data entry. We would like to thank the team at the Clinical Trials Unit, including Jennifer Wilkinson, Andrew Thorpe, Leanne Marsay and Catherine Frost for their work in managing the trial and its data.

Data Sharing Statement

Anonymised data from this study may be available to the scientific community subject to

appropriate ethical approval. Requests for data should be directed to the senior author.

to perteries only

Table 1. Baseline characteristics of participants by group

	Mini-sternotomy group	Conventional sternotomy group
	(n=135)	(n=135)
Baseline characteristics		
Age: (years)		
Mean ± SD	69·3 ± 9·3	68·7 ± 8·4
Range	43 - 85	39 - 88
Gender: n (%)		
Male	78 (57·8)	87 (64·4)
Female	57 (42·2)	48 (35·6)
Ethnicity: n (%)		
White British	135 (100)	135 (100)
Body Mass Index (kg.m ⁻²)		
Mean <u>+</u> SD	30.5 ± 5.6	30.4 ± 6.1
Range (Min – Max)	19.0 - 45.4	19.3 - 52.0
EuroSCORE: Mean + SD (Min-Max)		
Logistic	5·2 ± 3·5 (1·5 - 29·5)	5·1 ± 3·5 (1·5 - 21·0)
II – Mean	1·5 ± 1·1 (0·5 - 10·2)	1·5 ± 1·2 (0·5 - 10·0)
Diagnosis echocardiogram: n (%)		
Regurgitation	3 (2·2)	8 (5·9)
Stenosis	132 (97·8)	127 (94·1)
NYHA class: n (%)		
	24 (17·8)	18 (13·3)
	68 (50·4)	66 (48.9)
	40 (29.6)	46 (34.1)
IV	3 (2·2)	5 (3.7)
*Haemoglobin prior to randomisation: g/dl		
Mean <u>+</u> SD	137·9 ± 14·3	137·1 ± 16·1
Range (Min – Max)	97 -173	90 -175
Surgery type: n (%)		
Elective	111 (82·2)	112 (82.6)
In-house urgent	24 (17·8)	23 (17.4)
in nouse argent		()

*One patient had a baseline hemoglobin (Hb) of 95 g/L at randomisation, which had fallen to 83 immediately prior to surgery. This Hb drop was not identified until after surgery and the patient continued in the trial with their data included in the analyses based on the intention to treat principle.

Table 2. The number and proportion of patients receiving a Red Cell Transfusion*, and the number of units received, to 7 days and to discharge following index surgery, by group.

	Mini- sternotomy group	Conventional sternotomy group	Odds Ratio (95% Cl; p value)	Risk difference (95% Cl; p value)
Red Cell Transfusions				
Post-operatively to 7 days number of patients (%)	23/135 (17·0)	23/135 (17·0)	1·0 (0·5, 2·0; p=0·9052)	0·0 (-0·1, 0·1; p=0·9999)
Post-operatively to discharge number of patients (%)	34/135 (25·2)	29/135 (21·5)	1.4 (0.7, 2.7)	
Red Cell Units – post operatively to 7 days				
Number of patients	23/135	23/135		
Mean <u>+</u> SD	1.6 ± 0.7	2·3 ± 1·7		
Range (Min – Max)	1 - 3	1 - 9		
Red Cell Units – post operatively to				
discharge				
Number of patients	34/135	29/135		
Mean ± SD	2·5 ± 2·5	2.6 ± 2.0		
Range (Min – Max)	1 - 13	1 - 11		

*Reprinted from Journal of the American College of Cardiology Vol 73 (19); Hancock HC, Maier RH, Kasim AS, Mason JM, Murphy GJ, Goodwin AT, Owens WA, Kirmani BH, Akowuah EF. Mini-Sternotomy Versus Conventional Sternotomy for Aortic Valve Replacement. pp. 2491-2492. 2019²⁸, with permission from Elsevier.

Table 3. The number and proportion of patients receiving a Non-Red Cell Transfusion, and the number of units received, to 7 days and to discharge following index surgery, by group.

6/135 (4·4) 13/135 (9·6)	18/135 (13·3)	0·3 (0·1, 0·8; p=0·0137)
	18/135 (13·3)	
13/135 (9.6)		p 0 0 10,)
13/133 (5 0)	21/135 (15·6)	0.6 (0.3, 1.2)
6	18	
3.2 ± 0.9	4·6 ± 1·6	
2 - 5	1 - 7	
13	21	
4·8 ± 2·3	4·9 ± 2·3	
1 - 8	1 - 12	
6 (4·4)	18 (13·3)	0·3 (0·1, 0·8)
13 (9·6)	21 (15·6)	0.6 (0.3, 1.2)
	3.2 ± 0.9 2 - 5 13 4.8 ± 2.3 1 - 8 6 (4.4)	$\begin{array}{cccc} 3 \cdot 2 \pm 0 \cdot 9 & 4 \cdot 6 \pm 1 \cdot 6 \\ 2 \cdot 5 & 1 \cdot 7 \\ \\ 13 & 21 \\ 4 \cdot 8 \pm 2 \cdot 3 & 4 \cdot 9 \pm 2 \cdot 3 \\ 1 \cdot 8 & 1 \cdot 12 \\ 6 & (4 \cdot 4) & 18 & (13 \cdot 3) \end{array}$

60

1 2				
3	Table 4. Outcomes during in	dev hosnital stav	for cardionulmona	ry hypass and aortic cro
4	-	dex nospital stay		i y bypass and aortic cro
5	times and drain losses.	.		
6		Mini-sternotomy group (n=135)	Conventional sternotomy group	Mean Difference (95% Cl; p value)
7		8.000 (200)	(n=135)	(00/0 0) p 10/00)
8	Cardio Pulmonary Bypass time			
9 10	(minutes) Mean <u>+</u> SD	82·7 ± 23·5	59·6 ± 15·1	
10	Range (Min – Max)	41.0 - 199	37.0 -170.0	
12	Aortic cross clamp time			
13	(minutes)			
14	Mean ± SD	64·1 ± 17·1	46·3 ± 10·7	
15	Range (Min – Max) Drain losses at 12 hours	32.0 - 132.0	32.0 -97.0	
16	Mean ± SD	181·6 ± 138·7	306·9 ± 348·6	-127.7
17				(-191·7,-63·8;
18	Range (Min – Max)	25 - 925	25 - 3000	p=0·0001)
19 20	Drain losses at drain removal	23-323	23-3000	
20	Mean ± SD	251·7 ± 198·4	393·7 ± 378·7	-145·3
22				(-218·1,-72·3;
23	Range (Min – Max)	25 - 1425	50 - 3000	p=0·0001)
24				
25				
26				
27				
28				
29 30				
30				
32				
33				
34				
35				
36				
37				
38				
39 40				
40				
42				
43				
44				
45				
46				
47				
48 49				
49 50				
50				
52				
53				
54				
55				
56				
57				
58				
59 60				

oss clamp

3			
1	Table 5. Outcomes during in	day hosnital stay	for va
5	-		
	regurgitation to 6 weeks by	group.	
7			
3		Mini-sternotomy	C
)	Valve Characteristics	group	ster
0		(n=135)	
1	Valve size: mm		
12	19-21mm n (%)	40 (29.6)	
13	23-25mm n (%)	84 (62.2)	
4	27-29mm n (%)	11 (8.2)	
15	Mean <u>+</u> SD	23·1 ± 2·1	2
16	Range (Min – Max)	19.0 - 29.0	1
17			
8	Valve type: n (%)		
19	Biological and	4 (3·0)	
20	sutureless		
21	Biological prosthesis	96 (71.1)	
22	Mechanical prosthesis	35 (25·9)	
23	Valve function		
24	Mean Gradient Baseline		
25		111*	
26	n Mean ± SD	47·9± 15·7	4
27	Min - Max	10-93	
28	6 weeks	10.00	
29	n	120*	
30	Mean ± SD	15·7 ± 5·5	6
31	Min - Max	6-33	
32	Peak Gradient		
33	Baseline		
34	n	125*	
35	Mean ± SD	82·3 ± 25·9	7
36	Min - Max	16-152	
37	6 weeks		
37 38	n	130*	2
	Mean ± SD	29·9 ± 10·5	2
39	Min - Max	12-62	:+-
10 1 1	* It was not possible to quantify va **After adjusting for randomisation		
41 12	Artic Valve Regurgitation		e uala
12 12	Nil/trivial		
13	n/n (%)	109/134* (81·3)	109
14	Mild	, , ,	
45	n/n (%)	19/134* (14·2)	18,
16	Moderate		
17	n/n (%)	5/134* (3·7)	2,
18	Severe		
19	n/n (%)	1/134* (0.8)	1,
50	* It was not possible to record valve re	egurgitation in all patient	S
51			
52			
53			
54			

hospital stay for valve size and type, and for valve function and ıp.

Conventional

sternotomy group

(n=135)

38 (28.1)

80 (59.3)

17 (12.6)

23.6 ± 2.5

19.0 - 31.0

3 (2·2)

98 (72.6)

34 (25·2)

110*

47·7 ± 20·2

8-110

126*

15·7 ± 5·8

4-34

124*

77·1 ± 29·1

8-173

130*

29·7 ± 10·8

11-61

109/130* (83.8)

18/130* (13.9)

2/130* (1.5)

1/130* (0.8)

Mean Difference

(95% CI; p value)

0.2 (-4.6,5.0)

0.5**(-1.0,2.1)

5.2 (-1.7,2.3)

-0.3** (-2.9,2.3)

218/264 (82.6)

37/264 (14.0)

7/264 (2.7)

2/264 (0.8)

Table 6. Cost-effectiveness, cost/QALY (£): mini-sternotomy versus conventional surgery

- 1 probability cost-effective or net monetary benefit if willing to pay £20,000/QALY
- 2 probability cost-effective or net monetary benefit if willing to pay £30,000/QALY
- 3 dominance indicates average costs were less and average benefit greater for conventional surgery

4 regression estimates adjusted for trial stratifying covariates and baseline EQ-5D

	Model	Incremental cost (95%CI)	Incremental QALYs (95%CI)	ICER (95%CI)	p¹	p²
1	Multiple imputation,	508	-0.007	Dominated ³	0.058	0.052
-	covariate adjusted⁴	(-202 to 1217)	(-0·016 to 0·002)			
2	Multiple imputation, unadjusted	859	-0.008	Dominated	0.022	0.024
		(-116 to 1833)	(-0.018 to 0.003)	Dominated	0.023	0.021
3	Complete case, covariate adjusted ⁴	630	-0.007	Dominated	0.013	0.011
		(25 to 1224) 544	(-0·016 to 0·002) -0·009	Dominated	0.027	0.022
4	Complete case, unadjusted	(-99 to 1142)	-0.009 (-0.02 to 0.002)	Dominated	0.027	0.022

References

- 1. Matiasz R, Rigolin VH. 2017 Focused Update for Management of Patients With Valvular Heart Disease: Summary of New Recommendations. Journal of the American Heart Association 2018: https://doi.org/10.1161/JAHA.117.007596
- 2. NATIONAL ADULT CARDIAC SURGERY AUDIT 2020 Summary Report (2016/17-2018/19 data)
- Blue Book Online. The Society for Cardiothoracic Surgery in Great Britain & Ireland http://bluebook.scts.org/# (accessed 23rd July, 2018).
- 4. Leontyev S, Walther T, Borger MA, et al. Aortic Valve Replacement in Octogenarians: Utility of Risk Stratification With EuroSCORE. *Ann Thorac Surg* 2009; **87**: 1440–5.
- Phan K, Xie A, Di Eusanio M, Yan TD. The Collaborative Research (CORE) Group. Meta-Analysis of Minimally Invasive Versus Conventional Sternotomy for Aortic Valve Replacement. Ann Thorac Surg 2014; 98: 1499–511.
- 6. Ghanta RK, Lapar DJ, Kern JA, et al. Minimally invasive aortic valve replacement provides equivalent outcomes at reduced cost compared with conventional aortic valve replacement: A real-world multi-institutional analysis. *J Thorac Cardiovasc Surg* 2015; **149**: 1060–5.
- 7. Kirmani BH, Jones SG, Malaisrie SC, Chung DA, Williams RJ. Limited versus full sternotomy for aortic valve replacement. *Cochrane Database Syst Rev* **2017**; 4: CD011793.
- 8. Fujita B, Ensminger S, Bauer T, et al; GARY Executive Board. Trends in practice and outcomes from 2011 to 2015 for surgical aortic valve replacement: an update from the German Aortic Valve Registry on 42,776 patients. *Eur J Cardiothorac Surg.* **2018**; 53: 552–559.
- 9. Lehmann S, Merk DR, Etz CD, et al. Minimally invasive aortic valve replacement: the Leipzig experience. *Ann Cardiothorac Surg* **2015**; 4: 49–56.
- 10. Johnston DR, Roselli EE. Minimally invasive aortic valve surgery: Cleveland Clinic Experience. *Ann Cardiothorac Surg* 2015; **4**: 140–147.
- 11. Patel NN, Avlonitis VS, Jones HE, Reevesw BC, Sterne JA, Murphy GJ. Indications for red blood cell transfusion in cardiac surgery: a systematic review and meta-analysis. *Lancet Haem* 2015; **12**: e543–53.
- 12. Chen QH, Wang HL, Liu L, Shao J, Yu J, Zheng RQ. Effects of restrictive red blood cell transfusion on the prognoses of adult patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials. *Crit Care* 2018; **22**: 142.
- Pagano D, Milojevic M, Meestersa MI, et al. The Task Force on Patient Blood Management for Adult Cardiac Surgery of the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Cardiothoracic Anaesthesiology (EACTA). EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery. *Eur J Cardio-Thorac Surg* 2018; 53: 79–111.
- 14. Dixon JR. The International Conference on Harmonization Good Clinical Practice guideline. ICH GCP *Qual Assur* 1998; **6**: 65–74.
- 15. Akowuah E, Goodwin AT, Owens WA, et al. Manubrium-limited ministernotomy versus conventional sternotomy for aortic valve replacement (MAVRIC): study protocol for a randomised controlled trial.


https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-016-1768-4 Trials 2017; 18: 46.


- 16. NICE. Guide to the methods of Technology Appraisal. London, National Institute for Health and Care Excellence, 2013.
- 17. NHS Reference Costs 2015-16. London: Department of Health, 2016.
- 18. Curtis L, Burns A. Unit costs of health and social care 2015. Canterbury: the University of Kent, 2015.


- 19. Sterne Jonathan A C, White Ian R, Carlin John B, Spratt Michael, Royston Patrick, Kenward Michael G et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls BMJ 2009; 338 :b2393
- 20. White Ian R, Horton Nicholas J, Carpenter James, Pocock Stuart J. Strategy for intention to treat analysis in randomised trials with missing outcome data BMJ 2011; 342 :d40
- Faria R, Gomes M, Epstein D, White IR. A Guide to Handling Missing Data in Cost-Effectiveness Analysis Conducted Within Randomised Controlled Trials. PharmacoEconomics (2014) 32:1157–1170
- 22. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011 Feb 20;30(4):377-99
- 23. Aris A, Camara ML, Montiel J Delgado LJ, Galan J, Litvan H. Ministernotomy versus median sternotomy for aortic valve replacement: a prospective, randomized study. *Ann Thor Surg* 1999; **67**: 1583–7.
- 24. Moustafa MA, Abdelsamad AA, Zakaria G, Omarah MM. Minimal vs median sternotomy for aortic valve replacement. *Asian Cardiovasc Thorac Annals* 2007; **15**: 472–5.
- Rodríguez-Caulo EA, ArantzaGuzón A, Otero-Forero J, José Mataró M, Sánchez-Espín G, Porras C, Villaescusa J.M, Melero-Tejedor JM, Jiménez-Navarro M. Quality of life after ministernotomy versus full sternotomy aortic valve replacement doi.org/10.1053/j.semtcvs.2020.07.013
- 26. Vukovic P.M, Milojevic P, Stojanovic I, Micovic S, Zivkovic I, Miodrag P, Milicic M, Milacic P, Milojevic M, Bojic M. The role of ministernotomy in aortic valve surgery-A prospective randomized study doi: 10.1111/jocs.14053. Epub 2019 Apr 24.
- National Comparative Audit of Blood Transfusion http://hospital.blood.co.uk/media/26859/nca-2011_use_of_blood_in_adult_cardiac_surgery_ report.pdf (accessed 23rd July, 2018).
- Hancock HC, Maier RH, Kasim AS, Mason JM, Murphy GJ, Goodwin AT, Owens WA, Kirmani BH, Akowuah EF. Mini-Sternotomy Versus Conventional Sternotomy for Aortic Valve Replacement. Journal of the American College of Cardiology 2019 Vol 73; 2491-2492


- Figure 2. Valve size distribution: mini-sternotomy group
- Figure 3. Valve size distribution: conventional sternotomy group
- Figure 4. Cost-effectiveness plane, cost/QALY (£): mini-sternotomy versus conventional surgery.

to peer terier only









Supplementary Material

Study Investigators: trial site, clinical trials unit, statistics, health economics, committees	2
Table 1. Eligibility criteria	3
Figure 1. Trial recruitment by month	4
Table 2. Conversion from mini-sternotomy to conventional sternotomy	5
Table 3. Number of operations by Consultant Surgeon	6
Figure 2. Haemoglobin profiles	7
Table 4. Analgesic use and Pain scores	8-9
Table 5. Adverse Events	10
Table 6. Health status, resource use and cost (complete cases)	11
Table 7. ICU Length of Stay, Fitness for Discharge and Hospital Length of Stay	12
Table 8. Pulmonary function tests	13

/ function tests

Study Investigators: trial site, trials unit, statistics, health economics, committees

Trial Site

1 2 3

4 5

6

7

8 9

10

11

12

13 14

15

16

17

18 19

20

21

22

23

24 25

26

27

28 29

30

31

32 33

34

35 36

37

38

39

40 41

42

43

44

45

46

47

48

49 50

51

52

53

The James Cook University Hospital, South Tees Hospitals NHS Foundation Trust, Middlesbrough, United Kingdom

Investigators

- Mr Enoch Akowuah (Chief Investigator)
- Mr Andrew Goodwin (co-Investigator)
- Professor W Andrew Owens (co-Investigator)

Research Team

- Heather Robinson
- Jonathan Broughton
- Dr Khalid Khan

Clinical Trials Unit

Durham Clinical Trials Unit, Durham University; now Newcastle Clinical Trials Unit, Newcastle University

Investigators

- Professor Helen Hancock (co-Investigator)
- Rebecca Maier (co-Investigator)

Research Team

- Andrew Thorpe
- Jennifer Wilkinson
- Dr Leanne Marsay

Statistics

Statistics Group, Wolfson Research Institute for Health and Wellbeing, Durham University

Investigator

• Dr Adetayo Kasim (co-Investigator)

Health Economics

Durham Clinical Trials Unit, Durham University; now University of Warwick

Investigator

• Professor James Mason (co-Investigator)

Committees

Data Monitoring Committee Membership

- Mr Graham Cooper (Chair)
- Mr Heyman Luckraz
- Professor Chris Rogers

Trial Steering Committee Membership

- Mr Sukumaran Nair (Chair until Sep 2014)
- Professor Gavin Murphy (Acting Chair Oct 2014 to June 2015)
- Mr Peter Braidley (Chair, from July 2015)
- Mr Paul Modi
- Mr Brendan Ellis

Table 1. Eligibility criteria

Inclusion Criteria

- Aged 18 years or older at the time of consent
- Requiring first-time, non-emergency, isolated Aortic Valve Replacement surgery
- Able and willing to provide written informed consent

Exclusion Criteria

- requiring concomitant cardiac procedure(s) including redo surgery, emergency or salvage surgery,
- only conventional median sternotomy indicated*,
- haemoglobin level < 90g/L,
- pregnant**,
- currently participating in another interventional clinical trial,
- previous cardiac surgery,
- are unable to stop currently prescribed treatment affecting clotting (e.g., heparin, warfarin), ***
- a history of thrombophilia, thrombocytopenia or other haematological conditions that would affect participation in the trial as determined by one of the three operating surgeons,
- infective endocarditis,
- prevented from having red blood cells and blood products according to a system of beliefs (e·g· Jehovah's Witnesses),
- having any other medical, psychiatric and or social reason as determined by the consenting surgeon that precludes participation.

* patients were excluded if only conventional median sternotomy was indicated, for example in the presence of significant skeletal abnormalities like kyphosis. They were also excluded if transoesophageal echocardiography could not be performed, as this was mandatory to perform safe peripheral venous cannulation. All 3 surgeons used consistent criteria.

** in women of child bearing age (18 - 50) a pregnancy test was be performed within 14 days of surgery prior to randomisation.

***for patients in both trial arms, pre-operative antiplatelet drugs (including clopidogrel and ticagrelor), and anti-coagulants (including warfarin and heparin) were discontinued 5 days prior to surgery. These drugs were re-started following surgery at the discretion of the clinical team. The exception to this was aspirin, which was stopped 5 days prior to surgery where possible, however continuation until the day of surgery did not exclude a patient from the trial.




Figure 1. Trial recruitment by month.

R ONL

Table 2. Conversion from mini-sternotomy to conventional sternotomy

Reason for conversion	Number of patients	Details
Anaesthetic emergency	2	 Patient became unstable as they were transferred into theatre a dropped – required conventional to re-stabilise Anaphylactic reaction on induction needing CPR· Operation cancelled, patient taken to ITU· Widespread rash· Decision ma following morning to proceed to AVR (via full sternotomy)
Difficult vascular access (venous or arterial)	9	 Venous Femoral vessels unsuitable for cannulation Poor venous drainage Unable to pass venous dilators Unable to insert pipe. Resistance felt, no back flow of blood. I cannulation abandoned Impossible to dilate femoral vein. Despite re-wiring, guide win coiling within pelvic venous system
		 Arterial Difficulties cannulating femoral artery leading to haemodynaminstability Poor access, unable to clamp aorta Severe calcification of ascending aorta Difficult access; aorta displaced to the left Body habitus limit access
Intra-operative complications	5	 Bleeding from aortotomy site Bleeding Intra-operative decision to performed bypass graft to LAD Post implant TOE showed small paravalvular leak and bleedin aortotomy incision Mild/moderate paravalvar leak on TOE. Required valve re-implant reaction
TOTAL	16	

Table 3. Number of operations performed by Consultant Surgeon

	Mini-sternotomy group n=patients (%)	Conventional sternotomy group	Total n=patients (%)
	• • • •	n=patients (%)	• • •
Consultant Surgeon A	58 (43.0)	58 (430)	116 (43.0)
Consultant Surgeon B	43 (31.9)	35 (25.9)	78 (28.9)
Consultant Surgeon C	34 (25.1)	42 (31.1)	76 (28.1)




Figure 2. Haemoglobin profiles at Baseline, during CICU stay, and day 1 to day 4 post index surgery, by group

Table 4. Analgesic use and pain scores

Medication	Mini-sternotomy Group (135 patients) n = patients (%)	Conventional Sternotomy Group (135 patients) n = patients (%)	Total (270 patier n = patients
Analgesic use at baseline			n putteria
Buprenorphine patch	3 (2.2)	1 (0.7)	4 (1.5)
Codeine Phosphate	4 (3.0)	3 (0.7)	7 (2.6)
		· · · · · ·	· · · ·
Dihydrocodeine Tartrate	0 (0.0)	1 (0.7)	1 (0.4)
Durogesic patch	0	1 (0.7)	1 (0.4)
Fentanyl	1 (0.7)	0 (0.0)	1(0.4)
Gabapentin	1 (0.7)	0 (0.0)	1(0.4)
Morphine Sulfate	0.0	1(0.7)	1(0.4)
1			
Naxoproxen	1 (0.7)	0 (0.0)	1 (0.4)
Paracetamol	13 (9.6)	8 (5.9)	21 (7.8)
Tramadol Hydrochloride	0 (0.0)	2 (1.5)	2(0.7)
At least one med at baseline	16 (11.9)	12 (8.9)	28 (10.4
Analgesic use at day 2			
Buprenorphine patch	1 (0.7)	0 (0.0)	1(0.4)
Codeine Phosphate	18 (13.3)	16 (11.9)	34 (12.6
		· · · · · · · · · · · · · · · · · · ·	
Dihydrocodeine Tartrate	4 (3.0)	6 (4.4)	10 (3.7)
Fentanyl	1 (0.7)	0 (0.0)	1(0.4)
Gabapentin	1 (0.7)	0 (0.0)	1(0.4)
Morphine Sulfate	13 (9.6)	13 (9.6)	26 (9.6)
		· · · ·	
Oramorph	1 (0.7)	1 (0.7)	2 (0.7)
Paracetamol	94 (69.6)	80 (59.3)	174 (64-4
Pregabalin	1(0.7)	0 (0.0)	1(0.1)
Tramadol Hydrochloride	7 (5.2)	5 (3.7)	12(4.4)
At least one med at day 2	99 (73·3)	86 (63·7)	185 (68-
Analgesic use at day 3			
		0(0,0)	1 (0 1)
Buprenorphine patch	1 (0.7)	0(0.0)	1 (0.4)
Codeine Phosphate	14 (10.4)	21 (15.6)	35 (13-0
Dihydrocodeine Tartrate	4 (3.0)	7 (5.2)	11 (4.1)
Fentanyl	0 (0.0)	1 (0.7)	1(0.4)
		· · · · · · · · · · · · · · · · · · ·	. ,
Gabapentin	1 (0.7)	1 (0.7)	2 (0.7)
Ibuprofen	0	1 (0.7)	1 (0.4)
Morphine Sulfate	6 (4.4)	1 (0.7)	7 (2.6)
Nefopam Hydrochloride	0	1 (0.7)	1(0.4)
Oramorph	0	3 (2.2)	$3(1\cdot1)$
-			
Paracetamol	89 (65.9)	99 (73.3)	188 (69-0
Pregabalin	1 (0.7)	0 (0.0)	1(0.4)
Tramadol Hydrochloride	8 (5.9)	3 (2.2)	11 (4.1)
At least one med at day 3	90 (66·7)	101 (74.8)	191 (70-2
Analgesic use at Day 4			
Buprenorphine patch	1 (0.7)	0 (0.0)	1 (0.4)
			. ,
Codeine Phosphate	15 (11.1)	15 (11.1)	30 (11.1
Dihydrocodeine Tartrate	4 (3.0)	9 (6.7)	13 (4.8)
Fentanyl	1 (0.7)	1 (0.7)	2(0.7)
Gabapentin	1(0,7)	1(0,7)	2(0.7)
Ibuprofen	0 (0.0)	1 (0.7)	1 (0.4)
Paracetamol	86 (63.7)	75 (55.6)	161 (59-
Morphine Sulfate	1 (0.7)	2 (1.5)	3 (1.1)
Pregabalin	1 (0.7)	0 (0.0)	1(0.4)
Tramadol Hydrochloride	$3(2\cdot 2)$	3 (2.2)	6 (2.2)
At least one med at day 4	88 (65·2)	81 (60·0)	169 (62·
Analgesic use at Week 6			
Buprenorphine Patch	3(2.2)	0(0.0)	3(1.1)
Codeine Phosphate	7(5.1)	5(3.7)	12(4.5)
Dihydrocodeine Tartrate	1(0.7)	3(2.2)	4(1.5)
Fentanyl	1(0,7) 1(0.7)	0(0.0)	
			1(0.4)
Gabapentin	2(1.5)	1(0.7)	3(1.1)
Ibuprofen	0(0.0)	1(0.7)	1(0.4)
Morphine Sulfate	0(0.0)	1(0.7)	1(0.4)
1			
Paracetamol	35(25.9)	38(28.1)	73(27.0
Pregabalin	1(0.7)	0(0.0)	1(0.4)
Tramadol Hydrochloride	2(1.5)	2(1.5)	4(1.5)
At least one med at week 6	41(30·4)	41(30.4)	82(30.4
Analgesic use at Week 12			
	3(2.2)	0(0.0)	$3(1 \cdot 1)$
Buprenorphine Patch	5(2:2)	0(0.0)	.1(1+1)

At least one med at week 12	23(17·0)	22(16·3)	45(16.7)
Tramadol Hydrochloride	1(0.7)	1(0.7)	2(0.7)
Paracetamol	19(14.1)	20(14.8)	39(14.4)
Naproxen	1(0.7)	0(0.0)	1(0.4)
Morphine Sulfate	1(0.7)	1(0.7)	2(0.7)
Ibuprofen	1(0.7)	0(0.0)	1(0.4)
Gabapentin	2(1.5)	0(0.0)	2(0.7)
Dihyrocodeine Tartrate	0(0.0)	1(0.7)	1(0.4)

	Mini-sternotomy Group (n=135 patients)	Conventional sternotomy group (n=135)
Baseline pain score		
n	128*	130*
Mean± SD	$1 \cdot 3 \pm 2 \cdot 1$	0.9 ± 1.9
(min-max)	0 - 10	0 - 8
Day 2 pain score**		
n	123*	126*
Mean± SD	3.4 ± 2.4	3.7 ± 2.7
(min-max)	0 - 10	0 - 10
Day 3 pain score		
n	120*	129*
Mean± SD	$2 \cdot 8 \pm 2 \cdot 5$	$2 \cdot 7 \pm 2 \cdot 3$
(min-max)	0 - 9	0 - 8
Day 4 pain score		
n	116*	120*
Mean± SD	2.5 ± 2.2	$2 \cdot 1 \pm 2 \cdot 3$
(min-max)	0 - 8	0 - 10
6 week pain score		
n	112*	118*
Mean± SD	1.5 ± 1.9	$1 \cdot 2 \pm 1 \cdot 8$
(min-max)	0 - 8	0 - 8
12 week pain score		
'n	128*	122*
Mean± SD	$1 \cdot 1 \pm 1 \cdot 9$	$1 \cdot 0 \pm 1 \cdot 7$
(min-max)	0 - 8	0-6

*Pain scores were assessed wherever possible

**Assessment on Day 2 was conducted with the patient blinded to their surgical allocation

Table 5. Adverse Events

Table 6. Health status, resource use and cost (complete cases)

	Conv	Conventional [C]		Mini-sternotomy [M]			[M]-[C] ¹	
	mean	(SD)	Ν	mean	(SD)	Ν	mean	(95%CI)
Health status ²								
EQ-5D Baseline	0.764	0.245	130	0.763	0.235	128	-0.001	(-0.060 to 0.057
EQ-5D 2 days	0.349	0.349	133	0.353	0.291	128	0.004	(-0.074 to 0.082
EQ-5D 6 weeks	0.798	0.194	118	0.751	0.221	112	-0.048	(-0.101 to 0.006
EQ-5D 12 weeks	0.838	0.207	124	0.782	0.248	127	-0.056	(-0·112 to 0·001
EQ-5D AUC (0-12 weeks)	0.162	0.041	105	0.153	0.040	98	-0.009	(-0.020 to 0.002
Resource use								
Index Admission								
Length of stay $(d)^3$	8.26	4.28	135	9.29	7.88	135	1.03	(-0.48 to 2.54)
CICU (d)	1.21	0.99	135	1.61	5.52	135	0.39	(-0.55 to 1.34)
HDU (d)	1.27	1.52	135	1.60	1.75	135	0.33	(-0.07 to 0.72)
Cardiac ward (d)	5.67	3.52	135	5.70	3.18	135	0.03	(-0.77 to 0.83)
Stroke ward (d)	0.03	0.34	135	0.11	$1 \cdot 00$	135	0.08	(-0.10 to 0.26)
Time in first surgery (h)	2.24	0.51	135	2.98	0.69	135	0.74	(0.60 to 0.89)
Time in further surgery $(h)^4$	0.08	0.34	135	0.03	0.17	135	-0.05	(-0·11 to 0·02)
Time in surgery (h) 4	2.32	0.63	135	3.01	0.71	135	0.69	(0.53 to 0.85)
RBC (u) ⁴	0.59	1.45	135	0.55	1.28	135	-0.04	(-0·37 to 0·28)
$FFP(u)^4$	0.57	1.43	135	0.34	1.21	135	-0.23	(-0.55 to 0.09)
Platelets (u) ⁴	0.22	0.64	135	0.12	0.46	135	-0.10	(-0·24 to 0·03)
Cryoprecipitate (u) ⁴	0.01	0.09	135	0.00	0.00	135	-0.01	(-0.02 to 0.01)
Post discharge contacts								
GP surgery	1.47	1.52	129	$1 \cdot 40$	1.32	131	-0.07	(-0·41 to 0·28)
GP home	0.09	0.32	129	0.19	0.56	131	0.10	(-0.01 to 0.21)
GP telephone	0.12	0.45	129	0.15	0.63	131	0.03	(-0.10 to 0.16)
Nurse surgery	1.38	2.56	129	2.07	3.54	131	0.69	(-0.06 to 1.44)
Nurse home	0.43	1.30	129	0.56	1.87	131	0.12	(-0.27 to 0.51)
Nurse telephone	0.05	0.25	129	0.04	0.26	131	-0.01	(-0.07 to 0.05)
Outpatient hospital	0.40	0.78	129	0.57	1.98	131	0.17	(-0·20 to 0·53)
Inpatient hospital	0.30	0.68	129	0.27	0.60	131	-0.03	(-0·18 to 0·13)
Inpatient hospital (d)	2.09	7.79	129	1.09	2.69	131	-1.00	(-2·42 to 0·42)
Total Contacts	4.29	3.53	129	5.47	4.90	131	1.18	(0.14 to 2.22)
Cost ⁵								
Cost of index admission	7674	2055	135	8815	4517	135	1140	(303 to 1977)
Cost post discharge	824	2485	129	547	925	131	-277	(-734 to 180)
Cost	8527	3558	129	9274	4542	131	746	(-245 to 1737)

1 OLS regression-estimated means and 95% confidence intervals

2 EQ-5D-3L index score

3 Length stay by ward does not sum to length of stay due to theatre and transit time, and rounding

4 Item includes index and post-discharge usage

5 Resource items were costed using national reference costs except for the index procedures which were costed by South Tees Hospitals NHS Foundation Trust

Table 7. ICU Length of Stay, Fitness for Discharge and Hospital Length of Stay

	Mini-sternotomy group (n=135)	Conventional sternotomy group (n=135)
ICU stay (days)		
n	135	135
Mean \pm SD	1.9 ± 5.8	$1 \cdot 3 \pm 1 \cdot 1$
Min-Max	0 - 64*	0 - 7
Fitness for discharge (days)		
n	129**	133**
Mean \pm SD	6.5 ± 3.7	6.3 ± 3.2
Min - Max	3 - 36	3 - 31
Post-operative length of stay (days)		
n	135	135
Mean \pm SD	$7 \cdot 4 \pm 7 \cdot 5$	6.3 ± 3.1
Min - Max	3 - 79	3 - 31

*3 patients in the mini-sternotomy group were in ICU for more than 7 days. Excluding these patients, the range would have been 0-5 days for the mini-sternotomy group.

**Fitness for discharge was assessed by the surgical and physiotherapy teams. For 6 patients in the mini-sternotomy group and 2 patients in the conventional sternotomy group this was not possible due staff availability at the point of discharge.

or oper teries only

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

		Mini-sternotomy group (n=135)	Conventional sternotomy group (n=135)	Mean Difference (95% CI; p valu
1				
1	n Marina SD	123*	123*	15 4
	Mean \pm SD	$2196{\cdot}2\pm712{\cdot}2$	$2207{\cdot}7\pm748{\cdot}2$	-15·4 (-169·2,138·4
Day 4	Min - Max	1000- 4340	1020-4090	
. 1	n Na ar	105*	110*	171 044
	Mean \pm SD	$1122 \cdot 6 \pm 433 \cdot 0$	$1320{\cdot}7\pm523{\cdot}5$	-171·3** (-265·3,-77·2; p=0·
l 6 weeks	Min - Max	99-2400	76-2910	
1	n	106*	97*	
]	Mean ± SD	$1962{\cdot}0\pm468{\cdot}7$	$2018 \cdot 1 \pm 662 \cdot 8$	-7·3** (-104·3,89·6)
] FVC	Min - Max	650-3570	870-3570	
Baseline				
	n Mean ± SD	123^* 2908.5 ± 926.4	123^{*} 2929.2 ± 955.7	-31.6
				(-238-8,175-7
Day 4	Min - Max	1250-6060	1200-5650	
	n Mean ± SD	105* 1478.9 ± 583.3	110^{*} 1697.5 ± 706.8	-129.7**
				(-259·2,-0·1; p=0·
l 6 weeks	Min - Max	139-2910	109-3920	
1	n	106*	97*	
1	Mean \pm SD	$2529{\cdot}4 \pm 824{\cdot}0$	$2615{\cdot}9\pm864{\cdot}0$	-36·0** (-173·2,101·2
	Min - Max	1180-4760 complete pulmonary function tests	1000-4840	
**After adj	usting for randomisation fac	ctors and baseline data		



CONSORT 2010 checklist of information to include when reporting a randomised trial*

Section/Topic	ltem No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	2
Introduction			
Background and	2a	Scientific background and explanation of rationale	3
objectives	2b	Specific objectives or hypotheses	3,5
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	3,4,5
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	NA
Participants	4a	Eligibility criteria for participants	4 (+appendix)
	4b	Settings and locations where the data were collected	4
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were	
		actually administered	4,5
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they	
		were assessed	6
	6b	Any changes to trial outcomes after the trial commenced, with reasons	NA
Sample size	7a	How sample size was determined	7
	7b	When applicable, explanation of any interim analyses and stopping guidelines	NA
Randomisation:			
Sequence	8a	Method used to generate the random allocation sequence	2,4
generation	8b	Type of randomisation; details of any restriction (such as blocking and block size)	2,4

Page	47	of	48
------	----	----	----

BMJ Open

 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how If relevant, description of the similarity of interventions Statistical methods used to compare groups for primary and secondary outcomes Methods for additional analyses, such as subgroup analyses and adjusted analyses For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up Why the trial ended or was stopped 	2,4 4 2,4,5 4 7 7 9 9,17 9
 interventions If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how If relevant, description of the similarity of interventions Statistical methods used to compare groups for primary and secondary outcomes Methods for additional analyses, such as subgroup analyses and adjusted analyses For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up 	2,4,5 4 7 7 9 9,17
 assessing outcomes) and how If relevant, description of the similarity of interventions Statistical methods used to compare groups for primary and secondary outcomes Methods for additional analyses, such as subgroup analyses and adjusted analyses For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up 	4 7 7 9 9,17
 If relevant, description of the similarity of interventions Statistical methods used to compare groups for primary and secondary outcomes Methods for additional analyses, such as subgroup analyses and adjusted analyses For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up 	7 7 9 9,17
 Methods for additional analyses, such as subgroup analyses and adjusted analyses For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up 	7 9 9,17
 Methods for additional analyses, such as subgroup analyses and adjusted analyses For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up 	9 9,17
were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up	9,17
were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up	9,17
were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up	9,17
 For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up 	9,17
a Dates defining the periods of recruitment and follow-up	
	9
A table showing baseline demographic and clinical characteristics for each group	Table
For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	Table
For each primary and secondary outcome, results for each group, and the estimated effect size and its	
precision (such as 95% confidence interval)	9, Ta
For binary outcomes, presentation of both absolute and relative effect sizes is recommended	Table
Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	12
All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	11
Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	13
Generalisability (external validity, applicability) of the trial findings	13,14
	 For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval) For binary outcomes, presentation of both absolute and relative effect sizes is recommended Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)

BMJ Open

Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	13,14
Other information			
Registration	23	Registration number and name of trial registry	1,4
Protocol	24	Where the full trial protocol can be accessed, if available	4
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	4, 15

*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

For peer review only For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml